US20200040103A1

Movatterモバイル変換

Info

Publication number: US20200040103A1
Application number: US16/352,619
Authority: US
Inventors: Cecilia P. C. Chiu; Hilda Y. Hernandez-Barry; David B. Iaea; Moulay Hicham Alaoui-Ismaili; James T. Koerber; Wei Yu Lin; Kelly Loyet; Yonglian Sun; Benjamin T. Walters; Jawahar Sudhamsu
Original assignee: Genentech Inc
Current assignee: F Hoffmann La Roche AG
Priority date: 2018-03-14
Filing date: 2019-03-13
Publication date: 2020-02-06
Also published as: US20210301032A1; JP7422671B2; US20250002609A1; JP2024054130A; RU2020133229A; PE20210629A1; JP2021518105A; TW201946935A; CR20200404A; MX2020009465A; US12037412B2; AU2019235881A1; CL2020002333A1; KR20200130823A; CA3091836A1; RU2020133229A3; AR114281A1; CN111868241A; PH12020551336A1; IL277212A

Abstract

The invention provides anti-KLK5 antibodies and methods of using the same.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Ser. No. 62/643,034 filed on Mar. 14, 2018, the entire contents of which are incorporated herein by reference.

SEQUENCE LISTING

The instant application contains a Sequence Listing submitted via EFS-Web and hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 12, 2019, is named P34707-US-1_SL.txt, and is 424,527 bytes in size.

FIELD OF THE INVENTION

The present invention relates to anti-KLK5 antibodies and methods of using the same.

BACKGROUND

Human kallikrein-related peptidases (KLKs) are (chymo)-trypsin-like serine proteases that are expressed in a variety of tissues such as prostate, ovary, breast, testis, brain, and skin. KLKs belong to a subgroup of the chymotrypsin-like serine protease family S1A of clan PA(S). The 15 human KLK genes are located on chromosome 19q13.4 and constitute the largest contiguous serine protease cluster in the human genome. These genes, generally composed of five coding exons and in some cases one or two 5′ non-coding exons, encode the kallikrein-related peptidases KLK1 to KLK15. All KLK genes encode single-chain pre-pro-proteins containing a chymotrypsin- or trypsin-like catalytic domain of 224-237 residues with an amino acid sequence identity of approximately 40% among KLK4 to KLK15. KLK1 and its close homologs KLK2 and KLK3 form a clade of their own, KLK4, 5, and 7 belong to another subgroup, whereas KLK6 shares more similarity with KLK13 and KLK14. See Debela et al.,Biol Chem389, 623-632 (2008).

KLK5 appears to be most abundantly expressed in human skin, specifically in the upper spinous and granular layers of the skin, where keratinocytes undergo terminal differentiation and are transformed into flattened brick-like structures that form the stratum corneum, the outermost epidermal layer and the barrier to the outside environment. See Debela et al.,J Mol Biol,373, 1017-1031 (2007); and Tan et al.,J Med Chem.2015 Jan. 22; 58(2):598-612 (2014). KLK5 is described to play pathological roles in skin disorders such as Netherton Syndrome. See Furio et al.,PLOS Genet11(9), e1005389 (2015). Netherton Syndrome is caused by loss-of-function mutations in the SPINK5 gene, encoding the serine protease inhibitor Kazal-type 5 (SPINK5). See Descargues et al.,Nat Genet.2005 January; 37(1):56-65 (2004). SPINK5 has been shown to inhibit several members of the KLK serine protease family (e.g. KLK5 and KLK7). See Wang et al., Exp Dermatol. July; 23(7):524-6 (2014). The absence of SPINK5 in Netherton Syndrome results in unopposed KLKs activities. KLK5 hyperactivity is thought to be a key element in the pathophysiology of Netherton Syndrome as KLK5 is a regulator of proteolysis in the epidermis. Ablation of KLK5 and KLK7 rescues lethality of Netherton Syndrome-like phenotype. See Briot et al., J Exp Med. May 11; 206(5):1135-47 (2009); Furio et al., J Exp Med. March 10; 211(3):499-513 (2014); and Kasparek et al., PLoS Genet. 2017 Jan. 17; 13(1):e1006566 (2017). Netherton Syndrome is a complex systemic disease with multiple effects for which currently no satisfactory treatment is available.

Asthma is a clinically heterogeneous disorder associated with both genetic and environmental risk factors. Estimates of heritability from asthma twin studies vary from 35% to 80%, indicating an important role for genetic risk. See e.g., Ullemar et al.,Allergy71, 230-238 (2016). Several large scale GWAS have been performed for asthma and asthma related phenotypes, and many of the loci identified such as those near ORMDL3, IL13, IL1RL1 and TSLP genes have been confirmed in multiple study populations. See e.g., Bonnelykke et al.,Nat Genet46, 51-55 (2014). Recent studies identified a SNP at the KLK4/5 locus which is protective for the risk regarding periostin low, ortype 2 low inflammation asthma. In the same study, KLK5 levels were found to be elevated in bronchoalveolar lavage of severe asthma patients supporting the hypothesis that KLK5 plays a role in bronchial obstruction and asthma pathogenesis.

Despite the advances in the field of diseases such as Netherton Syndrome and asthma, there remains a need to identify targets and develop means that can supplement or enhance the efficacy of existing therapies.

SUMMARY

Provided herein are anti-KLK5 antibodies and methods of using the same.

Further provided herein is an isolated antibody that binds to KLK5, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:28; (b) HVR-H2 comprising the amino acid sequence selected from the group consisting of SEQ ID NO:38, SEQ ID NO:45, and SEQ ID NO:54; (c) HVR-H3 comprising the amino acid sequence selected from the group consisting of SEQ ID NO:65, SEQ ID NO:69, and SEQ ID NO:72; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:96; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:109; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:127.

In some embodiments, the antibody comprises (a) HVR-H1 comprising the amino acid sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:22, and SEQ ID NO:24; (b) HVR-H2 comprising the amino acid sequence selected from the group consisting of SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, and SEQ ID NO:53; (c) HVR-H3 comprising the amino acid sequence selected from the group consisting of SEQ ID NO:65, SEQ ID NO:69, and SEQ ID NO:72; (d) HVR-L1 comprising the amino acid sequence selected from the group consisting of SEQ ID NO:82, SEQ ID NO:87, and SEQ ID NO:91; (e) HVR-L2 comprising the amino acid sequence selected from the group consisting of SEQ ID NO:99, SEQ ID NO:101, and SEQ ID NO:105; and (f) HVR-L3 comprising the amino acid sequence selected from the group consisting of SEQ ID NO:115, SEQ ID NO:119, and SEQ ID NO:122.

In some embodiments of any of the antibodies, the antibody comprises a) a VH sequence of SEQ ID NO:202 and a VL sequence of SEQ ID NO:140; b) a VH sequence of SEQ ID NO:225 and a VL sequence of SEQ ID NO:151; or c) a VH sequence of SEQ ID NO:257 and a VL sequence of SEQ ID NO:162.

In some embodiments of any of the antibodies, the antibody comprises a) a VH sequence of SEQ ID NO:201 and a VL sequence of SEQ ID NO:139; b) a VH sequence of SEQ ID NO:221 and a VL sequence of SEQ ID NO:149; or c) a VH sequence of SEQ ID NO:248 or SEQ ID NO:254, and a VL sequence of SEQ ID NO:160.

Further provided herein is an isolated antibody that binds to KLK5, wherein the antibody comprises a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:201 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:139; b) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:221 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:149; or c) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:248 or SEQ ID NO:254, and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:160.

In some embodiments, the antibody comprises a VH sequence selected from the group consisting of SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:226, SEQ ID NO:227, and SEQ ID NO:228, and a VL sequence selected from the group consisting of SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:152, SEQ ID NO:153, and SEQ ID NO:154.

In some embodiments of any of the antibodies, the antibody is an IgG1 or IgG4.

In some embodiments of any of the antibodies, the antibody inhibits the biological activity of KLK5 by at least 50% as measured by one or more methods as described in the Examples herein below. In some embodiments, the one or more methods is selected from the group consisting of a recombinant KLK5 direct activity assay, coupled pro-KLK1 fluorescent peptide assay, a coupled pro-KLK7 fluorescent peptide assay, a pro-KLK1 LC/MS assay, a pro-KLK7 LC/MS assay, and a K_i(app)assay. In some embodiments, the biological activity is the serine protease activity of KLK5.

In some embodiments of any of the antibodies, the antibody is a monoclonal antibody.

In some embodiments of any of the antibodies, the antibody is a human, humanized, or chimeric antibody.

In some embodiments of any of the antibodies, the antibody is an antibody fragment that binds KLK5.

Further provided herein is an antibody that forms a thermodynamic epitope when bound to KLK5 comprising one or more of the sequences selected from the group consisting of SEQ ID NO:316, SEQ ID NO:317, SEQ ID NO:318, and SEQ ID NO:319 as measured by hydrogen exchange mass spectrometry.

Further provided herein is an antibody that competes for binding with any of the antibodies described herein.

Further provided herein is an antibody that binds to the same epitope as any of the antibodies described herein.

Further provided herein is an isolated nucleic acid encoding any of the antibodies described herein.

Further provided herein is a host cell comprising the nucleic acid described herein.

Further provided herein is a method of producing an antibody comprising culturing the host cell described herein so that the antibody is produced.

Further provided herein is an immunoconjugate comprising the antibody described herein.

Further provided herein is a pharmaceutical formulation comprising the antibody described herein and a pharmaceutically acceptable carrier.

Further provided herein is the antibody as described herein for use as a medicament.

Further provided herein is the antibody as described herein for use in treating a disease selected from the group consisting of Netherton Syndrome, asthma, atopic dermatitis, psoriasis, and rosacea. In some embodiments, the disease is selected from the group consisting of Netherton Syndrome, asthma, atopic dermatitis, psoriasis, rosacea and eosinophilic esophagitis. In some embodiments, the asthma is selected from the group consisting of atopic asthma, allergic asthma, non-allergic asthma, exercise-induced asthma, aspirin sensitive/exacerbated asthma, mild asthma, moderate to severe asthma, corticosteroid naïve asthma, chronic asthma, corticosteroid resistant asthma, corticosteroid refractory asthma, newly diagnosed and untreated asthma, asthma due to smoking, asthma uncontrolled on corticosteroids, T helper lymphocyte type 2 (Th2) or type 2 (Th2) high, or Type 2 (T2)-driven asthma, eosinophilic asthma, periostin-high asthma, eosinophil-high asthma, Th2-low asthma or nonTh2-driven asthma, periostin-low asthma, and eosinophil-low asthma. In some embodiments, the asthma is TH2-low asthma.

Further provided is the antibody as described herein for use in inhibiting the biological activity of KLK5.

Further provided is the use of the antibody as described herein in the manufacture of a medicament. In some embodiments, the medicament is for treating a disease selected from the group consisting of Netherton Syndrome, asthma, atopic dermatitis, psoriasis, and rosacea. In some embodiments, the disease is selected from the group consisting of Netherton Syndrome, asthma, atopic dermatitis, psoriasis, rosacea and eosinophilic esophagitis. In some embodiments, the asthma is selected from the group consisting of atopic asthma, allergic asthma, non-allergic asthma, exercise-induced asthma, aspirin sensitive/exacerbated asthma, mild asthma, moderate to severe asthma, corticosteroid naïve asthma, chronic asthma, corticosteroid resistant asthma, corticosteroid refractory asthma, newly diagnosed and untreated asthma, asthma due to smoking, asthma uncontrolled on corticosteroids, T helper lymphocyte type 2 (Th2) or type 2 (Th2) high, or Type 2 (T2)-driven asthma, eosinophilic asthma, periostin-high asthma, eosinophil-high asthma, Th2-low asthma or nonTh2-driven asthma, periostin-low asthma, and eosinophil-low asthma. In some embodiments, the asthma is TH2-low asthma.

Further provided is the use of the antibody described herein in the manufacture of a medicament for inhibiting the biological activity of KLK5.

Further provided is a method of treating an individual having a disease, wherein the disease is selected from the group consisting of Netherton Syndrome, asthma, atopic dermatitis, psoriasis, and rosacea comprising administering to the individual an effective amount of the antibody described herein. In some embodiments, the disease is selected from the group consisting of Netherton Syndrome, asthma, atopic dermatitis, psoriasis, rosacea and eosinophilic esophagitis. In some embodiments, the asthma is selected from the group consisting of atopic asthma, allergic asthma, non-allergic asthma, exercise-induced asthma, aspirin sensitive/exacerbated asthma, mild asthma, moderate to severe asthma, corticosteroid naïve asthma, chronic asthma, corticosteroid resistant asthma, corticosteroid refractory asthma, newly diagnosed and untreated asthma, asthma due to smoking, asthma uncontrolled on corticosteroids, T helper lymphocyte type 2 (Th2) or type 2 (Th2) high, or Type 2 (T2)-driven asthma, eosinophilic asthma, periostin-high asthma, eosinophil-high asthma, Th2-low asthma or nonTh2-driven asthma, periostin-low asthma, and eosinophil-low asthma. In some embodiments, the asthma is Th2-low asthma.

Further provided is a method of inhibiting the biological activity of KLK5 in an individual comprising administering to the individual an effective amount of the antibody described herein to inhibit the biological activity of KLK5.

Further provided herein is an antibody that specifically binds to human KLK5, wherein the antibody binds to an epitope on human KLK5 comprising one or more amino acid residues selected from the group consisting of Pro130, Ser131, Ala132, Gly133, Val162, Leu163, Ser164, Gln165, Lys166, Arg167, Glu169, Asp170, Ala171, Tyr172, Pro173, Arg174, Gln174A, Ile176, Asp177, Asp178, Gly184, Asp185, Lys186, Ala186A, Arg188, Asn223, Arg224, Pro225, and Lys233 according to standard protease numbering. In some embodiments, the antibody binds to an epitope on human KLK5 comprising one or more amino acid residues selected from the group consisting of Pro130, Ser131, Ala132, Val162, Leu163, Ser164, Gln165, Lys166, Arg167, Glu169, Asp170, Ala171, Tyr172, Pro173, Arg174, Gln174A, Ile176, Asp177, Asp178, Arg224, and Lys233 according to standard protease numbering. In some embodiments, the antibody binds to an epitope on human KLK5 comprising one or more amino acid residues selected from the group consisting of Pro130, Ser131, Ala132, Gly133, Val162, Leu163, Ser164, Gln165, Lys166, Arg167, Glu169, Asp170, Ala171, Tyr172, Pro173, Arg174, Gln174A, Ile176, Asp177, and Lys233 according to standard protease numbering. In some embodiments, the antibody binds to an epitope on human KLK5 comprising one or more amino acid residues selected from the group consisting of Ser131, Ala132, Gly133, Leu163, Ser164, Gln165, Lys166, Arg167, Glu169, Asp170, Ala171, Pro173, Arg174, Gly184, Asp185, Lys186, Ala186A, Arg188, Asn223, Arg224, and Pro225 according to standard protease numbering.

Further provided herein is an antibody when bound to human KLK5 results in a conformational change of human KLK5, wherein the conformational change allosterically results in the disruption of the substrate binding site and/or the active site of human KLK5.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A-1N show the evaluation of each of the KLK5 inhibitors using fluorescent peptide substrate in the direct assay. 5 nM recombinant human KLK5 and 0.19-100 nM KLK5 inhibitors were pre-incubated for 30 minutes prior to addition of 50 μM Boc-VPR-AMC. Plates were examined every 102 s for 30-60 minute using a PHERAstar® Plus reader using a 340 nm excitation/460 nm emission module. The results for the KLK5 inhibitors are depicted as follows:FIG. 1A: Spink9.SRE.Fc (Spink9),FIG. 1B: mAb1108,FIG. 1C: 3-3F5,FIG. 1D: 1008,FIG. 1E: 9B6,FIG. 1F: 9F2,FIG. 1G: 9H3,FIG. 1H: 9H5,FIG. 1I: 8B7,FIG. 1J: 2B11,FIG. 1K: 8F5,FIG. 1L: 10C5,FIG. 1M: 10H3, andFIG. 1N: 2-3F4.

FIG. 2A-2N show the evaluation of KLK5 inhibitors in pro-KLK7 coupled assay. 5 nM recombinant human KLK5 and 0.19-100 nM anti-KLK5 inhibitors were pre-incubated for 30 minutes prior to addition of 125 nM pro-KLK7 and 100 μM suc-LLVY-AMC. After 24 hours, fluorescent readings were made every 102 s for 30-60 min and the RFU endpoint value was calculated by averaging the last 5 readings. The results for the KLK5 inhibitors are depicted as follows:FIG. 2A: Spink9.SRE.Fc,FIG. 2B: mAb1108,FIG. 2C: 3-3F5,FIG. 2D: 1008,FIG. 2E: 9B6,FIG. 2F: 9F2,FIG. 2G: 9H3,FIG. 2H: 9H5,FIG. 2I: 8B7,FIG. 2J: 2B11,FIG. 2K: 8F5,FIG. 2L: 10C5,FIG. 2M: 10H3, andFIG. 2N: 2-3F4.

FIG. 3A-3N show the evaluation of KLK5 inhibitors in pro-KLK1 coupled assay. 0.5 nM recombinant human KLK5 and 0.019-10 nM KLK5 inhibitors were pre-incubated for 30 minutes prior to addition of 31.25 nM pro-KLKland 50 μM PFR-AMC. Plates were examined every 102 s for 120 minute using a PHERAstar® Plus reader using a 340 nm excitation/460 nm emission module. The results for the KLK5 inhibitors are depicted as follows:FIG. 3A: Spink9.SRE.Fc,FIG. 3B: mAb1108,FIG. 3C: 3-3F5,FIG. 3D: 1008,FIG. 3E: 9B6,FIG. 3F: 9F2,FIG. 3G: 9H3,FIG. 3H: 9H5,FIG. 3I: 8B7,FIG. 3J: 2B11,FIG. 3K: 8F5,FIG. 3L: 10C5,FIG. 3M: 10H3, andFIG. 3N: 2-3F4.

FIG. 4A-4N shows the results of an LC/MS assay measuring the inhibition of proteolysis of pro-KLK7 by recombinant KLK5 by monitoring the KLK5-derived cleavage product peptides. A pre-incubation of SPINK9.SRE.Fc, mAb1108 and the 12 selected antibodies and KLK5 preceded a two-hour incubation of 5 nM KLK5 with 15 nM pro-KLK7. The results for the KLK5 inhibitors are depicted as follows:FIG. 4A: SPINK9.SRE.Fc,FIG. 4B: mAb1108,FIG. 4C: 10C8,FIG. 4D: 9B6,FIG. 4E: 2B11,FIG. 4F: 9F2,FIG. 4G: 2-3F4,FIG. 4H: 10H3,FIG. 4I: 9H3,FIG. 4J: 8B7,FIG. 4K: 8F5,FIG. 4L: 3-3F5,FIG. 4M: 10C5, andFIG. 4N: 9H5.

FIG. 5A-4N shows the results of an LC/MS assay measuring the inhibition of proteolysis of pro-KLK1 by recombinant KLK5 by monitoring the KLK5-derived cleavage product peptides. A pre-incubation of SPINK9.SRE.Fc, mAb1108 and 12 selected antibodies and KLK5 preceded a 20 minute incubation of 0.5 nM KLK5 with 300 nM pro-KLK1 (FIG. 5A-N). The results for the KLK5 inhibitors are depicted as follows:FIG. 5A: SPINK9.SRE.Fc,FIG. 5B: mAb1108,FIG. 5C: 10C8,FIG. 5D: 9B6,FIG. 5E: 2B11,FIG. 5F: 9F2,FIG. 5G: 2-3F4,FIG. 5H: 10H3,FIG. 5I: 9H3,FIG. 5J: 8B7,FIG. 5K: 8F5,FIG. 5L: 3-3F5,FIG. 5M: 10C5, andFIG. 5N: 9H5.

FIG. 6A-6N shows the Specificity of KLK5 inhibitors on KLK7 activity. 5 nM recombinant human KLK7 and 0.19-100 nM anti-KLK5 inhibitors were pre-incubated for 30 minutes prior to addition of 100 μM suc-LLVY-AMC. Plates were examined every 102 s for 75 minutes using a PHERAstar Plus reader using a 340 nm excitation/460 nm emission module. IC₅₀values are summarized in Table 6. The results for the KLK5 inhibitors are depicted as follows:FIG. 6A: Spink9.SRE.Fc,FIG. 6B: mAb1108,FIG. 6C: 3-3F5,FIG. 6D: 10C8,FIG. 6E: 9B6,FIG. 6F: 9F2,FIG. 6G: 9H3,FIG. 6H: 9H5,FIG. 6I: 2B11,FIG. 6J: 8B7,FIG. 6K: 8F5,FIG. 6L: 10C5,FIG. 6M: 10H3 andFIG. 6N: 2-3F4.

FIG. 7A-7N shows the specificity of KLK5 inhibitors on KLK1 activity. 3 nM recombinant human KLK1 and 0.19-100 nM anti-KLK5 inhibitors were pre-incubated for 30 minutes prior to addition of 100 μM PFR-AMC. Plates were examined every 102 s for 60 minutes using a PHERAstar® Plus reader using a 340 nm excitation/460 nm emission module. IC₅₀values are summarized in Table 7. The results for the KLK5 inhibitors are depicted as follows:FIG. 7A: Spink9.SRE.Fc,FIG. 7B: mAb1108,FIG. 7C: 3-3F5,FIG. 7D: 10C8,FIG. 7E: 9B6,FIG. 7F: 9F2,FIG. 7G: 9H3,FIG. 7H: 9H5,FIG. 7I: 8B7,FIG. 7J: 2B11,FIG. 7K: 8F5,FIG. 7L: 10C5,FIG. 7M: 10H3 andFIG. 7N: 2-3F4.

FIG. 8A-8N shows the specificity of KLK5 inhibitors on KLK4 activity. 2 nM recombinant human KLK4 and 0.19-100 nM anti-KLK5 inhibitors were pre-incubated for 30 minutes prior to addition of 50 μM Boc-VPR-AMC. Plates were examined every 102 s for 60 minutes using a PHERAstar® Plus reader using a 340 nm excitation/460 nm emission module. IC₅₀values are summarized in Table 8. The results for the KLK5 inhibitors are depicted as follows:FIG. 8A: Spink9.SRE.Fc,FIG. 8B: mAb1108,FIG. 8C: 3-3F5,FIG. 8D: 10C8,FIG. 8E: 9B6,FIG. 8F: 9F2,FIG. 8G: 9H3,FIG. 8H: 9H5,FIG. 8I: 8B7,FIG. 8J: 2B11,FIG. 8K: 8F5,FIG. 8L: 10C5,FIG. 8M: 10H3 andFIG. 8N: 2-3F4.

FIG. 9A-9N shows the specificity of KLK5 inhibitors on Trypsin activity. 0.25 nM trypsin isolated from bovine pancreas and 0.19-100 nM anti-KLK5 inhibitors were pre-incubated for 30 minutes prior to addition of 50 μM Boc-VPR-AMC. Plates were examined every 102 s for 60 minutes using a PHERAstar® Plus reader using a 340 nm excitation/460 nm emission module. IC₅₀values for selected antibodies (FIG. 9C-N) are summarized in Table 9. The results for the KLK5 inhibitors are depicted as follows:FIG. 9A: Spink9.SRE.Fc,FIG. 9B: mAb1108,FIG. 9C: 3-3F5,FIG. 9D: 10C8,FIG. 9E: 9B6,FIG. 9F: 9F2,FIG. 9G: 9H3,FIG. 9H: 9H5,FIG. 9I: 8B7,FIG. 9J: 2B11,FIG. 9K: 8F5,FIG. 9L: 10C5,FIG. 9M: 10H3 andFIG. 9N: 2-3F4.

FIG. 10A-10AB shows the analysis of KLK5 inhibitor potency by determination of Ki_app. KLK5 at various concentrations (0.5, 0.25, 0.125, and 0.0625 nM) and 0.0019-10 nM anti-KLK5 inhibitors were pre-incubated for 30 minutes prior to addition of 300 μM Z-VPR-pNA. Plates were read in a Versamax tunable microplate reader with measurements at 405 nm taken every 102 seconds for 3 hours. The derived Ki_appvalues are summarized in Table 10. The results for the KLK5 inhibitors are depicted as follows (respective left panels show IC₅₀values of KLK5 inhibitors at various KLK5 concentrations (0.5, 0.25, 0.125, and 0.0625 nM); respective right panels show IC₅₀values determined and plotted as a function of KLK5 concentration):FIG. 10A andFIG. 10B: Spink9.SRE.Fc,FIG. 10C andFIG. 10D: mAb1108,FIG. 10E andFIG. 10F: 3-3F5,FIG. 10G andFIG. 10H: 10C8,FIG. 10I andFIG. 10J: 9B6,FIG. 10K andFIG. 10L: 9F2,FIG. 10M andFIG. 10N: 9H3,FIG. 10O andFIG. 10P: 9H5,FIG. 10Q andFIG. 10R: 8B7,FIG. 10S andFIG. 10T: 2B11,FIG. 10U andFIG. 10V: 8F5,FIG. 10W andFIG. 10X: 10C5,FIG. 10Y andFIG. 10Z: 10H3,FIG. 10AA andFIG. 10AB: 2-3F4.

FIG. 11 shows a table summarizing the IC₅₀values as evaluated and shown inFIGS. 1-10.

FIGS. 12A and 12B.FIG. 12A shows sequence regions that are identified by hydrogen exchange measurements to be affected when in complex with each antibody, these sequence regions (underlined) are: region 1 (56-68, pH_exp8.0), region 2 (107-124, pH_exp6.0), region 3 (184-195, pH_exp8.0), region 4 (232-246, pH_exp6.0), effective time correction uses pH_ref=7.5.FIG. 12B shows the actual hydrogen exchange data for a representative peptide for each sequence region underlined inFIG. 12A.

FIGS. 13A and 13B.FIG. 13A shows alignment of the light chain variable sequences of anti-KLK5 antibody clones 14C8, 14E12, 8E11, 8G10, 9B6, 2-3F4, 10C5, 2B11, 10H3, 9H3, 8B7, 9H5, 9F2, 1008, 8F5, 3-3F5, 9E3, 10D10, 12B3, 1D10.FIG. 13B shows alignment of the heavy chain variable sequences of anti-KLK5 antibody clones 14C8, 14E12, 8E11, 8G10, 9B6, 2-3F4, 10C5, 2B11, 10H3, 9H3, 8B7, 9H5, 9F2, 1008, 8F5, 3-3F5, 9E3, 10D10, 12B3, 1D10. Shown are also the CDR regions according to Kabat numbering.

FIGS. 14A and 14B.FIG. 14A shows alignment of the light chain variable sequences of the anti-KLK5 antibody clone 10C5 and six humanized 10C5 clones.FIG. 14B shows alignment of the heavy chain variable sequences of the anti-KLK5 antibody clone 10C5 and 28 humanized 10C5 clones. The amino acid residues highlighted in black are the residues which were changed. Shown are also the CDR regions according to Kabat numbering.

FIGS. 15A and 15B.FIG. 15A shows alignment of the light chain variable sequences of the anti-KLK5 antibody clone 9H5 and four humanized 9H5 clones.FIG. 15B shows alignment of the heavy chain variable sequences of the anti-KLK5 antibody clone 9H5 and 17 humanized 9H5 clones. The amino acid residues highlighted in black are the residues which were changed. Shown are also the CDR regions according to Kabat numbering.

FIGS. 16A and 16B.FIG. 16A shows alignment of the light chain variable sequences of the anti-KLK5 antibody clone 3-3F5 and five humanized 3-3F5 clones.FIG. 16B shows alignment of the heavy chain variable sequences of the anti-KLK5 antibody clone 3-3F5 and 27 humanized 3-3F5 clones. The amino acid residues highlighted in black are the residues which were changed. Shown are also the CDR regions according to Kabat numbering.

FIG. 17 shows the evaluation of KLK5 inhibitors in the A549 cell-based IL-8 secretion assay. The KLK5-induced IL-8 secretion level (gray star) was set at 100% residual activity while the buffer (starvation media) alone (gray circle) was set at 0% residual activity. Dose response curves are shown for Spink5.Fc (black circle and dotted black line), humanized 3.3F5 (black diamond and solid black line) anti-KLK5 antibody, humanized 9H5 anti-KLK5 antibody (open gray square and solid gray line), and humanized 10C5 anti-KLK5 antibody (black open circle and dotted gray line). The data shown are the mean±standard deviation of at least three independent experiments.

FIGS. 18A and 18B.FIG. 18A shows an overlay of human KLK5 with KLK5-10C5 Fab complex.FIG. 18B shows the interface between human KLK5 and 10C5 Fab. The numbering of the amino acid residues of human KLK5 is based on the standard numbering for proteases. See Debela et al.,J Mol Biol,373, 1017-1031 (2007). The numbering of the amino acid residues of the Fab fragments is based on Kabat.

FIGS. 19A and 19B.FIG. 19A shows an overlay of human KLK5 with KLK5-9H5 Fab complex.FIG. 19B shows the interface between human KLK5 and 9H5 Fab. The numbering of the amino acid residues of human KLK5 is based on the standard numbering for proteases. The numbering of the amino acid residues of the Fab fragments is based on Kabat.

FIGS. 20A and 20B.FIG. 20A shows an overlay of human KLK5 with KLK5-3-3F5 Fab complex.FIG. 20B shows the interface between human KLK5 and 3-3F5 Fab. The numbering of the amino acid residues of human KLK5 is based on the standard numbering for proteases. The numbering of the amino acid residues of the Fab fragments is based on Kabat.

DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTIONI. Definitions

The terms “anti-KLK5 antibody” and “an antibody that binds to KLK5” refer to an antibody that is capable of binding KLK5 with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting KLK5. In some embodiments, the extent of binding of an anti-KLK5 antibody to an unrelated polypeptide (polypeptide other than KLK5) is less than about 10% of the binding of the antibody to KLK5 as measured, e.g., by a radioimmunoassay (RIA). In some embodiments, an antibody that binds to KLK5 has a dissociation constant (Kd) of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10⁻⁸M or less, e.g., from 10⁻⁸M to 10⁻¹³M, e.g., from 10⁻⁹M to 10⁻¹³M). In some embodiments, an antibody that binds to KLK5 has an IC₅₀value (concentration of an inhibitor, e.g. an antibody or fragment thereof, required to reduce the rate of an enzymatic reaction by 50%) of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10⁻⁸M or less, e.g., from 10⁻⁸M to 10⁻¹³M, e.g., from 10⁻⁹M to 10⁻¹³M). In some embodiments, an anti-KLK5 antibody binds to a binding region (e.g. an epitope) of KLK5 that is conserved among different species of KLK polypeptides.

The term “antibody” herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.

The term “isolated” as used in reference to antibody, binding polypeptide, polynucleotide or small molecule is one which has been separated from a component of its natural environment. In some embodiments, an antibody, binding polypeptide, polynucleotide or small molecule is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC). For review of methods for assessment of antibody purity, see, e.g., Flatman et al.,J. Chromatogr. B848:79-87 (2007).

The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same binding region (e.g., epitope), except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies described herein may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies.

A “blocking antibody” or an “antagonist antibody” is one which inhibits or reduces biological activity of the antigen it binds. Preferred blocking antibodies or antagonist antibodies substantially or completely inhibit the biological activity of the antigen.

The term “chimeric” antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.

The terms “full length antibody,” “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody (e.g., an anti-KLK5 antibody) having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region.

A “human antibody” is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.

A “humanized” antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In some embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A “humanized form” of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.

“Native antibodies” refer to naturally occurring immunoglobulin molecules with varying structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain. The light chain of an antibody may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.

The “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

An “antibody fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab′, Fab′-SH, F(ab′)₂; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multi specific antibodies formed from antibody fragments.

An “antibody that binds to the same epitope” or an “antibody that binds to the same binding region” as a reference antibody refers to an antibody that blocks binding of the reference antibody to its binding partner (e.g., an antigen) in a competition assay by 50% or more, and conversely, the reference antibody blocks binding of the antibody to its binding partner in a competition assay by 50% or more.

The term “thermodynamic epitope”, e.g. in the context of epitope mapping using hydrogen exchange mass spectrometry, refers to those portions of a protein whose backbone structural dynamics or local free energy of unfolding is altered in response to a specific binding event such as becoming bound by an antibody. The structural epitope may or may not be partially or entirely contained within the thermodynamic epitope.

The term “hypervariable region” or “HVR” as used herein refers to each of the regions of an antibody variable domain which are hypervariable in sequence (“complementarity determining regions” or “CDRs”) and/or form structurally defined loops (“hypervariable loops”) and/or contain the antigen-contacting residues (“antigen contacts”). Generally, antibodies comprise six HVRs: three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). Exemplary HVRs herein include:

(a) hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk,J. Mol. Biol.196:901-917 (1987));

(b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al.,Sequences of Proteins of Immunological Interest,5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991));

(c) antigen contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al.J. Mol. Biol.262: 732-745 (1996)); and

(d) combinations of (a), (b), and/or (c), including HVR amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3), and 94-102 (H3).

Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al., supra, e.g. as set out inFIGS. 13-16 as well as in the Table of Sequences herein below. Unless otherwise indicated, the CDRs are determined according to Kabat et al., supra.

The term “variable region” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to an antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). (See, e.g., Kindt et al.Kuby Immunology,6^thed., W.H. Freeman and Co., page 91 (2007).) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al.,J. Immunol.150:880-887 (1993); Clarkson et al.,Nature352:624-628 (1991).

The term “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al.,Sequences of Proteins of Immunological Interest,5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.

“Framework” or “FR” refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

An “acceptor human framework” for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework “derived from” a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.

A “human consensus framework” is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al.,Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda Md. (1991), vols. 1-3. In one embodiment, for the VL, the subgroup is subgroup kappa I as in Kabat et al., supra. In one embodiment, for the VH, the subgroup is subgroup III as in Kabat et al., supra.

“Affinity” or “Binding Affinity” refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., antibody, binding polypeptide, polynucleotide, small molecule) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., either of antibody, binding polypeptide, polynucleotide, small molecule and the antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described in the following.

An “affinity matured” antibody refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs), compared to a parent antibody which does not possess such alterations, such alterations resulting in an improvement in the affinity of the antibody for antigen.

A “binding region” is the portion of the binding partner (e.g., an antigen) to which a KLK5 antibody selectively binds. For a binding polypeptide binding partner, a linear binding region can be a peptide portion of about 4-15 (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15) amino acid residues. A non-linear, conformational binding region may comprise residues of a polypeptide sequence brought to close vicinity in the three-dimensional (3D) structure of the binding polypeptide binding partner.

“Effector functions” refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation.

The terms “KLK5” and “Kallikrein-5,” as used herein, refers to any native KLK5 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated. The term encompasses “full-length,” unprocessed KLK5 as well as any form of KLK5 that results from processing in the cell. The term also encompasses naturally occurring variants of KLK5, e.g., splice variants or allelic variants. In some embodiments, the amino acid sequence of an exemplary human KLK5 is UNIPROT Q9Y337. In some embodiments, the amino acid sequence of an exemplary human KLK5 is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8. In some embodiments, the amino acid sequence of an exemplary human KLK5 is amino acid residues 23-293 (minus signal peptide) of UNIPROT Q9Y337 (G55, D153 variant) and is shown in SEQ ID NO:2. In some embodiments, the amino acid sequence of an exemplary human KLK5 is amino acid residues 23-293 (minus signal peptide) of the G55, N153 variant shown in SEQ ID NO:4. In some embodiments, the amino acid sequence of an exemplary human KLK5 is amino acid residues 23-293 (minus signal peptide) of the R55, N153 variant shown in SEQ ID NO:6. In some embodiments, the amino acid sequence of an exemplary human KLK5 is amino acid residues 23-293 (minus signal peptide) of the R55, D153 variant shown in SEQ ID NO:8.

The terms “SPINK5” and “Serine protease inhibitor Kazal-type 5,” as used herein, refers to any native SPINK5 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated. The term encompasses “full-length,” unprocessed SPINK5 as well as any form of SPINK5 that result from processing in the cell. The term also encompasses naturally occurring variants of SPINK5, e.g., splice variants or allelic variants. In some embodiments, the amino acid sequence of an exemplary human SPINK5 is UNIPROT Q9NQ38 and is shown in SEQ ID NO:9. In some embodiments, the amino acid sequence of an exemplary human SPINK5 is amino acid residues 23-1064 (minus signal peptide) of UNIPROT Q9NQ38 and is shown in SEQ ID NO:10.

The term “SPINK fusion polypeptide” as used herein refers to a fusion polypeptide in which a SPINK polypeptide or a fragment thereof (e.g., certain domains of the SPINK polypeptide (e.g., SPINK5 and/or SPINK9) is linked, directly or indirectly, to another polypeptide (e.g., non-SPINK polypeptide).

The term “polypeptide” as used herein, refers to any native polypeptide of interest (e.g., KLK5, or SPINK5) from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated. The term encompasses “full-length,” unprocessed polypeptide as well as any form of the polypeptide that results from processing in the cell. The term also encompasses naturally occurring variants of the polypeptide, e.g., splice variants or allelic variants.

“Percent (%) amino acid sequence identity” with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, Calif., or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

100 times the fraction X/Y

where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

“Polynucleotide,” or “nucleic acid,” as used interchangeably herein, refer to polymers of nucleotides of any length, and include DNA and RNA. The nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and/or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase, or by a synthetic reaction. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and their analogs. If present, modification to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after synthesis, such as by conjugation with a label. Other types of modifications include, for example, “caps”, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), those containing pendant moieties, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, ply-L-lysine, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidative metals, etc.), those containing alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleotide(s). Further, any of the hydroxyl groups ordinarily present in the sugars may be replaced, for example, by phosphonate groups, phosphate groups, protected by standard protecting groups, or activated to prepare additional linkages to additional nucleotides, or may be conjugated to solid or semi-solid supports. The 5′ and 3′ terminal OH can be phosphorylated or substituted with amines or organic capping group moieties of from 1 to 20 carbon atoms. Other hydroxyls may also be derivatized to standard protecting groups. Polynucleotides can also contain analogous forms of ribose or deoxyribose sugars that are generally known in the art, including, for example, 2′-O-methyl-, 2′-O-allyl, 2′-fluoro- or 2′-azido-ribose, carbocyclic sugar analogs, α-anomeric sugars, epimeric sugars such as arabinose, xyloses or lyxoses, pyranose sugars, furanose sugars, sedoheptuloses, acyclic analogs and abasic nucleoside analogs such as methyl riboside. One or more phosphodiester linkages may be replaced by alternative linking groups. These alternative linking groups include, but are not limited to, embodiments wherein phosphate is replaced by P(O)S (“thioate”), P(S)S (“dithioate”), “(O)NR₂(“amidate”), P(O)R, P(O)OR′, CO or CH₂(“formacetal”), in which each R or R′ is independently H or substituted or unsubstituted alkyl (1-20 C) optionally containing an ether (—O—) linkage, aryl, alkenyl, cycloalkyl, cycloalkenyl or araldyl. Not all linkages in a polynucleotide need be identical. The preceding description applies to all polynucleotides referred to herein, including RNA and DNA.

An “isolated” polynucleotide or nucleic acid refers to a molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

“Isolated nucleic acid encoding an anti-KLK5 antibody” refers to one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a host cell.

The term “KLK5 genomic sequence” as used herein, refers to either the cDNA and/or the genomic form of the KLK5 gene, which may include introns as well as upstream and downstream regulatory sequences.

The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.

The term “vector,” as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as “expression vectors.”

A “reference sample”, “reference cell”, “reference tissue”, “control sample”, “control cell”, or “control tissue”, as used herein, refers to a sample, cell, tissue, standard, or level that is used for comparison purposes. In one embodiment, a reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from a healthy and/or non-diseased part of the body (e.g., tissue or cells) of the same subject. For example, healthy and/or non-diseased cells or tissue adjacent to the diseased cells or tissue (e.g., cells or tissue adjacent to a tumor). In another embodiment, a reference sample is obtained from an untreated tissue and/or cell of the body of the same subject. In yet another embodiment, a reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from a healthy and/or non-diseased part of the body (e.g., tissues or cells) of another subject. In even another embodiment, a reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from an untreated tissue and/or cell of the body of another subject.

The term “sample,” as used herein, refers to a formulation that is obtained or derived from a subject of interest that contains a cellular and/or other molecular entity that is to be characterized and/or identified, for example based on physical, biochemical, chemical and/or physiological characteristics. For example, the phrase “disease sample” and variations thereof refers to any sample obtained from a subject of interest that would be expected or is known to contain the cellular and/or molecular entity that is to be characterized. Samples include, but are not limited to, primary or cultured cells or cell lines, cell supernatants, cell lysates, platelets, serum, plasma, vitreous fluid, lymph fluid, synovial fluid, follicular fluid, seminal fluid, amniotic fluid, milk, whole blood, blood-derived cells, urine, cerebrospinal fluid, saliva, sputum, tears, perspiration, mucus, tumor lysates, and tissue culture medium, tissue extracts such as homogenized tissue, tumor tissue, cellular extracts, and combinations thereof.

By “tissue sample” or “cell sample” is meant a collection of similar cells obtained from a tissue of a subject. The source of the tissue or cell sample may be solid tissue as from a fresh, frozen and/or preserved organ, tissue sample, biopsy, and/or aspirate; blood or any blood constituents such as plasma; bodily fluids such as cerebral spinal fluid, amniotic fluid, peritoneal fluid, or interstitial fluid; cells from any time in gestation or development of the subject. The tissue sample may also be primary or cultured cells or cell lines. Optionally, the tissue or cell sample is obtained from a disease tissue/organ. The tissue sample may contain compounds which are not naturally intermixed with the tissue in nature such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, or the like.

An “effective amount” of an agent, e.g., a pharmaceutical formulation, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result.

A “subject” is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In some embodiments, the subject is a human.

The term “patient” as used herein, refers to an animal, such as a mammal. In one embodiment, patient refers to a human.

The term “pharmaceutical formulation” refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.

A “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.

“Treatment” (and variations such as “treat” or “treating”) refers to clinical intervention in an attempt to alter the natural course of the subject or cell being treated. Desirable effects of treatment include one or more of preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, stabilized (i.e., not worsening) state of disease, decreasing the rate of disease progression, amelioration or palliation of the disease state, prolonging survival as compared to expected survival if not receiving treatment and improved prognosis.

The term “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.

The use of the terms “a” and “an” and “the” and similar terms in the context of describing embodiments herein are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to”) unless otherwise noted. It is understood that aspects and embodiments provided herein include “consisting” and/or “consisting essentially of” aspects and embodiments.

As is understood by one skilled in the art, reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X”.

The phrase “substantially different,” refers to a sufficiently high degree of difference between two numeric values (generally one associated with a molecule and the other associated with a reference/comparator molecule) such that one of skill in the art would consider the difference between the two values to be of statistical significance within the context of the biological characteristic measured by said values (e.g., Kd values). The difference between said two values may be, for example, greater than about 10%, greater than about 20%, greater than about 30%, greater than about 40%, and/or greater than about 50% as a function of the value for the reference/comparator molecule.

II. Compositions and Methods

In some embodiments of any of the anti-KLK5 antibodies, the anti-KLK5 antibody substantially or completely inhibits binding of SPINK5 to KLK5. In some embodiments, binding of SPINK5 to KLK5 is inhibited by at least about any of 40%, 50%, 60%, 70%, 80%, 90% and/or more. In some embodiments, binding of SPINK5 to KLK5 is inhibited by about any of 40%, 50%, 60%, 70%, 80%, 90% and/or more. In some embodiments, binding of SPINK5 to KLK5 is inhibited by between any of 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, and/or 90-100%.

In some embodiments of any of the anti-KLK5 antibodies, the anti-KLK5 antibody has an IC₅₀value of less than about any of 1000 nM, 500 nM, 100 nM, 50 nM, 10 nM, 5 nM, 1 nM, 500 pM, 100 pM, 50 pM, 10 pM, 5 pM, and/or 1 pM. In some embodiments, the anti-KLK5 antibody has an IC₅₀value of less than any of 1000 nM, 500 nM, 100 nM, 50 nM, 10 nM, 5 nM, 1 nM, 500 pM, 100 pM, 50 pM, 10 pM, 5 pM, and/or 1 pM. In some embodiments, the anti-KLK5 antibody has an IC₅₀value of between about any of 50 μM-1 μM, 1-500 nM, 500 nM-100 nM, 100 nM-10 nM, 10 nM-1 nM, 1000 pM-500 pM, 500 pM-200 pM, 200 pM-150 pM, 150 pM-100 pM, 100 pM-10 pM, and/or 10 pM-1 pM.

A. Exemplary Anti-KLK5 Antibodies

Provided herein are isolated antibodies that bind to KLK5. In one embodiment, the antibody inhibits the biological activity of KLK5 by at least 50%. KLK5 is a (chymo)-trypsin-like serine proteases that is expressed in human skin, specifically in the upper spinous and granular layers of the skin. KLK5 is known to play pathological roles in skin disorders such as Netherton Syndrome.

An exemplary naturally occurring human KLK5 precursor protein sequence, with signal peptide (amino acids 1-22) is provided in SEQ ID NO:1. The corresponding mature KLK5 protein sequence corresponding to amino acids 23-293 of SEQ ID NO:1 is provided in SEQ ID NO:2. Exemplary variants of human KLK5 precursor proteins with signal peptides containing either one or both of the amino acid exchanges R55 and N153 are provided in SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, respectively.

In certain embodiments, an anti-KLK5 antibody has one or more of the following characteristics, in any combination:

- a) inhibits the biological activity of KLK5 by at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100%;
- b) inhibits the serine protease activity of KLK5;
- c) binds specifically to human KLK5;
- d) has an IC₅₀value of less than 10 nM, less than 5 nM, less than 3 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.1 nM; and/or
- e) has an IC₅₀value of less than 500 pM, less than 200 pM, less than 100 pM, less than 50 pM, less than 25 pM, less than 10 pM, less than 5 pM, less than 1 pM.

Antibody 8G10, 9B6, 2-3F4, 10C5, 2B11, 10H3, 9H3, 8B7, 9H5, 9F2, 1008, 8F5, 3-3F5 and Other Embodiments

In one aspect, an anti-KLK5 antibody is provided comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence selected from any one of SEQ ID NOs:14-24; (b) HVR-H2 comprising the amino acid sequence selected from any one of SEQ ID NOs:32-53; (c) HVR-H3 comprising the amino acid sequence selected from any one of SEQ ID NOs:62-72; (d) HVR-L1 comprising the amino acid sequence selected from any one of SEQ ID NOs:79-91; (e) HVR-L2 comprising the amino acid sequence selected from any one of SEQ ID NOs:99-106; and (f) HVR-L3 comprising the amino acid sequence selected from any one of SEQ ID NOs:112-122.

In another aspect, an anti-KLK5 antibody is provided comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence selected from any one of SEQ ID NOs:79-91; (b) HVR-L2 comprising the amino acid sequence selected from any one of SEQ ID NOs:99-106; and (c) HVR-L3 comprising the amino acid sequence selected from any one of SEQ ID NOs:112-122. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence selected from any one of SEQ ID NOs:79-91; (b) HVR-L2 comprising the amino acid sequence selected from any one of SEQ ID NOs:99-106; and (c) HVR-L3 comprising the amino acid sequence selected from any one of SEQ ID NOs:112-122.

In another aspect, an anti-KLK5 antibody is provided comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence selected from any one of SEQ ID NOs:14-24, (ii) HVR-H2 comprising the amino acid sequence selected from any one of SEQ ID NOs:32-53, and (iii) HVR-H3 comprising the amino acid sequence selected from any one of SEQ ID NOs:62-72; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence selected from any one of SEQ ID NOs:79-91, (ii) HVR-L2 comprising the amino acid sequence selected from any one of SEQ ID NOs:99-106, and (c) HVR-L3 comprising the amino acid sequence selected from any one of SEQ ID NOs:112-122.

In another aspect, an anti-KLK5 antibody is provided comprising (a) HVR-H1 comprising the amino acid sequence selected from any one of SEQ ID NOs:14-24; (b) HVR-H2 comprising the amino acid sequence selected from any one of SEQ ID NOs:32-53; (c) HVR-H3 comprising the amino acid sequence selected from any one of SEQ ID NOs:62-72; (d) HVR-L1 comprising the amino acid sequence selected from any one of SEQ ID NOs:79-91; (e) HVR-L2 comprising the amino acid sequence selected from any one of SEQ ID NOs:99-106; and (f) HVR-L3 comprising the amino acid sequence selected from any one of SEQ ID NOs:112-122.

In any of the above embodiments, an anti-KLK5 antibody is humanized. In one embodiment, an anti-KLK5 antibody comprises HVRs as in any of the above embodiments, and further comprises an acceptor human framework, e.g. a human immunoglobulin framework or a human consensus framework.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence selected from any one of SEQ ID NO:170-257. In certain embodiments, a VH sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence selected from any one of SEQ ID NO:170-257 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in any one of SEQ ID NO:170-257. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VH sequence selected from any one of SEQ ID NO:170-257, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence selected from any one of SEQ ID NOs:14-24; (b) HVR-H2 comprising the amino acid sequence selected from any one of SEQ ID NOs:32-53; (c) HVR-H3 comprising the amino acid sequence selected from any one of SEQ ID NOs:62-72.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence selected from any one of SEQ ID NO:131-161. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence selected from any one of SEQ ID NO:131-162 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in the amino acid sequence selected from any one of SEQ ID NO:131-162. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VL sequence of the amino acid sequence selected from any one of SEQ ID NO:131-162, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence selected from any one of SEQ ID NOs:79-91; (b) HVR-L2 comprising the amino acid sequence selected from any one of SEQ ID NOs:99-106; and (c) HVR-L3 comprising the amino acid sequence selected from any one of SEQ ID NOs:112-122.

In a further aspect, an anti-KLK5 antibody is provided that binds to the same epitope as an anti-KLK5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-KLK5 antibody comprising a VH sequence of the amino acid sequence selected from any one of SEQ ID NO:170-257. In certain embodiments, an antibody is provided that, when bound to KLK5 results in a thermodynamic epitope comprising one or more of the sequences selected from the group consisting of SEQ ID NO:316, SEQ ID NO:317, SEQ ID NO:318, and SEQ ID NO:319 as measured by hydrogen exchange mass spectrometry.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a HC sequence of the amino acid sequence selected from any one of SEQ ID NO:288-306. In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a LC sequence of the amino acid sequence selected from any one of SEQ ID NO:265-280.

Provided herein are antibodies comprising a light chain variable domain comprising the HVR1-LC, HVR2-LC and HVR3-LC sequence according to Kabat numbering as depicted inFIGS. 14A, 15A and/or 16A and a heavy chain variable domain comprising the HVR1-HC, HVR2-HC and HVR3-HC sequence according to Kabat numbering as depicted inFIGS. 14B, 15B and/or 16B. In some embodiments, the antibody comprises a light chain variable domain comprising the HVR1-LC, HVR2-LC and/or HVR3-LC sequence, and the FR1-LC, FR2-LC, FR3-LC and/or FR4-LC sequence as depicted inFIGS. 14A, 15A and/or 16A. In some embodiments, the antibody comprises a heavy chain variable domain comprising the HVR1-HC, HVR2-HC and/or HVR3-HC sequence, and the FR1-HC, FR2-HC, FR3-HC and/or FR4-HC sequence as depicted inFIGS. 14B, 15B and/or 16B.

In a further aspect, an anti-KLK5 antibody is provided that binds to the same epitope as an anti-KLK5 antibody provided herein.

In a further aspect, an anti-KLK5 antibody is provided that, when bound to KLK5 results in a thermodynamic epitope comprising one or more of the sequences selected from the group consisting of SEQ ID NO:316, SEQ ID NO:317, SEQ ID NO:318, and SEQ ID NO:319 as measured by hydrogen exchange mass spectrometry.

In a further aspect, an anti-KLK5 antibody according to any of the above embodiments is a monoclonal antibody, including a chimeric, humanized or human antibody. In one embodiment, an anti-KLK5 antibody is humanized. In one embodiment, an anti-KLK5 antibody comprises HVRs as in any of the above embodiments, and further comprises an acceptor human framework, e.g. a human immunoglobulin framework or a human consensus framework. In one embodiment, an anti-KLK5 antibody is an antibody fragment, e.g., a Fv, Fab, Fab′, scFv, diabody, or F(ab′)₂fragment. In another embodiment, the antibody is a full length antibody, e.g an intact IgG1 antibody or an intact IgG4 antibody or other antibody class or isotype as defined herein.

In a further aspect, an anti-KLK5 antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described below.

Antibody 10C5, 9H5, 3-3F5 and Other Embodiments

In one aspect, an anti-KLK5 antibody is provided comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:28; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:38, SEQ ID NO:45, or SEQ ID NO:54; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:65, SEQ ID NO:69, or SEQ ID NO:72; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:96; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:109; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:127.

In one aspect, an anti-KLK5 antibody is provided comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:17, SEQ ID NO:22, or SEQ ID NO:24; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, or SEQ ID NO:53; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:65, SEQ ID NO:69, or SEQ ID NO:72; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:82, SEQ ID NO:87, or SEQ ID NO:91; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99, SEQ ID NO:101, or SEQ ID NO:105; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:115, SEQ ID NO:119, or SEQ ID NO:122.

In another aspect, an anti-KLK5 antibody is provided comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:82, SEQ ID NO:87, or SEQ ID NO:91; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99, SEQ ID NO:101, or SEQ ID NO:105; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:115, SEQ ID NO:119, or SEQ ID NO:122.

In another aspect, an anti-KLK5 antibody is provided comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:35, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:65; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:82, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:101, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:115.

In another aspect, an anti-KLK5 antibody is provided comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:35; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:65; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:82; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:101; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:115.

In another aspect, an anti-KLK5 antibody is provided comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:42, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:69; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:87, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:119.

In another aspect, an anti-KLK5 antibody is provided comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:42; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:69; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:87; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:119.

In another aspect, an anti-KLK5 antibody is provided comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:24, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:52, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:72; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:91, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:122.

In another aspect, an anti-KLK5 antibody is provided comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:24; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:52; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:72; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:91; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:122.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence having SEQ ID NO:202. In another aspect, an anti-KLK5 antibody is provided comprising a light chain variable domain (VL) sequence having SEQ ID NO:140.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence selected from any one of SEQ ID NOs:173-201. In another aspect, an anti-KLK5 antibody is provided comprising a light chain variable domain (VL) sequence selected from any one of SEQ ID NOs:134-139 and SEQ ID NO:321.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:201. In certain embodiments, a VH sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:201. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VH sequence in SEQ ID NO:201, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:17, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:35, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:65.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:139. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:139. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VL sequence in SEQ ID NO:139, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:82; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:101; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:115.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:201 and SEQ ID NO:139, respectively, including post-translational modifications of those sequences.

In a further aspect, an anti-KLK5 antibody is provided that binds to the same epitope as an anti-KLK5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-KLK5 antibody comprising a VH sequence of SEQ ID NO:201 and a VL sequence of SEQ ID NO:139. In certain embodiments, an antibody is provided that, when bound to KLK5 results in a thermodynamic epitope comprising one or more of the sequences selected from the group consisting of SEQ ID NO:316, SEQ ID NO:317, SEQ ID NO:318, and SEQ ID NO:319 as measured by hydrogen exchange mass spectrometry.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence having SEQ ID NO:225. In another aspect, an anti-KLK5 antibody is provided comprising a light chain variable domain (VL) sequence having SEQ ID NO:151.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence selected from any one of SEQ ID NOs:207-224. In another aspect, an anti-KLK5 antibody is provided comprising a light chain variable domain (VL) sequence selected from any one of SEQ ID NOs:145-150.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:221. In certain embodiments, a VH sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:221. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VH sequence in SEQ ID NO:221, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:42, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:69.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:149. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:149. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VL sequence in SEQ ID NO:149, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:87; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:119.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:221 and SEQ ID NO:149, respectively, including post-translational modifications of those sequences.

In a further aspect, an anti-KLK5 antibody is provided that binds to the same epitope as an anti-KLK5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-KLK5 antibody comprising a VH sequence of SEQ ID NO:221 and a VL sequence of SEQ ID NO:149. In certain embodiments, an antibody is provided that, when bound to KLK5 results in a thermodynamic epitope comprising one or more of the sequences selected from the group consisting of SEQ ID NO:316, SEQ ID NO:317, SEQ ID NO:318, and SEQ ID NO:319 as measured by hydrogen exchange mass spectrometry.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence having SEQ ID NO:257. In another aspect, an anti-KLK5 antibody is provided comprising a light chain variable domain (VL) sequence having SEQ ID NO:162.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence selected from any one of SEQ ID NOs:229-256. In another aspect, an anti-KLK5 antibody is provided comprising a light chain variable domain (VL) sequence selected from any one of SEQ ID NOs:155-161.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:248. In certain embodiments, a VH sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:248. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VH sequence in SEQ ID NO:248, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:24, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:52, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:72.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:160. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:160. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VL sequence in SEQ ID NO:160, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:91; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:122.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:248 and SEQ ID NO:160, respectively, including post-translational modifications of those sequences.

In a further aspect, an anti-KLK5 antibody is provided that binds to the same epitope as an anti-KLK5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-KLK5 antibody comprising a VH sequence of SEQ ID NO:248 and a VL sequence of SEQ ID NO:160.

In a further aspect, an anti-KLK5 antibody according to any of the above embodiments is a monoclonal antibody, including a chimeric, humanized or human antibody. In one embodiment, an anti-KLK5 antibody is humanized. In one embodiment, an anti-KLK5 antibody comprises HVRs as in any of the above embodiments, and further comprises an acceptor human framework, e.g. a human immunoglobulin framework or a human consensus framework.

In one embodiment, an anti-KLK5 antibody is an antibody fragment, e.g., a Fv, Fab, Fab′, scFv, diabody, or F(ab′)2 fragment. In another embodiment, the antibody is a full length antibody, e.g an intact IgG1 antibody or an intact IgG4 antibody or other antibody class or isotype as defined herein.

Antibody 8G10 and Other Embodiments

In one aspect, an anti-KLK5 antibody is provided comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:14; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:32; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:62; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:79; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:112.

In another aspect, an anti-KLK5 antibody is provided comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:79; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:112. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:79; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:112.

In another aspect, an anti-KLK5 antibody is provided comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:14, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:32, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:62; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:79, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:112.

In another aspect, an anti-KLK5 antibody is provided comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:14; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:32; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:62; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:79; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:112.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:170. In certain embodiments, a VH sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:170. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VH sequence in SEQ ID NO:170, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:14, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:32, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:62.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:131. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:131. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VL sequence in SEQ ID NO:131, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:79; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:112.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:170 and SEQ ID NO:131, respectively, including post-translational modifications of those sequences.

In a further aspect, an anti-KLK5 antibody is provided that binds to the same epitope as an anti-KLK5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-KLK5 antibody comprising a VH sequence of SEQ ID NO:170 and a VL sequence of SEQ ID NO:131.

Antibody 9B6 and Other Embodiments

In one aspect, an anti-KLK5 antibody is provided comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:15; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:80; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:100; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:113.

In another aspect, an anti-KLK5 antibody is provided comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:80; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:100; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:113. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:80; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:100; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:113.

In another aspect, an anti-KLK5 antibody is provided comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:15, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:33, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:80, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:100, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:113.

In another aspect, an anti-KLK5 antibody is provided comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:15; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:80; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:100; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:113.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:171. In certain embodiments, a VH sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:171. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VH sequence in SEQ ID NO:171, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:15, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:33, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:63.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:132. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:132. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VL sequence in SEQ ID NO:132, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:80; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:100; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:113.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:171 and SEQ ID NO:132, respectively, including post-translational modifications of those sequences.

In a further aspect, an anti-KLK5 antibody is provided that binds to the same epitope as an anti-KLK5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-KLK5 antibody comprising a VH sequence of SEQ ID NO:171 and a VL sequence of SEQ ID NO:132.

Antibody 2-3F4 and Other Embodiments

In one aspect, an anti-KLK5 antibody is provided comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:16; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:34; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:64; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:81; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:114.

In another aspect, an anti-KLK5 antibody is provided comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:81; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:114. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:81; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:114.

In another aspect, an anti-KLK5 antibody is provided comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:16, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:34, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:64; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:81, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:114.

In another aspect, an anti-KLK5 antibody is provided comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:16; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:34; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:64; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:81; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:114.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:172. In certain embodiments, a VH sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:172. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VH sequence in SEQ ID NO:172, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:16, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:34, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:64.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:133. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:133. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VL sequence in SEQ ID NO:133, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:81; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:114.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:172 and SEQ ID NO:133, respectively, including post-translational modifications of those sequences.

In a further aspect, an anti-KLK5 antibody is provided that binds to the same epitope as an anti-KLK5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-KLK5 antibody comprising a VH sequence of SEQ ID NO:172 and a VL sequence of SEQ ID NO:133.

Antibody 10C5 and Other Embodiments

In one aspect, an anti-KLK5 antibody is provided comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:35; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:65; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:82; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:101; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:115.

In another aspect, an anti-KLK5 antibody is provided comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:82; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:101; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:115. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:82; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:101; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:115.

In one embodiment, the anti-KLK5 antibody comprises a VH domain comprising one or more heavy chain framework sequences selected from (a) a heavy chain frame work region 1 (HC-FR1) of SEQ ID NO:333, (b) a heavy chain frame work region 2 (HC-FR2) of SEQ ID NO:334, (c) a heavy chain frame work region 3 (HC-FR3) of SEQ ID NO:335, and (d) a heavy chain frame work region 4 (HC-FR4) of SEQ ID NO:336.

In one embodiment, the anti-KLK5 antibody comprises a VH domain comprising a HC-FR1 of SEQ ID NO:333. In one embodiment, the anti-KLK5 antibody comprises a VH domain comprising a HC-FR2 of SEQ ID NO:334. In one embodiment, the anti-KLK5 antibody comprises a VH domain comprising a HC-FR3 of SEQ ID NO:335. In one embodiment, the anti-KLK5 antibody comprises a VH domain comprising a HC-FR4 of SEQ ID NO:336.

In one embodiment, the anti-KLK5 antibody comprises a VL domain comprising one or more light chain framework sequences selected from (a) a light chain frame work region 1 (LC-FR1) of SEQ ID NO:329, (b) a light chain frame work region 2 (LC-FR2) of SEQ ID NO:330, (c) a light chain frame work region 3 (LC-FR3) of SEQ ID NO:331, and (d) a light chain frame work region 4 (LC-FR4) of SEQ ID NO:332.

In one embodiment, the anti-KLK5 antibody comprises a VL domain comprising a LC-FR1 of SEQ ID NO:329. In one embodiment, the anti-KLK5 antibody comprises a VL domain comprising a LC-FR2 of SEQ ID NO:330. In one embodiment, the anti-KLK5 antibody comprises a VL domain comprising a LC-FR3 of SEQ ID NO:331. In one embodiment, the anti-KLK5 antibody comprises a VL domain comprising a LC-FR4 of SEQ ID NO:332.

Further provided herein is an antibody that specifically binds to human KLK5, wherein the antibody binds to an epitope on human KLK5 comprising one or more amino acid residues selected from the group consisting of Pro130, Ser131, Ala132, Val162, Leu163, Ser164, Gln165, Lys166, Arg167, Glu169, Asp170, Ala171, Tyr172, Pro173, Arg174, Gln174A, Ile176, Asp177, Asp178, Arg224, and Lys233 according to standard protease numbering. In one embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:35; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:65; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:82; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:101; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:115. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:201 and SEQ ID NO:139

Further provided herein is an antibody when bound to human KLK5 results in a conformational change of human KLK5, wherein the conformational change allosterically results in the disruption of the substrate binding site and/or the active site of human KLK5. In one embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:35; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:65; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:82; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:101; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:115. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:201 and SEQ ID NO:139.

Antibody 2B11 and Other Embodiments

In one aspect, an anti-KLK5 antibody is provided comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:18; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:66; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:83; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:102; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:116.

In another aspect, an anti-KLK5 antibody is provided comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:83; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:102; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:116. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:83; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:102; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:116.

In another aspect, an anti-KLK5 antibody is provided comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:18, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:66; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:83, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:102, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:116.

In another aspect, an anti-KLK5 antibody is provided comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:18; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:66; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:83; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:102; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:116.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:203. In certain embodiments, a VH sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:203. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VH sequence in SEQ ID NO:203, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:18, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:66.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:141. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:141. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VL sequence in SEQ ID NO:141, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:83; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:102; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:116.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:203 and SEQ ID NO:141, respectively, including post-translational modifications of those sequences.

In a further aspect, an anti-KLK5 antibody is provided that binds to the same epitope as an anti-KLK5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-KLK5 antibody comprising a VH sequence of SEQ ID NO:203 and a VL sequence of SEQ ID NO:141.

Antibody 10H3 and Other Embodiments

In one aspect, an anti-KLK5 antibody is provided comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:19; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:40; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:67; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:84; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:103; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:117.

In another aspect, an anti-KLK5 antibody is provided comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:84; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:103; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:117. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:84; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:103; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:117.

In another aspect, an anti-KLK5 antibody is provided comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:19, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:40, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:67; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:84, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:103, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:117.

In another aspect, an anti-KLK5 antibody is provided comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:19; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:40; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:67; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:84; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:103; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:117.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:204. In certain embodiments, a VH sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:204. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VH sequence in SEQ ID NO:204, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:40, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:67.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:142. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:142. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VL sequence in SEQ ID NO:142, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:84; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:103; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:117.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:204 and SEQ ID NO:142, respectively, including post-translational modifications of those sequences.

In a further aspect, an anti-KLK5 antibody is provided that binds to the same epitope as an anti-KLK5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-KLK5 antibody comprising a VH sequence of SEQ ID NO:204 and a VL sequence of SEQ ID NO:142. In certain embodiments, an antibody is provided that, when bound to KLK5 results in a thermodynamic epitope comprising one or more of the sequences selected from the group consisting of SEQ ID NO:316, SEQ ID NO:317, SEQ ID NO:318, and SEQ ID NO:319 as measured by hydrogen exchange mass spectrometry.

Antibody 9H3 and Other Embodiments

In one aspect, an anti-KLK5 antibody is provided comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:20; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:68; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:85; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:103; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118.

In another aspect, an anti-KLK5 antibody is provided comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:85; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:103; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:85; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:103; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118.

In another aspect, an anti-KLK5 antibody is provided comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:20, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:33, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:68; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:85, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:103, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118.

In another aspect, an anti-KLK5 antibody is provided comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:20; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:68; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:85; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:103; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:205. In certain embodiments, a VH sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:205. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VH sequence in SEQ ID NO:205, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:20, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:33, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:68.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:143. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:143. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VL sequence in SEQ ID NO:143, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:85; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:103; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:205 and SEQ ID NO:1143, respectively, including post-translational modifications of those sequences.

In a further aspect, an anti-KLK5 antibody is provided that binds to the same epitope as an anti-KLK5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-KLK5 antibody comprising a VH sequence of SEQ ID NO:205 and a VL sequence of SEQ ID NO:143.

In one embodiment, an anti-KLK5 antibody is an antibody fragment, e.g., a Fv, Fab, Fab′, scFv, diabody, or F(ab′)₂fragment. In another embodiment, the antibody is a full length antibody, e.g an intact IgG1 antibody or an intact IgG4 antibody or other antibody class or isotype as defined herein.

Antibody 8B7 and Other Embodiments

In one aspect, an anti-KLK5 antibody is provided comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:21; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:41; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:69; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:86; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:104; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118.

In another aspect, an anti-KLK5 antibody is provided comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:86; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:104; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:86; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:104; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118.

In another aspect, an anti-KLK5 antibody is provided comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:21, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:41, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:69; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:86, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:104, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118.

In another aspect, an anti-KLK5 antibody is provided comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:21; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:41; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:69; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:86; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:104; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:206. In certain embodiments, a VH sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:206. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VH sequence in SEQ ID NO:206, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:21, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:41, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:69.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:144. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:144. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VL sequence in SEQ ID NO:144, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:86; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:104; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:206 and SEQ ID NO:144, respectively, including post-translational modifications of those sequences.

In a further aspect, an anti-KLK5 antibody is provided that binds to the same epitope as an anti-KLK5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-KLK5 antibody comprising a VH sequence of SEQ ID NO:206 and a VL sequence of SEQ ID NO:144.

Antibody 9H5 and Other Embodiments

In one aspect, an anti-KLK5 antibody is provided comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:42; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:69; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:87; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:119.

In another aspect, an anti-KLK5 antibody is provided comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:87; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:119. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:87; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:119.

In one embodiment, the anti-KLK5 antibody comprises a VH domain comprising one or more heavy chain framework sequences selected from (a) a heavy chain frame work region 1 (HC-FR1) of SEQ ID NO:341, (b) a heavy chain frame work region 2 (HC-FR2) of SEQ ID NO:342, (c) a heavy chain frame work region 3 (HC-FR3) of SEQ ID NO:343, and (d) a heavy chain frame work region 4 (HC-FR4) of SEQ ID NO:344.

In one embodiment, the anti-KLK5 antibody comprises a VH domain comprising a HC-FR1 of SEQ ID NO:341. In one embodiment, the anti-KLK5 antibody comprises a VH domain comprising a HC-FR2 of SEQ ID NO:342. In one embodiment, the anti-KLK5 antibody comprises a VH domain comprising a HC-FR3 of SEQ ID NO:343. In one embodiment, the anti-KLK5 antibody comprises a VH domain comprising a HC-FR4 of SEQ ID NO:344.

In one embodiment, the anti-KLK5 antibody comprises a VL domain comprising one or more light chain framework sequences selected from (a) a light chain frame work region 1 (LC-FR1) of SEQ ID NO:337, (b) a light chain frame work region 2 (LC-FR2) of SEQ ID NO:338, (c) a light chain frame work region 3 (LC-FR3) of SEQ ID NO:339, and (d) a light chain frame work region 4 (LC-FR4) of SEQ ID NO:340.

In one embodiment, the anti-KLK5 antibody comprises a VL domain comprising a LC-FR1 of SEQ ID NO:337. In one embodiment, the anti-KLK5 antibody comprises a VL domain comprising a LC-FR2 of SEQ ID NO:338. In one embodiment, the anti-KLK5 antibody comprises a VL domain comprising a LC-FR3 of SEQ ID NO:339. In one embodiment, the anti-KLK5 antibody comprises a VL domain comprising a LC-FR4 of SEQ ID NO:340.

Further provided herein is an antibody that specifically binds to human KLK5, wherein the antibody binds to an epitope on human KLK5 comprising one or more amino acid residues selected from the group consisting of Pro130, Ser131, Ala132, Gly133, Val162, Leu163, Ser164, Gln165, Lys166, Arg167, Glu169, Asp170, Ala171, Tyr172, Pro173, Arg174, Gln174A, Ile176, Asp177, and Lys233 according to standard protease numbering. In one embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:42; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:69; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:87; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:119. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:221 and SEQ ID NO:149.

Further provided herein is an antibody when bound to human KLK5 results in a conformational change of human KLK5, wherein the conformational change allosterically results in the disruption of the substrate binding site and/or the active site of human KLK5. In one embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:42; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:69; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:87; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:119. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:221 and SEQ ID NO:149.

Antibody 9F2 and Other Embodiments

In one aspect, an anti-KLK5 antibody is provided comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:46; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:69; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:88; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:120.

In another aspect, an anti-KLK5 antibody is provided comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:88; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:120. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:88; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:120.

In another aspect, an anti-KLK5 antibody is provided comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:46, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:69; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:88, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:120.

In another aspect, an anti-KLK5 antibody is provided comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:46; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:69; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:88; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:120.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:226. In certain embodiments, a VH sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:226. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VH sequence in SEQ ID NO:226, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:46, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:69.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:152. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:152. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VL sequence in SEQ ID NO:152, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:88; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:120.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:226 and SEQ ID NO:152, respectively, including post-translational modifications of those sequences.

In a further aspect, an anti-KLK5 antibody is provided that binds to the same epitope as an anti-KLK5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-KLK5 antibody comprising a VH sequence of SEQ ID NO:226 and a VL sequence of SEQ ID NO:152.

Antibody 1008 and Other Embodiments

In one aspect, an anti-KLK5 antibody is provided comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:42; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:70; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:89; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118.

In another aspect, an anti-KLK5 antibody is provided comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:89; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:89; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118.

In another aspect, an anti-KLK5 antibody is provided comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:42, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:70; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:89, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118.

In another aspect, an anti-KLK5 antibody is provided comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:42; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:70; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:89; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:227. In certain embodiments, a VH sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:227. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VH sequence in SEQ ID NO:227, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:42, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:70.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:153. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:153. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VL sequence in SEQ ID NO:153, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:89; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:105; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:118.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:227 and SEQ ID NO:153, respectively, including post-translational modifications of those sequences.

In a further aspect, an anti-KLK5 antibody is provided that binds to the same epitope as an anti-KLK5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-KLK5 antibody comprising a VH sequence of SEQ ID NO:227 and a VL sequence of SEQ ID NO:153.

Antibody 8F5 and Other Embodiments

In one aspect, an anti-KLK5 antibody is provided comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:23; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:47; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:71; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:90; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:106; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:121.

In another aspect, an anti-KLK5 antibody is provided comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:90; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:106; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:121. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:90; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:106; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:121.

In another aspect, an anti-KLK5 antibody is provided comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:23, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:47, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:71; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:90, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:106, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:121.

In another aspect, an anti-KLK5 antibody is provided comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:23; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:47; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:71; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:90; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:106; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:121.

In another aspect, an anti-KLK5 antibody is provided comprising a heavy chain variable domain (VH) sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:228. In certain embodiments, a VH sequence having at least any of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:228. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VH sequence in SEQ ID NO:228, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:23, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:47, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:71.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:154. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-KLK5 antibody comprising that sequence retains the ability to bind to KLK5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO:154. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-KLK5 antibody comprises the VL sequence in SEQ ID NO:154, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:90; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:106; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:121.

In another aspect, an anti-KLK5 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:228 and SEQ ID NO:154, respectively, including post-translational modifications of those sequences.

In a further aspect, an anti-KLK5 antibody is provided that binds to the same epitope as an anti-KLK5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-KLK5 antibody comprising a VH sequence of SEQ ID NO:228 and a VL sequence of SEQ ID NO:154.

Antibody 3-3F5 and Other Embodiments

In one aspect, an anti-KLK5 antibody is provided comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:24; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:52; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:72; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:91; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:122.

In another aspect, an anti-KLK5 antibody is provided comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:91; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:122. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:91; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:122.

In another aspect, an anti-KLK5 antibody is provided comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:24 (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:52; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:72; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:91; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:122.

In one embodiment, the anti-KLK5 antibody comprises a VH domain comprising one or more heavy chain framework sequences selected from (a) a heavy chain frame work region 1 (HC-FR1) of SEQ ID NO:349, (b) a heavy chain frame work region 2 (HC-FR2) of SEQ ID NO:350, (c) a heavy chain frame work region 3 (HC-FR3) of SEQ ID NO:351, and (d) a heavy chain frame work region 4 (HC-FR4) of SEQ ID NO:352.

In one embodiment, the anti-KLK5 antibody comprises a VH domain comprising a HC-FR1 of SEQ ID NO:349. In one embodiment, the anti-KLK5 antibody comprises a VH domain comprising a HC-FR2 of SEQ ID NO:350. In one embodiment, the anti-KLK5 antibody comprises a VH domain comprising a HC-FR3 of SEQ ID NO:351. In one embodiment, the anti-KLK5 antibody comprises a VH domain comprising a HC-FR4 of SEQ ID NO:352.

In one embodiment, the anti-KLK5 antibody comprises a VL domain comprising one or more light chain framework sequences selected from (a) a light chain frame work region 1 (LC-FR1) of SEQ ID NO:345, (b) a light chain frame work region 2 (LC-FR2) of SEQ ID NO:346, (c) a light chain frame work region 3 (LC-FR3) of SEQ ID NO:347, and (d) a light chain frame work region 4 (LC-FR4) of SEQ ID NO:348.

In one embodiment, the anti-KLK5 antibody comprises a VL domain comprising a LC-FR1 of SEQ ID NO:345. In one embodiment, the anti-KLK5 antibody comprises a VL domain comprising a LC-FR2 of SEQ ID NO:346. In one embodiment, the anti-KLK5 antibody comprises a VL domain comprising a LC-FR3 of SEQ ID NO:347. In one embodiment, the anti-KLK5 antibody comprises a VL domain comprising a LC-FR4 of SEQ ID NO:348.

Further provided herein is an antibody that specifically binds to human KLK5, wherein the antibody binds to an epitope on human KLK5 comprising one or more amino acid residues selected from the group consisting of Ser131, Ala132, Gly133, Leu163, Ser164, Gln165, Lys166, Arg167, Glu169, Asp170, Ala171, Pro173, Arg174, Gly184, Asp185, Lys186, Ala186A, Arg188, Asn223, Arg224, and Pro225 according to standard protease numbering. In one embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:24 (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:52; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:72; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:91; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:122. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:248 and SEQ ID NO:160.

Further provided herein is an antibody when bound to human KLK5 results in a conformational change of human KLK5, wherein the conformational change allosterically results in the disruption of the substrate binding site and/or the active site of human KLK5. In one embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:24 (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:52; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:72; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:91; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:99; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:122. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:248 and SEQ ID NO:160.

2. Antibody Affinity

In some embodiments of any of the anti-KLK5 antibodies, the anti-KLK5 antibody has a binding affinity (dissociation constant Kd) to KLK5 of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g. 10⁻⁸M or less, e.g. from 10⁻⁸M to 10⁻¹³M, e.g., from 10⁻⁹M to 10⁻¹³M).

In one embodiment, Kd is measured by a radiolabeled antigen binding assay (RIA). In one embodiment, an RIA is performed with the Fab version of an antibody of interest and its antigen. For example, solution binding affinity of Fabs for antigen is measured by equilibrating Fab with a minimal concentration of (¹²⁵I)-labeled antigen in the presence of a titration series of unlabeled antigen, then capturing bound antigen with an anti-Fab antibody-coated plate (see, e.g., Chen et al.,J. Mol. Biol.293:865-881(1999)). To establish conditions for the assay, MICROTITER® multi-well plates (Thermo Scientific) are coated overnight with 5 μg/ml of a capturing anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), and subsequently blocked with 2% (w/v) bovine serum albumin in PBS for two to five hours at room temperature (approximately 23° C.). In a non-adsorbent plate (Nunc #269620), 100 pM or 26 pM [¹²⁵I]-antigen are mixed with serial dilutions of a Fab of interest (e.g., consistent with assessment of the anti-VEGF antibody, Fab-12, in Presta et al.,Cancer Res.57:4593-4599 (1997)). The Fab of interest is then incubated overnight; however, the incubation may continue for a longer period (e.g., about 65 hours) to ensure that equilibrium is reached. Thereafter, the mixtures are transferred to the capture plate for incubation at room temperature (e.g., for one hour). The solution is then removed and the plate washed eight times with 0.1% polysorbate 20 (TWEEN-20®) in PBS. When the plates have dried, 150 μl/well of scintillant (MICROSCINT-20™; Packard) is added, and the plates are counted on a TOPCOUNT™ gamma counter (Packard) for ten minutes. Concentrations of each Fab that give less than or equal to 20% of maximal binding are chosen for use in competitive binding assays.

According to another embodiment, Kd is measured using a BIACORE® surface plasmon resonance assay. For example, an assay using a BIACORE®-2000 or a BIACORE®-3000 (BIAcore, Inc., Piscataway, N.J.) is performed at 25° C. with immobilized antigen CM5 chips at ˜10 response units (RU). In one embodiment, carboxymethylated dextran biosensor chips (CM5, BIACORE, Inc.) are activated with N-ethyl-N′-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NETS) according to the supplier's instructions. Antigen is diluted with 10 mM sodium acetate, pH 4.8, to 5 μg/ml (˜0.2 μM) before injection at a flow rate of 5 μl/minute to achieve approximately 10 response units (RU) of coupled protein. Following the injection of antigen, 1 M ethanolamine is injected to block unreacted groups. For kinetics measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) are injected in PBS with 0.05% polysorbate 20 (TWEEN-20™) surfactant (PBST) at 25° C. at a flow rate of approximately 25 μl/min. Association rates (k_on) and dissociation rates (k_off) are calculated using a simple one-to-one Langmuir binding model (BIACORE® Evaluation Software version 3.2) by simultaneously fitting the association and dissociation sensorgrams. The equilibrium dissociation constant (Kd) is calculated as the ratio k_off/k_on. See, e.g., Chen et al.,J. Mol. Biol.293:865-881 (1999). If the on-rate exceeds 106 M-1 s-1 by the surface plasmon resonance assay above, then the on-rate can be determined by using a fluorescent quenching technique that measures the increase or decrease in fluorescence emission intensity (excitation=295 nm; emission=340 nm, 16 nm band-pass) at 25° C. of a 20 nM anti-antigen antibody (Fab form) in PBS, pH 7.2, in the presence of increasing concentrations of antigen as measured in a spectrometer, such as a stop-flow equipped spectrophometer (Aviv Instruments) or a 8000-series SLM-AMINCO™ spectrophotometer (ThermoSpectronic) with a stirred cuvette.

3. Antibody Fragments

In some embodiments, the anti-KLK5 antibody provided herein is an antibody fragment. Antibody fragments include, but are not limited to, Fab, Fab′, Fab′-SH, F(ab′)₂, Fv, and scFv fragments, and other fragments described below. For a review of certain antibody fragments, see Hudson et al.Nat. Med.9:129-134 (2003). For a review of scFv fragments, see, e.g., Pluckthün, inThe Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93/16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For discussion of Fab and F(ab′)₂fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Pat. No. 5,869,046.

Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific. See, for example, EP 404,097; WO 1993/01161; Hudson et al.,Nat. Med.9:129-134 (2003); and Hollinger et al.,Proc. Natl. Acad. Sci. USA90: 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al.,Nat. Med.9:129-134 (2003).

Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, Mass.; see, e.g., U.S. Pat. No. 6,248,516 B1).

Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g.E. colior phage), as described herein.

4. Chimeric and Humanized Antibodies

In some embodiments, the anti-KLK5 antibody provided herein is a chimeric antibody. Certain chimeric antibodies are described, e.g., in U.S. Pat. No. 4,816,567; and Morrison et al.,Proc. Natl. Acad. Sci. USA,81:6851-6855 (1984)). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region. In a further example, a chimeric antibody is a “class switched” antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.

In certain embodiments, a chimeric antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody. Generally, a humanized antibody comprises one or more variable domains in which HVRs, e.g., CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences. A humanized antibody optionally will also comprise at least a portion of a human constant region. In some embodiments, some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.

Humanized antibodies and methods of making them are reviewed, e.g., in Almagro and Fransson,Front. Biosci.13:1619-1633 (2008), and are further described, e.g., in Riechmann et al.,Nature332:323-329 (1988); Queen et al.,Proc. Nat'l Acad. Sci. USA86:10029-10033 (1989); U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al.,Methods36:25-34 (2005) (describing specificity determining region (SDR) grafting); Padlan,Mol. Immunol.28:489-498 (1991) (describing “resurfacing”); Dall'Acqua et al.,Methods36:43-60 (2005) (describing “FR shuffling”); and Osbourn et al.,Methods36:61-68 (2005) and Klimka et al.,Br. J. Cancer,83:252-260 (2000) (describing the “guided selection” approach to FR shuffling).

Human framework regions that may be used for humanization include but are not limited to: framework regions selected using the “best-fit” method (see, e.g., Sims et al.J. Immunol.151:2296 (1993)); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter et al.Proc. Natl. Acad. Sci. USA,89:4285 (1992); and Presta et al.J. Immunol.,151:2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson,Front. Biosci.13:1619-1633 (2008)); and framework regions derived from screening FR libraries (see, e.g., Baca et al.,J. Biol. Chem.272:10678-10684 (1997) and Rosok et al.,J. Biol. Chem.271:22611-22618 (1996)).

5. Human Antibodies

In some embodiments, the anti-KLK5 antibody provided herein is a human antibody. Human antibodies can be produced using various techniques known in the art. Human antibodies are described generally in van Dijk and van de Winkel,Curr. Opin. Pharmacol.5: 368-74 (2001) and Lonberg,Curr. Opin. Immunol.20:450-459 (2008).

Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or which are present extrachromosomally or integrated randomly into the animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin loci have generally been inactivated. For review of methods for obtaining human antibodies from transgenic animals, see Lonberg,Nat. Biotech.23:1117-1125 (2005). See also, e.g., U.S. Pat. Nos. 6,075,181 and 6,150,584 describing XENOMOUSE™ technology; U.S. Pat. No. 5,770,429 describing HUMAB® technology; U.S. Pat. No. 7,041,870 describing K-M MOUSE® technology, and U.S. Patent Application Publication No. US 2007/0061900, describing VELOCIMOUSE® technology). Human variable regions from intact antibodies generated by such animals may be further modified, e.g., by combining with a different human constant region.

Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, e.g., KozborJ. Immunol.,133: 3001 (1984); Brodeur et al.,Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al.,J. Immunol.,147: 86 (1991).) Human antibodies generated via human B-cell hybridoma technology are also described in Li et al.,Proc. Natl. Acad. Sci. USA,103:3557-3562 (2006). Additional methods include those described, for example, in U.S. Pat. No. 7,189,826 (describing production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni,Xiandai Mianyixue,26(4):265-268 (2006) (describing human-human hybridomas). Human hybridoma technology (Trioma technology) is also described in Vollmers and Brandlein,Histology and Histopathology,20(3):927-937 (2005) and Vollmers and Brandlein,Methods and Findings in Experimental and Clinical Pharmacology,27(3):185-91 (2005).

Human antibodies may also be generated by isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences may then be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries are described below.

6. Library-Derived Antibodies

Anti-KLK5 antibodies may be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics. Such methods are reviewed, e.g., in Hoogenboom et al. inMethods in Molecular Biology178:1-37 (O'Brien et al., ed., Human Press, Totowa, N.J., 2001) and further described, e.g., in the McCafferty et al.,Nature348:552-554; Clackson et al.,Nature352: 624-628 (1991); Marks et al.,J. Mol. Biol.222: 581-597 (1992); Marks and Bradbury, inMethods in Molecular Biology248:161-175 (Lo, ed., Human Press, Totowa, N.J., 2003); Sidhu et al.,J. Mol. Biol.338(2): 299-310 (2004); Lee et al.,J. Mol. Biol.340(5): 1073-1093 (2004); Fellouse,Proc. Natl. Acad. Sci. USA101(34): 12467-12472 (2004); and Lee et al.,J Immunol. Methods284(1-2): 119-132(2004).

In certain phage display methods, repertoires of VH and VL genes are separately cloned by polymerase chain reaction (PCR) and recombined randomly in phage libraries, which can then be screened for antigen-binding phage as described in Winter et al.,Ann. Rev. Immunol.,12: 433-455 (1994). Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments. Libraries from immunized sources provide high-affinity antibodies to the immunogen without the requirement of constructing hybridomas. Alternatively, the naive repertoire can be cloned (e.g., from human) to provide a single source of antibodies to a wide range of non-self and also self antigens without any immunization as described by Griffiths et al.,EMBO J,12: 725-734 (1993). Finally, naive libraries can also be made synthetically by cloning unrearranged V-gene segments from stem cells, and using PCR primers containing random sequence to encode the highly variable CDR3 regions and to accomplish rearrangement in vitro, as described by Hoogenboom and Winter,J. Mol. Biol.,227: 381-388 (1992). Patent publications describing human antibody phage libraries include, for example: U.S. Pat. No. 5,750,373, and US Patent Publication Nos. 2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598, 2007/0237764, 2007/0292936, and 2009/0002360.

Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.

6. Multispecific Antibodies

In some embodiments, the anti-KLK5 antibody provided herein is a multispecific antibody, e.g. a bispecific antibody. Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. In certain embodiments, one of the binding specificities is for KLK5 and the other is for any other antigen. In certain embodiments, bispecific antibodies may bind to two different epitopes of KLK5. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express KLK5. Bispecific antibodies can be prepared as full length antibodies or antibody fragments.

Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (see Milstein and Cuello,Nature305: 537 (1983)), WO 93/08829, and Traunecker et al.,EMBO J.10: 3655 (1991)), and “knob-in-hole” engineering (see, e.g., U.S. Pat. No. 5,731,168). Multi-specific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009/089004A1); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980, and Brennan et al.,Science,229: 81 (1985)); using leucine zippers to produce bi-specific antibodies (see, e.g., Kostelny et al.,J. Immunol.,148(5):1547-1553 (1992)); using “diabody” technology for making bispecific antibody fragments (see, e.g., Hollinger et al.,Proc. Natl. Acad. Sci. USA,90:6444-6448 (1993)); and using single-chain Fv (sFv) dimers (see, e.g. Gruber et al.,J. Immunol.,152:5368 (1994)); and preparing trispecific antibodies as described, e.g., in Tutt et al.J. Immunol.147: 60 (1991).

Engineered antibodies with three or more functional antigen binding sites, including “Octopus antibodies,” are also included herein (see, e.g. US 2006/0025576A1).

The antibody or fragment herein also includes a “Dual Acting FAb” or “DAF” comprising an antigen binding site that binds to KLK5 as well as another, different antigen (see, US 2008/0069820, for example).

7. Antibody Variants

In some embodiments, amino acid sequence variants of the anti-KLK5 antibodies provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding.

a) Substitution, Insertion, and Deletion Variants

In some embodiments, anti-KLK5 antibody variants having one or more amino acid substitutions are provided. Sites of interest for substitutional mutagenesis include the HVRs and FRs. Conservative substitutions are shown in Table 1 under the heading of “preferred substitutions.” More substantial changes are provided in Table 1 under the heading of “exemplary substitutions,” and as further described below in reference to amino acid side chain classes. Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, or improved ADCC or CDC.

TABLE 1

Original	Exemplary	Preferred
Residue	Substitutions	Substitutions

Ala (A)	Val; Leu; Ile	Val
Arg (R)	Lys; Gln; Asn	Lys
Asn (N)	Gln; His; Asp, Lys; Arg	Gln
Asp (D)	Glu; Asn	Glu
Cys (C)	Ser; Ala	Ser
Gln (Q)	Asn; Glu	Asn
Glu (E)	Asp; Gln	Asp
Gly (G)	Ala	Ala
His (H)	Asn; Gln; Lys; Arg	Arg
Ile (I)	Leu; Val; Met; Ala; Phe; Norleucine	Leu
Leu (L)	Norleucine; Ile; Val; Met; Ala; Phe	Ile
Lys (K)	Arg; Gln; Asn	Arg
Met (M)	Leu; Phe; Ile	Leu
Phe (F)	Trp; Leu; Val; Ile; Ala; Tyr	Tyr
Pro (P)	Ala	Ala
Ser (S)	Thr	Thr
Thr (T)	Val; Ser	Ser
Trp (W)	Tyr; Phe	Tyr
Tyr (Y)	Trp; Phe; Thr; Ser	Phe
Val (V)	Ile; Leu; Met; Phe; Ala; Norleucine	Leu

Amino acids may be grouped according to common side-chain properties:

(1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;

(2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;

(3) acidic: Asp, Glu;

(4) basic: His, Lys, Arg;

(5) residues that influence chain orientation: Gly, Pro;

(6) aromatic: Trp, Tyr, Phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g. a humanized or human antibody). Generally, the resulting variant(s) selected for further study will have modifications (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antibody and/or will have substantially retained certain biological properties of the parent antibody. An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, e.g., using phage display-based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated and the variant antibodies displayed on phage and screened for a particular biological activity (e.g. binding affinity).

Alterations (e.g., substitutions) may be made in HVRs, e.g., to improve antibody affinity. Such alterations may be made in HVR “hotspots,” i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury,Methods Mol. Biol.207:179-196 (2008)), and/or residues that contact antigen, with the resulting variant VH or VL being tested for binding affinity. Affinity maturation by constructing and reselecting from secondary libraries has been described, e.g., in Hoogenboom et al. inMethods in Molecular Biology178:1-37 (O'Brien et al., ed., Human Press, Totowa, N.J., (2001).) In some embodiments of affinity maturation, diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity. Another method to introduce diversity involves HVR-directed approaches, in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding may be specifically identified, e.g., using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted.

In certain embodiments, substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antibody to bind antigen. For example, conservative alterations (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in HVRs. Such alterations may, for example, be outside of antigen contacting residues in the HVRs. In certain embodiments of the variant VH and VL sequences provided above, each HVR either is unaltered, or contains no more than one, two or three amino acid substitutions.

A useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called “alanine scanning mutagenesis” as described by Cunningham and Wells (1989)Science,244:1081-1085. In this method, a residue or group of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) are identified and replaced by a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with antigen is affected. Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions. Alternatively, or additionally, a crystal structure of an antigen-antibody complex to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they contain the desired properties.

Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g. for ADEPT) or a polypeptide which increases the serum half-life of the antibody.

b) Glycosylation Variants

In certain embodiments, the anti-KLK5 antibody provided herein is altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an antibody may be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites is created or removed.

Where the antibody comprises an Fc region, the carbohydrate attached thereto may be altered. Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, e.g., Wright et al.TIBTECH15:26-32 (1997). The oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the “stem” of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharide in an antibody of the invention may be made in order to create antibody variants with certain improved properties.

In some embodiments, anti-KLK5 antibody variants are provided having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region. For example, the amount of fucose in such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65% or from 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297, relative to the sum of all glycostructures attached to Asn 297 (e. g. complex, hybrid and high mannose structures) as measured by MALDI-TOF mass spectrometry, as described in WO 2008/077546, for example. Asn297 refers to the asparagine residue located at about position 297 in the Fc region (Eu numbering of Fc region residues); however, Asn297 may also be located about ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in antibodies. Such fucosylation variants may have improved ADCC function. See, e.g., US Patent Publication Nos. US 2003/0157108 (Presta, L.); US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd). Examples of publications related to “defucosylated” or “fucose-deficient” antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778; WO2005/053742; WO2002/031140; Okazaki et al.J. Mol. Biol.336:1239-1249 (2004); Yamane-Ohnuki et al.Biotech. Bioeng.87: 614 (2004). Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells deficient in protein fucosylation (Ripka et al.Arch. Biochem. Biophys.249:533-545 (1986); US Pat Appl No US 2003/0157108 A1, Presta, L; and WO 2004/056312 A1, Adams et al., especially at Example 11), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki et al.Biotech. Bioeng.87: 614 (2004); Kanda, Y. et al.,Biotechnol. Bioeng.,94(4):680-688 (2006); and WO2003/085107).

Anti-KLK5 antibody variants are further provided with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and/or improved ADCC function. Examples of such antibody variants are described, e.g., in WO 2003/011878 (Jean-Mairet et al.); U.S. Pat. No. 6,602,684 (Umana et al.); and US 2005/0123546 (Umana et al.). Antibody variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described, e.g., in WO 1997/30087 (Patel et al.); WO 1998/58964 (Raju, S.); and WO 1999/22764 (Raju, S.).

c) Fc Region Variants

In some embodiments, one or more amino acid modifications may be introduced into the Fc region of the anti-KLK5 antibody provided herein, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g. a substitution) at one or more amino acid positions.

In some embodiments, the invention contemplates an antibody variant that possesses some but not all effector functions, which make it a desirable candidate for applications in which the half-life of the antibody in vivo is important yet certain effector functions (such as complement and ADCC) are unnecessary or deleterious. In vitro and/or in vivo cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities. For example, Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks FcγR binding (hence likely lacking ADCC activity), but retains FcRn binding ability. The primary cells for mediating ADCC, NK cells, express Fc(RIII only, whereas monocytes express Fc(RI, Fc(RII and Fc(RIII FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet,Annu. Rev. Immunol.9:457-492 (1991). Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest is described in U.S. Pat. No. 5,500,362 (see, e.g. Hellstrom, I. et al.Proc. Nat'l Acad. Sci. USA83:7059-7063 (1986)) and Hellstrom, I et al.,Proc. Nat'l Acad. Sci. USA82:1499-1502 (1985); U.S. Pat. No. 5,821,337 (see Bruggemann, M. et al.,J. Exp. Med.166:1351-1361 (1987)). Alternatively, non-radioactive assays methods may be employed (see, for example, ACTI™ non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, Calif.; and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, Wis.). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in a animal model such as that disclosed in Clynes et al.Proc. Nat'l Acad. Sci. USA95:652-656 (1998). Clq binding assays may also be carried out to confirm that the antibody is unable to bind Clq and hence lacks CDC activity. See, e.g., Clq and C3c binding ELISA in WO 2006/029879 and WO 2005/100402. To assess complement activation, a CDC assay may be performed (see, for example, Gazzano-Santoro et al.,J. Immunol. Methods202:163 (1996); Cragg, M. S. et al.,Blood101:1045-1052 (2003); and Cragg, M. S. and M. J. Glennie,Blood103:2738-2743 (2004)). FcRn binding and in vivo clearance/half-life determinations can also be performed using methods known in the art (see, e.g., Petkova, S. B. et al.,Int'l. Immunol.18(12):1759-1769 (2006)).

Antibodies with reduced effector function include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Pat. No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called “DANA” Fc mutant with substitution of residues 265 and 297 to alanine (U.S. Pat. No. 7,332,581).

Certain antibody variants with improved or diminished binding to FcRs are described. (See, e.g., U U.S. Pat. No. 6,737,056; WO 2004/056312, and Shields et al.,J. Biol. Chem.9(2): 6591-6604 (2001).)

In certain embodiments, an antibody variant comprises an Fc region with one or more amino acid substitutions which improve ADCC, e.g., substitutions at positions 298, 333, and/or 334 of the Fc region (EU numbering of residues).

In some embodiments, alterations are made in the Fc region that result in altered (i.e., either improved or diminished) Clq binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as described in U.S. Pat. No. 6,194,551, WO 99/51642, and Idusogie et al.J. Immunol.164: 4178-4184 (2000).

Antibodies with increased half-lives and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al.,J. Immunol.117:587 (1976) and Kim et al.,J. Immunol.24:249 (1994)), are described in US2005/0014934A1 (Hinton et al.). Those antibodies comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn. Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (U.S. Pat. No. 7,371,826).

d) Cysteine Engineered Antibody Variants

In some embodiments, it may be desirable to create cysteine engineered anti-KLK5 antibodies, e.g., THIOMAB™ antibodies in which one or more residues of an antibody are substituted with cysteine residues. In particular embodiments, the substituted residues occur at accessible sites of the antibody. By substituting those residues with cysteine, reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create an immunoconjugate, as described further herein. In certain embodiments, any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and 5400 (EU numbering) of the heavy chain Fc region. Cysteine engineered antibodies may be generated as described, e.g., in U.S. Pat. No. 7,521,541.

e) Antibody Derivatives

In some embodiments, the anti-KLK5 antibody provided herein may be further modified to contain additional nonproteinaceous moieties that are known in the art and readily available. The moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers. Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propropylene glycol homopolymers, prolypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight, and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer are attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.

In some embodiments, conjugates of the anti-KLK5 antibody and nonproteinaceous moiety that may be selectively heated by exposure to radiation are provided. In one embodiment, the nonproteinaceous moiety is a carbon nanotube (Kam et al.,Proc. Natl. Acad. Sci. USA102: 11600-11605 (2005)). The radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the nonproteinaceous moiety to a temperature at which cells proximal to the antibody-nonproteinaceous moiety are killed.

B. Recombinant Methods and Compositions

Anti-KLK5 antibodies may be produced using recombinant methods and compositions, e.g., as described in U.S. Pat. No. 4,816,567. In one embodiment, isolated nucleic acid encoding an anti-KLK5 antibody described herein is provided. Such nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chains of the antibody). In a further embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acid are provided. In a further embodiment, a host cell comprising such nucleic acid is provided. In one such embodiment, a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody. In one embodiment, the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell). In one embodiment, a method of making an anti-KLK5 antibody is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).

For recombinant production of an anti-KLK5 antibody, nucleic acid encoding an antibody, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).

Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein. For example, antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Pat. Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton,Methods in Molecular Biology, Vol.248 (B.K.C. Lo, ed., Humana Press, Totowa, N.J., 2003), pp. 245-254, describing expression of antibody fragments inE. coli.). After expression, the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized,” resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross,Nat. Biotech.22:1409-1414 (2004), and Li et al.,Nat. Biotech.24:210-215 (2006).

Suitable host cells for the expression of glycosylated antibody are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection ofSpodoptera frugiperdacells.

Plant cell cultures can also be utilized as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES™ technology for producing antibodies in transgenic plants).

Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al.,J. Gen Virol.36:59 (1977)); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather,Biol. Reprod.23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al.,Annals N.Y. Acad. Sci.383:44-68 (1982);MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR⁻ CHO cells (Urlaub et al.,Proc. Natl. Acad. Sci. USA77:4216 (1980)); and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268 (2003).

C. Assays

Anti-KLK5 antibodies provided herein may be identified, screened for, or characterized for their physical/chemical properties and/or biological activities by various assays known in the art.

1. Binding Assays and Other Assays

In one aspect, an antibody of the invention is tested for its antigen binding activity, e.g., by known methods such as ELISA, BIACore®, FACS, or Western blot, etc.

In another aspect, competition assays may be used to identify an antibody that competes with any of the antibodies described herein for binding to KLK5. In certain embodiments, such a competing antibody binds to the same epitope (e.g., a linear or a conformational epitope) that is bound by any of the antibodies described herein. Detailed exemplary methods for mapping an epitope to which an antibody binds are provided in Morris (1996) “Epitope Mapping Protocols,” inMethods in Molecular Biologyvol. 66 (Humana Press, Totowa, N.J.).

In an exemplary competition assay, immobilized KLK5 is incubated in a solution comprising a first labeled antibody that binds to KLK5 (e.g., any of the antibodies described herein) and a second unlabeled antibody that is being tested for its ability to compete with the first antibody for binding to KLK5. The second antibody may be present in a hybridoma supernatant. As a control, immobilized KLK5 is incubated in a solution comprising the first labeled antibody but not the second unlabeled antibody. After incubation under conditions permissive for binding of the first antibody to KLK5, excess unbound antibody is removed, and the amount of label associated with immobilized KLK5 is measured. If the amount of label associated with immobilized KLK5 is substantially reduced in the test sample relative to the control sample, then that indicates that the second antibody is competing with the first antibody for binding to KLK5. See Harlow and Lane (1988)Antibodies: A Laboratory Manualch.14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).

2. Activity Assays

In one aspect, assays are provided for identifying anti-KLK5 antibodies having biological activity. Biological activity may include, e.g. inhibition of KLK5. In one embodiment, the anti-KLK5 antibodies inhibit the serine protease activity of KLK5. Antibodies having such biological activity in vivo and/or in vitro are also provided.

In some embodiments, the anti-KLK5 antibodies are tested for such biological activity. In some embodiments, the biological activity is tested by one or more methods selected from the group consisting of a direct activity assay, fluorescent peptide assay, an LC/MS assay, and a K_i(app)assay. In some embodiments, the biological activity is measured by one or more methods selected from the group consisting of a recombinant KLK5 direct activity assay, coupled pro-KLK1 fluorescent peptide assay, a coupled pro-KLK7 fluorescent peptide assay, a pro-KLK1 LC/MS assay, a pro-KLK7 LC/MS assay, and a K_i(app)assay. In some embodiments, the IC₅₀values are measured by the assays described herein above and in detail in the Examples below.

D. Immunoconjugates

The invention also provides immunoconjugates comprising an anti-KLK5 antibody provided herein conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), or radioactive isotopes.

In one embodiment, an immunoconjugate is an antibody-drug conjugate (ADC) in which an antibody is conjugated to one or more drugs, including but not limited to a maytansinoid (see U.S. Pat. Nos. 5,208,020, 5,416,064 andEuropean Patent EP 0 425 235 B1); an auristatin such as monomethylauristatin drug moieties DE and DF (MMAE and MMAF) (see U.S. Pat. Nos. 5,635,483 and 5,780,588, and 7,498,298); a dolastatin; a calicheamicin or derivative thereof (see U.S. Pat. Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, and 5,877,296; Hinman et al.,Cancer Res.53:3336-3342 (1993); and Lode et al.,Cancer Res.58:2925-2928 (1998)); an anthracycline such as daunomycin or doxorubicin (see Kratz et al.,Current Med. Chem.13:477-523 (2006); Jeffrey et al.,Bioorganic&Med. Chem. Letters16:358-362 (2006); Torgov et al.,Bioconj. Chem.16:717-721 (2005); Nagy et al.,Proc. Natl. Acad. Sci. USA97:829-834 (2000); Dubowchik et al.,Bioorg. &Med. Chem. Letters12:1529-1532 (2002); King et al.,J. Med. Chem.45:4336-4343 (2002); and U.S. Pat. No. 6,630,579); methotrexate; vindesine; a taxane such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel; a trichothecene; and CC1065.

In another embodiment, an immunoconjugate comprises an antibody as described herein conjugated to an enzymatically active toxin or fragment thereof, including but not limited to diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (fromPseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin,Aleurites fordiiproteins, dianthin proteins,Phytolaca americanaproteins (PAPI, PAPII, and PAP-S),Momordica charantiainhibitor, curcin, crotin,Sapaonaria officinalisinhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.

In another embodiment, an immunoconjugate comprises an antibody as described herein conjugated to a radioactive atom to form a radioconjugate. A variety of radioactive isotopes are available for the production of radioconjugates. Examples include At²¹¹, I¹³¹, I¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³², Pb²¹²and radioactive isotopes of Lu. When the radioconjugate is used for detection, it may comprise a radioactive atom for scintigraphic studies, for example tc99m or I123, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, mri), such as iodine-123 again, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.

Conjugates of an antibody and cytotoxic agent may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such astoluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al.,Science238:1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026. The linker may be a “cleavable linker” facilitating release of a cytotoxic drug in the cell. For example, an acid-labile linker, peptidase-sensitive linker, photolabile linker, dimethyl linker or disulfide-containing linker (Chari et al.,Cancer Res.52:127-131 (1992); U.S. Pat. No. 5,208,020) may be used.

The immunuoconjugates or ADCs herein expressly contemplate, but are not limited to such conjugates prepared with cross-linker reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-vinylsulfone)benzoate) which are commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, Ill., U.S.A).

E. Methods and Compositions for Diagnostics and Detection

In some embodiments, any of the anti-KLK5 antibodies provided herein is useful for detecting the presence of KLK5 in a biological sample. The term “detecting” as used herein encompasses quantitative or qualitative detection. In some embodiments, a biological sample comprises a cell or tissue, such as skin epidermis, lung parenchyma, bronchial sub-epithelium. In some embodiments, a biological sample comprises bronchial alveolar lavage.

In one embodiment, an anti-KLK5 antibody for use in a method of diagnosis or detection is provided. In a further aspect, a method of detecting the presence of KLK5 in a biological sample is provided. In certain embodiments, the method comprises contacting the biological sample with an anti-KLK5 antibody as described herein under conditions permissive for binding of the anti-KLK5 antibody to KLK5, and detecting whether a complex is formed between the anti-KLK5 antibody and KLK5. Such method may be an in vitro or in vivo method. In one embodiment, an anti-KLK5 antibody is used to select subjects eligible for therapy with an anti-KLK5 antibody, e.g. where KLK5 is a biomarker for selection of patients.

Exemplary disorders that may be diagnosed using an anti-KLK5 antibody of the invention include Netherton Syndrome, asthma, atopic dermatitis, psoriasis, and rosacea. In some embodiments, the disease is selected from the group consisting of Netherton Syndrome, asthma, atopic dermatitis, psoriasis, rosacea and eosinophilic esophagitis. In some embodiments, the asthma is selected from the group consisting of atopic asthma, allergic asthma, non-allergic asthma, exercise-induced asthma, aspirin sensitive/exacerbated asthma, mild asthma, moderate to severe asthma, corticosteroid naïve asthma, chronic asthma, corticosteroid resistant asthma, corticosteroid refractory asthma, newly diagnosed and untreated asthma, asthma due to smoking, asthma uncontrolled on corticosteroids, T helper lymphocyte type 2 (Th2) or type 2 (Th2) high, or Type 2 (T2)-driven asthma, eosinophilic asthma, periostin-high asthma, eosinophil-high asthma, Th2-low asthma or nonTh2-driven asthma, periostin-low asthma, and eosinophil-low asthma. In some embodiments, the asthma is TH2-low asthma.

In certain embodiments, labeled anti-KLK5 antibodies are provided. Labels include, but are not limited to, labels or moieties that are detected directly (such as fluorescent, chromophoric, electron-dense, chemiluminescent, and radioactive labels), as well as moieties, such as enzymes or ligands, that are detected indirectly, e.g., through an enzymatic reaction or molecular interaction. Exemplary labels include, but are not limited to, the radioisotopes³²P,¹⁴C,¹²⁵I,³H, and¹³¹I, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luceriferases, e.g., firefly luciferase and bacterial luciferase (U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP, lactoperoxidase, or microperoxidase, biotin/avidin, spin labels, bacteriophage labels, stable free radicals, and the like.

F. Pharmaceutical Formulations

Pharmaceutical formulations of an anti-KLK5 antibody as described herein are prepared by mixing such antibody having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers herein further include insterstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in US Patent Publication Nos. 2005/0260186 and 2006/0104968. In one aspect, a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.

Exemplary lyophilized antibody formulations are described in U.S. Pat. No. 6,267,958. Aqueous antibody formulations include those described in U.S. Pat. No. 6,171,586 and WO2006/044908, the latter formulations including a histidine-acetate buffer.

The formulation herein may also contain more than one active ingredients as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.

Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed inRemington's Pharmaceutical Sciences16th edition, Osol, A. Ed. (1980).

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. films, or microcapsules.

The formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.

G. Therapeutic Methods and Compositions

Any of the anti-KLK5 antibodies provided herein may be used in therapeutic methods.

In one aspect, an anti-KLK5 antibody for use as a medicament is provided. In further aspects, an anti-KLK5 antibody is provided for use in treating a disease selected from the group consisting of Netherton Syndrome, asthma, atopic dermatitis, psoriasis, and rosacea. In some embodiments, the disease is selected from the group consisting of Netherton Syndrome, asthma, atopic dermatitis, psoriasis, rosacea and eosinophilic esophagitis. In some embodiments, the asthma is selected from the group consisting of atopic asthma, allergic asthma, non-allergic asthma, exercise-induced asthma, aspirin sensitive/exacerbated asthma, mild asthma, moderate to severe asthma, corticosteroid naïve asthma, chronic asthma, corticosteroid resistant asthma, corticosteroid refractory asthma, newly diagnosed and untreated asthma, asthma due to smoking, asthma uncontrolled on corticosteroids, T helper lymphocyte type 2 (Th2) or type 2 (Th2) high, or Type 2 (T2)-driven asthma, eosinophilic asthma, periostin-high asthma, eosinophil-high asthma, Th2-low asthma or nonTh2-driven asthma, periostin-low asthma, and eosinophil-low asthma. In some embodiments, the asthma is TH2-low asthma.

In certain embodiments, an anti-KLK5 antibody for use in a method of treatment is provided. In certain embodiments, the invention provides an anti-KLK5 antibody for use in a method of treating an individual having a disease, wherein the disease is selected from the group consisting of Netherton Syndrome, asthma, atopic dermatitis, psoriasis, and rosacea comprising administering to the individual an effective amount of the anti-KLK5 antibody. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below. In some embodiments, provided is an anti-KLK5 antibody for use in inhibiting the biological activity of KLK5. In some embodiments, provided is an anti-KLK5 antibody for use in a method of inhibiting the biological activity of KLK5 in an individual comprising administering to the individual an effective of the anti-KLK5 antibody to inhibit the biological activity of KLK5. An “individual” according to any of the above embodiments is preferably a human. In some embodiments, the disease is selected from the group consisting of Netherton Syndrome, asthma, atopic dermatitis, psoriasis, rosacea and eosinophilic esophagitis. In some embodiments, the asthma is selected from the group consisting of atopic asthma, allergic asthma, non-allergic asthma, exercise-induced asthma, aspirin sensitive/exacerbated asthma, mild asthma, moderate to severe asthma, corticosteroid naïve asthma, chronic asthma, corticosteroid resistant asthma, corticosteroid refractory asthma, newly diagnosed and untreated asthma, asthma due to smoking, asthma uncontrolled on corticosteroids, T helper lymphocyte type 2 (Th2) or type 2 (Th2) high, or Type 2 (T2)-driven asthma, eosinophilic asthma, periostin-high asthma, eosinophil-high asthma, Th2-low asthma or nonTh2-driven asthma, periostin-low asthma, and eosinophil-low asthma. In some embodiments, the asthma is TH2-low asthma.

In a further aspect, the invention provides for the use of an anti-KLK5 antibody in the manufacture or preparation of a medicament. In one embodiment, the medicament is for treatment a disease, wherein the disease is selected from the group consisting of Netherton Syndrome, asthma, atopic dermatitis, psoriasis, and rosacea. In a further embodiment, the medicament is for use in a method of treating a disease, wherein the disease is selected from the group consisting of Netherton Syndrome, asthma, atopic dermatitis, psoriasis, and rosacea comprising administering to an individual having said disease an effective amount of the medicament. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below. In a further embodiment, the medicament is for inhibiting the biological activity of KLK5. In a further embodiment, the medicament is for use in a method of inhibiting the biological activity of KLK5 in an individual comprising administering to the individual an amount effective of the medicament to inhibiting the biological activity of KLK5. An “individual” according to any of the above embodiments may be a human. In some embodiments, the disease is selected from the group consisting of Netherton Syndrome, asthma, atopic dermatitis, psoriasis, rosacea and eosinophilic esophagitis. In some embodiments, the asthma is selected from the group consisting of atopic asthma, allergic asthma, non-allergic asthma, exercise-induced asthma, aspirin sensitive/exacerbated asthma, mild asthma, moderate to severe asthma, corticosteroid naïve asthma, chronic asthma, corticosteroid resistant asthma, corticosteroid refractory asthma, newly diagnosed and untreated asthma, asthma due to smoking, asthma uncontrolled on corticosteroids, T helper lymphocyte type 2 (Th2) or type 2 (Th2) high, or Type 2 (T2)-driven asthma, eosinophilic asthma, periostin-high asthma, eosinophil-high asthma, Th2-low asthma or nonTh2-driven asthma, periostin-low asthma, and eosinophil-low asthma. In some embodiments, the asthma is TH2-low asthma.

In a further aspect, the invention provides a method for treating a disease, wherein the disease is selected from the group consisting of Netherton Syndrome, asthma, atopic dermatitis, psoriasis, and rosacea. In some embodiments, the disease is selected from the group consisting of Netherton Syndrome, asthma, atopic dermatitis, psoriasis, rosacea and eosinophilic esophagitis. In one embodiment, the method comprises administering to an individual having such Netherton Syndrome, asthma, atopic dermatitis, psoriasis, or rosacea an effective amount of an anti-KLK5 antibody. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, as described below. An “individual” according to any of the above embodiments may be a human. In some embodiments, the asthma is selected from the group consisting of atopic asthma, allergic asthma, non-allergic asthma, exercise-induced asthma, aspirin sensitive/exacerbated asthma, mild asthma, moderate to severe asthma, corticosteroid naïve asthma, chronic asthma, corticosteroid resistant asthma, corticosteroid refractory asthma, newly diagnosed and untreated asthma, asthma due to smoking, asthma uncontrolled on corticosteroids, T helper lymphocyte type 2 (Th2) or type 2 (Th2) high, or Type 2 (T2)-driven asthma, eosinophilic asthma, periostin-high asthma, eosinophil-high asthma, Th2-low asthma or nonTh2-driven asthma, periostin-low asthma, and eosinophil-low asthma. In some embodiments, the asthma is TH2-low asthma.

In a further aspect, the invention provides a method for inhibiting the biological activity of KLK5 in an individual. In one embodiment, the method comprises administering to the individual an effective amount of an anti-KLK5 antibody to inhibiting the biological activity of KLK5. In one embodiment, an “individual” is a human.

In a further aspect, the invention provides pharmaceutical formulations comprising any of the anti-KLK5 antibodies provided herein, e.g., for use in any of the above therapeutic methods. In one embodiment, a pharmaceutical formulation comprises any of the anti-KLK5 antibodies provided herein and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutical formulation comprises any of the anti-KLK5 antibodies provided herein and at least one additional therapeutic agent, e.g., as described below.

Antibodies of the invention can be used either alone or in combination with other agents in a therapy. For instance, an antibody of the invention may be co-administered with at least one additional therapeutic agent. In some embodiments, the additional therapeutic agent is an IL-13 axis binding antagonist, an IL-5 axis binding antagonist, an IL-33 axis binding antagonist, an M1 prime antagonist, an IgE antagonist, a TRPA1 antagonist, a CRTH2 antagonist, a broncodilator or asthma symptom controller medication, an immunomodulator, a corticosteroid, a Th2 pathway inhibitor, a tyrosine kinase inhibitor, or a phosphodiesterase inhibitor. In some embodiments, the IL-13 axis binding antagonist is an anti-IL-13 antibody. In some embodiments, the anti-IL-13 antibody is lebrikizumab. In some embodiments, the IL-5 axis binding antagonist is an IL-5 binding antagonist or an IL-5 receptor binding antagonist. In some embodiments, the IL-33 axis binding antagonist is an IL-33 binding antagonist or an ST2 binding antagonist. In some embodiments, the IL-33 binding antagonist is an anti-IL-33 antibody. In some embodiments, the M1 prime antagonist is quilizumab.

Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate formulations), and separate administration, in which case, administration of the antibody of the invention can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent or agents. In one embodiment, administration of the anti-KLK5 antibody and administration of an additional therapeutic agent occur within about one month, or within about one, two or three weeks, or within about one, two, three, four, five, or six days, of each other. Antibodies of the invention can also be used in combination with radiation therapy.

An antibody of the invention (and any additional therapeutic agent) can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic. Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.

Antibodies of the invention would be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The antibody need not be, but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.

For the prevention or treatment of disease, the appropriate dosage of an antibody of the invention (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the type of antibody, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 μg/kg to 15 mg/kg (e.g. 0.1 mg/kg-10 mg/kg) of antibody can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. One typical daily dosage might range from about 1 μg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs. One exemplary dosage of the antibody would be in the range from about 0.05 mg/kg to about 10 mg/kg. Thus, one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from about two to about twenty, or e.g. about six doses of the antibody). An initial higher loading dose, followed by one or more lower doses may be administered.

It is understood that any of the above formulations or therapeutic methods may be carried out using an immunoconjugate of the invention in place of or in addition to an anti-KLK5 antibody.

H. Articles of Manufacture

In another aspect of the invention, an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an antibody of the invention. The label or package insert indicates that the composition is used for treating the condition of choice. Moreover, the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises an antibody of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent. The article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition. Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

It is understood that any of the above articles of manufacture may include an immunoconjugate of the invention in place of or in addition to an anti-KLK5 antibody.

III. Examples

The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced, given the general description provided above.

Example 1—Material and MethodsGeneration of Anti-KLK5 Antibodies

New Zealand White rabbits were immunized with human KLK5 and single B cells were isolated using a modified protocol related to published literature, e.g. see Offner et al.,PLoS ONE9(2), 2014. This modified workflow included direct FACS sorting of IgG+ huKLK5+ B cells into single wells. The B cell culture supernatants were assayed by ELISA for binding to human KLK5 and an irrelevant control protein. KLK5 specific B cells were lysed and immediately frozen in −80° C. for storage until molecular cloning. Variable regions (VH and VL) of each monoclonal antibody from rabbit B cells were cloned into expression vectors from extracted mRNA as previously described, e.g. see Offner et al.,PLoS ONE9(2), 2014. Individual recombinant rabbit antibodies were expressed in Expi293 cells and subsequently purified with protein A. Purified anti-KLK5 antibodies were then subjected to functional activity assays and kinetic screening.

Rats were immunized in a similar manner and hybridomas were generated using a modified fusion partner (e.g. see Price et al.,J Immunol Methods31; 343(1):28-41 (2009)). Various conditions were optimized to enable sorting of individual IgG+ huKLK5+ hybridomas into single wells followed by additional culturing after sorting. The resulting hybridoma supernatants were assayed by ELISA and positive samples were purified using protein A for subsequent functional and kinetic characterization.

BIAcore™ Experiments

The binding affinity of the antibodies in this section was determined by BIAcore™ T200 machine. Briefly, BIAcore™ research grade CM5 chips were activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS) reagents according to the supplier's instructions. Goat anti-human Fc IgGs were coupled to the chips to achieve approximately 10,000 response units (RU) in each flow cell. Unreacted coupling groups were blocked with 1M ethanolamine. For kinetics measurements, antibodies were captured to achieve approximately 300 RU. Ten-fold serial dilutions of human KLK5 were injected in HBS-P buffer at 37° C. with a flow rate of 30 μL/min. Association rates (ka) and dissociation rates (kd) were calculated using a 1:1 Langmuir binding model (BIAcore™ T200 Evaluation Software version 2.0). The equilibrium dissociation constant (KD) was calculated as the ratio kd/ka.

Assays for Determination of KLK5 Inhibition

The inhibition of human KLK5 by anti-KLK5 antibodies was measured using a recombinant KLK5 direct activity assay. Recombinant human KLK5 (Genentech) was diluted to 5 nM in direct assay buffer (75 mM Tris (pH 8.0), 150 mM NaCl and 0.01% TWEEN® 20) and combined with anti-KLK5 antibodies in 384-well assay plate (384 Well Low Volume, Black, Round Bottom, Corning, Catalog No. 4514). Antibodies were supplied in either phosphate sample buffer (70 mM sodium phosphate (pH 6), 200 mM NaCl and 0.01% TWEEN® 20) or citrate/Tris sample buffer (10 mM citric acid, 30 mM Tris (pH 6) and 0.01% TWEEN® 20). Antibody dilutions were made in the appropriate sample buffer or in direct assay buffer. Plates were incubated for 30 minutes at ambient temperature. Fluorescent peptide substrate, Boc-VPR-AMC (Bachem, Part No. 1-1120) was added directly to the assay plate. Final in-well concentrations were 50 μM Boc-VPR-AMC, 5 nM recombinant human KLK5, and 0.19-100 nM anti-KLK5 antibodies. Plates were examined every 102 s for 30-60 minute using a PHERAstar® Plus reader using a 340 nm excitation/460 nm emission module. The Reaction rate (expressed as RFU) was calculated by linear regression of readings in the linear range, typically beginning at 204 s and continuing until the end of the assay. Buffer alone and 100 nM final SPINK9.SRE.Fc (Genentech) were used as 100% and 0% activity controls, respectively. The IC₅₀value of the anti-KLK5 antibodies were determined from a four-parameter fit for their respective curves.

The inhibition of human KLK5 by anti-KLK5 antibodies was measured using a coupled pro-KLK7 fluorescent peptide assay. Recombinant human KLK5 (Genentech) was diluted to 5 nM in pro-KLK7 citrate/Tris coupled buffer (50 mM Tris (pH 7.5), 150 mM NaCl and 0.01% TWEEN® 20) if antibody samples were in citrate/Tris sample buffer or pro-KLK7 phosphate coupled buffer (50 mM Tris (pH 8.0), 150 mM NaCl and 0.01% TWEEN® 20) if antibody samples were in phosphate sample buffer. Diluted KLK5 was then combined with anti-KLK5 antibodies in 384-well assay plate (384 Well Low Volume, Black, Round Bottom, Corning, Catalog No. 4514). Antibody dilutions were made as described for the direct KLK5 assay. Plates were incubated for 30 minutes at ambient temperature. Fluorescent peptide substrate, suc-LLVY-AMC (Bachem, Part No. I-1395) and pro-KLK7 (Genentech) were added directly to the assay plate and incubated at ambient temperature. Final in-well concentrations were 100 μM suc-LLVY-AMC, 125 nM pro-KLK7, 5 nM recombinant human KLK5, and 0.19-100 nM anti-KLK5 antibodies. After 24 hours, fluorescent readings were made every 102 s for 30-60 min and the RFU endpoint value was calculated by averaging the last 5 readings. Buffer alone and 100 nM final SPINK9.SRE.Fc (Genentech) were used as 100% and 0% activity controls, respectively. The IC₅₀value of the anti-KLK5 antibodies were determined from a four-parameter fit for their respective curves.

IC₅₀value of the anti-KLK5 antibodies was determined using a pro-KLK7 Assay by KLK5-derived cleavage peptide detection using LC/MS (pro-KLK7 LC/MS assay). The product peptide EEAQGDK from reaction between the enzyme KLK5 and substrate proKLK7 was detected by mass spectrometry coupled to liquid chromatography. All compounds were diluted with 50 mM ammonium bicarbonate buffer (Powder/Certified, Fisher Chemical, A643-500) with final concentrations in the assay at 5 nM KLK5 (Genentech) and antibodies ranging from 0.02 to 65 nM, diluted in 96-well plates (Bio-Rad, Hard-Shell 96-Well PCR Plates, low profile, thin wall, skirted, blue/clear # HSP9631). Plates were incubated at room temperature for 30 minutes. Afterward, 15 nM of substrate proKLK7 (Genentech) was added to the enzyme plus inhibitors. After 2 hours, the reaction was quenched using 0.5 μL of Formic Acid (99.5+%, Optima™ LC/MS Grade, Fisher Chemical, A117-10X1AMP). Peptide was detected using the combination of the following masses: Q1, 388.7 m/z and Q3, 319.0 m/z, in a QTRAP® 6500 LC-MS/MS mass spectrometer (Sciex, Framingham, Mass.). Quantitation of generated peptide was measured using a synthetic KLK7 peptide calibration curve. The IC₅₀values were determined usingPrism 6 Software (GraphPad Software, La Jolla, Calif.).

The inhibition of human KLK5 by anti-KLK5 antibodies was measured using a coupled pro-KLK1 fluorescent peptide assay. Recombinant human KLK5 (Genentech) was diluted to 0.5 nM in pro-KLK1 coupled assay buffer (100 mM Tris (pH 8.5) and 0.01% TWEEN® 20) and combined with anti-KLK5 antibodies in 384-well assay plate (384 Well Low Volume, Black, Round Bottom, Corning, Catalog No. 4514). Antibody dilutions were made as described for the direct KLK5 assay. Plates were incubated for 30 minutes at ambient temperature. Fluorescent peptide substrate, PFR-AMC (Bachem, Part No. I-1295) and pro-KLK1 (Genentech) were added directly to the assay plate and incubated at ambient temperature. Final in-well concentrations were 50 μM PFR-AMC, 31.25 nM pro-KLK1, 0.5 nM recombinant human KLK5, and 0.19-100 nM anti-KLK5 antibodies. Plates were examined every 102 s for 120 minute using a PHERAstar® Plus reader using a 340 nm excitation/460 nm emission module. The endpoint RFU values were calculated by averaging readings around a time dictated by the inflection point of a plot of RFU versus time for the no inhibitor controls. Buffer alone and 100 nM final SPINK9.SRE.Fc (Genentech) was used as 100% and 0% activity controls, respectively. The IC₅₀values of the anti-KLK5 antibodies were determined from a four-parameter fit for their respective curves.

IC₅₀values of the anti-KLK5 antibodies was determined using a pro-KLK1 Assay by KLK5-derived cleavage peptide detection using LC/MS (pro-KLK1 LC/MS Assay). The product peptide APPIQSR from reaction between the enzyme KLK5 and substrate proKLK1 was detected by mass spectrometry coupled to liquid chromatography. All compounds were diluted with 50 mM ammonium bicarbonate buffer (Powder/Certified, Fisher Chemical, A643-500) with final concentrations in the assay at 0.5 nM KLK5 (Genentech) and antibodies ranging from 0.01 to 29 nM, diluted in 96-well plates (Bio-Rad, Hard-Shell 96-Well PCR Plates, low profile, thin wall, skirted, blue/clear # HSP9631). Plates were incubated at room temperature for 60 minutes. Afterward, 300 nM of substrate proKLK1 (Genentech) was added to the enzyme plus inhibitors. After 20 minutes, the reaction was quenched using 0.5 μL of Formic Acid (99.5+%, Optima™ LC/MS Grade, Fisher Chemical, A117-10X1AMP). Peptide was detected using the combination of the following masses: Q1, 384.7 m/z and Q3, 600.3 m/z, in a QTRAP® 6500 LC-MS/MS mass spectrometer (Sciex, Framingham, Mass.). IC₅₀value were determined using peak areas andPrism 6 Software (GraphPad Software, La Jolla, Calif.).

K_i(app)assay using Z-VPR-pNA as substrate was performed at room temperature in a 96-well half-area plate (white with clear, flat bottom, Corning #3884). Inhibitor samples were diluted to 3× final concentration in assay buffer (100 mM Tris, pH 8.0, 100 mM NaCl, 0.01% TWEEN® 20). Buffer alone and 100 nM final SPINK9.SRE.Fc (Genentech) were used as 100% and 0% activity controls, respectively. Inhibitor or control samples (20 μL) were added to the plate followed by 20 μL KLK5 (Genentech) in assay buffer at final concentrations of 0.5, 0.25, 0.125, and 0.0625 nM. After 30 minutes, 20 μL of Z-VPR-pNA substrate (California Peptide, #876-08, prepared as a 30 mM stock solution in DMSO) in assay buffer was added at a final concentration of 300 μM. In some initial assays the final DMSO concentration was increased to 10% by making an initial dilution of the substrate to 3 mM in DMSO before diluting to 900 μM (i.e., 3× final) in assay buffer. After addition of substrate, the plate was read in a Versamax tunable microplate reader with measurements at 405 nm taken every 102 seconds for 3 hours. Reaction rates (expressed as μAU/s) were calculated by linear regression in the range 4182-10710 seconds. Reaction rates were normalized to the values of the 0% and 100% activity controls and fit with a 4-parameter equation to calculate IC₅₀values. In the case of a bivalent inhibitor, the raw IC₅₀value was multiplied by two. The IC₅₀value was then plotted versus KLK5 enzyme concentration, yielding the K_i(app)from the y-intercept value. In addition, if the inhibitor was potent enough, the combined purity of both enzyme and inhibitor could be judged by comparing the slope of the plot to the theoretical value of 0.5.

Assays for Determination of Antibody Selectivity

KLK1 selectivity assay was performed at room temperature in a 384-well plate (black, low-volume round bottom, Corning #4514) with a final reaction volume of 15 μL. Inhibitor samples were diluted to 3× final concentration in assay buffer (75 mM Tris, pH 8.0, 150 mM NaCl, 0.01% TWEEN® 20). Reactions lacking inhibitor and reactions lacking enzyme were used as 100% and 0% activity controls, respectively. Inhibitor or control samples (5 μL) were added to the plate followed by 5 μL KLK1 (R&D Systems, 2337-SE, Lot NLY0315111, activated according to R&D systems protocol) in assay buffer at a final concentration of 3 nM. After 30 minutes, 5 μL of H-Pro-Phe-Arg-AMC acetate salt (Bachem I-1295, 10 mM stock solution in water) in assay buffer was added at a final concentration of 100 μM. After addition of substrate, the plate was read in PHERAstar® microplate reader using optic module FI 340 460 with the gain set to 85%. Measurements were taken every 102 seconds for 1 hour. Reaction rates (expressed as RFU/s) were calculated by linear regression in the range 204-918 seconds. Reaction rates were normalized to the values of the 0% and 100% activity controls and fit with a 4-parameter equation to calculate IC₅₀values. In the case of bivalent inhibitors, the raw IC₅₀value was multiplied by two.

KLK4 selectivity assay was performed at room temperature in a 384-well plate (black, low-volume round bottom, Corning #4514) with a final reaction volume of 15 μL. Inhibitor samples were diluted to 3× final concentration in assay buffer (75 mM Tris, pH 8.0, 150 mM NaCl, 0.01% TWEEN® 20). Reactions lacking inhibitor and reactions lacking enzyme were used as 100% and 0% activity controls, respectively. Inhibitor or control samples (5 μL) were added to the plate followed by 5 μL KLK4 (R&D Systems, 1719-SE, Lot MSY0116011, activated according to R&D systems protocol) in assay buffer at a final concentration of 2 nM. After 30 minutes, 5 μL of Boc-Val-Pro-Arg-AMC (Bachem I-1120, 31.3 mM stock solution in water) in assay buffer was added at a final concentration of 50 μM. After addition of substrate, the plate was read in PHERAstar® microplate reader using optic module FI 340 460 with the gain set to 85%. Measurements were taken every 102 seconds for 1 hour. Reaction rates (expressed as RFU/s) were calculated by linear regression in the range 510-3570 seconds. Reaction rates were normalized to the values of the 0% and 100% activity controls and fit with a 4-parameter equation to calculate IC₅₀values. In the case of bivalent inhibitors, the raw IC₅₀value was multiplied by two.

Trypsin selectivity assay was performed at room temperature in a 384-well plate (black, low-volume round bottom, Corning #4514) with a final reaction volume of 15 μL. Inhibitor samples were diluted to 3× final concentration in assay buffer (75 mM Tris, pH 8.0, 150 mM NaCl, 0.01% TWEEN® 20). Reactions lacking inhibitor and reactions lacking enzyme were used as 100% and 0% activity controls, respectively. Inhibitor or control samples (5 μL) were added to the plate followed by 5 μL trypsin (Sigma Aldrich T8003, Lot SLBM2321V, 42.0 μM stock solution in 1 mM HCl) in assay buffer at a final concentration of 0.25 nM. After 30 minutes, 5 μL of Boc-Val-Pro-Arg-AMC (Bachem I-1120, 31.3 mM stock solution in water) in assay buffer was added at a final concentration of 50 μM. After addition of substrate, the plate was read in PHERAstar microplate reader using optic module FI 340 460 with the gain set to 85%. Measurements were taken every 102 seconds for 1 hour. Reaction rates (expressed as RFU/s) were calculated by linear regression in the range 204-3570 seconds. Reaction rates were normalized to the values of the 0% and 100% activity controls and fit with a 4-parameter equation to calculate IC₅₀values. In the case of bivalent inhibitors, the raw IC₅₀value was multiplied by two.

KLK7 selectivity assay was performed at room temperature in a 384-well plate (black, low-volume round bottom, Corning #4514) with a final reaction volume of 15 μL. Inhibitor samples were diluted to 3× final concentration in assay buffer (75 mM Tris, pH 8.0, 150 mM NaCl, 0.01% TWEEN® 20). Reactions lacking inhibitor and reactions lacking enzyme were used as 100% and 0% activity controls, respectively. Inhibitor or control samples (5 μL) were added to the plate followed by 5 μL KLK7 (Genentech) in assay buffer at a final concentration of 5 nM. After 30 min, 5 μL of Suc-Leu-Leu-Val-Tyr-AMC (Bachem I-1395, 25 mM stock solution in water) in assay buffer was added at a final concentration of 100 μM. After addition of substrate, the plate was read in PHERAstar® microplate reader using optic module FI 340 460 (AMC Module) with the gain set to 85%. Measurements were taken every 102 seconds for 1hour 15 minute. Reaction rates (expressed as RFU/s) were calculated by linear regression in the range 2040-4488 seconds. Reaction rates were normalized to the values of the 0% and 100% activity controls and fit with a 4-parameter equation to calculate IC₅₀values.

PHERAstar® Experiments

Pre MCA PHERAstar Module: After 30 min, 5 μL of Suc-Leu-Leu-Val-Tyr-AMC (Bachem I-1395, 25 mM stock solution in water) in assay buffer was added at a final concentration of 100 μM. After addition of substrate, the plate was read in PHERAstar® microplate reader using optic module FI 340 460 (AMC Module) with the gain set to 85%. Measurements were taken every 102 seconds for 1hour 15 minute. Reaction rates (expressed as RFU/s) were calculated by linear regression in the range 2040-4488 seconds. Reaction rates were normalized to the values of the 0% and 100% activity controls and fit with a 4-parameter equation to calculate IC₅₀values.

Post MCA PHERAstar® Module: After 30 min, 5 μL of Mca-RPKPVE-Nval-WRK(Dnp)-NH2 Fluorogenic MMP Substrate (R&D Systems ES002, 4.3 mM stock solution in DMSO) in assay buffer was added at a final concentration of 10 μM. After addition of substrate, the plate was read in PHERAstar microplate reader using optic module FI 320 405 (MCA Module) with the gain set to 85%. Measurements were taken every 102 seconds for 1hour 15 minute. Reaction rates (expressed as RFU/s) were calculated by linear regression in the range 204-1020 seconds. Reaction rates were normalized to the values of the 0% and 100% activity controls and fit with a 4-parameter equation to calculate IC₅₀values.

Wasatch Experiments

An array-based SPR imaging system (Carterra™, USA) was used to epitope bin a panel of 288 monoclonal antibodies. Purified antibodies were diluted at 10 μg/ml in 10 mM sodium acetate buffer pH 4.5. Using amine coupling, antibodies were directly immobilized onto a SPR sensorprism CMD 200M chip (XanTec Bioanalytics GmbH, Germany) using a Continuous Flow Microspotter (Carterra™, USA) to create an array of 288 antibodies. For analysis, the IBIS MX96 SPRi (Carterra™, USA) was used to evaluate analytes binding to the immobilized ligands. For kinetic analyses, human, cyno and murine KLK5 were injected for 3 minutes from 0 to 300 nM at 3-fold dilution followed by a dissociation period of 10 minutes. Human KLK1, KLK4, and KLK7 were injected at a single concentration of 500 nM to ensure the specificities of the antibodies. For epitope binning against SPINK9-Fc-SRE, human KLK5 was first injected for 4 minute at 100 nM and was followed by a second 4 minute injection of SPINK9-Fc-SRE at 10 μg/ml. The surface was regenerated with 10 mM glycine pH1.5 between cycles. The experiment was performed at 25° C. in a running buffer of HBS-T buffer (0.01M HEPES pH 7.4, 0.15M NaCl, 0.05% surfactant P20). The kinetic data was processed using Scrubber 2.0 (BioLogic™ Software) and the epitope binning data was processed using Wasatch binning software tool (Carterra™, USA).

Hydrogen Exchange Mass Spectrometry

Experimental starting material compositions are listed in Table 2. Two labeling solutions were prepared with²H₂O (heavy water) having a pH of either 6.0 or 8.0, and consisting of a mixture of anhydrous monobasic sodium phosphate and dibasic sodium phosphate dehydrate combined in an appropriate ratio to achieve the stated deuterium activity at atotal concentration 10 mM with 140 mM NaCl. Starting materials (Table 2) were diluted approximately 1:10 with labeling solutions using a leap robotics platform and incubated for various times before being diluted 1:1 with quench buffer (4M GdmCl, 0.5 M TCEP, 200 mM Citric acid), to a final pH of 2.5, and then prepared quickly for mass measurement. Quenched material was injected into an online flow system where it was digested using pepsin, buffer exchanged while bound to a trap column, separated by reversed-phase chromatography, and introduced into the gas phase by electrospray where individual peptides are assessed for the amount of carried deuterium.

	TABLE 2

	Starting Material
	Exp. Composition

	Sample	Mab:KLK5 Ratio	[Mab] μM	[KLK5] μM

KLK5.10C5	0.70	23.10	33.00
KLK5.10H3	0.65	20.98	33.00
KLK5.9H5	0.55	18.07	33.00
KLK5	0.00	0.00	33.00

At either pH 6.0 or 8.0, samples were labeled for 0.5, 5.0, 56.0, and 600.0 minutes. Independent experimental replicates were included; on plots shown, error bars represent the range of measurements, whose average shown by markers inFIG. 12B. Feature abstraction and data analysis involved custom in-house software.

Effective labeling time at a reference pH was defined by both experimental pH and actual labeling time: t_eff=t_exp*10{circumflex over ( )}(PH_ref−pH_exp). The reference pH inFIG. 12B is 6.0. To correct for a well-known proton activity offset that occurs as a result of²H₂O, the following relationship connects pH measurements with pH values referred herein:

pH=pH_measure+([²H₂O/²H₂O+¹H₂O]*0.4).

The sequence and retention time of experimental peptides derived from KLK5 was determined in initial experiments where the same procedural workflow described above was followed but with a labeling buffer in¹H₂O solvent. This provides a starting mass from which the amount of deuterium contained in each peptide during the labeling experiments may be determined; additionally, these experiments utilize tandem-MS for de novo sequencing by MS.

IL-8 Secretion Assay

IL-8 is secreted by several cell types in response to inflammatory stimuli. KLK5 stimulates A459 cells, resulting in the secretion of IL-8. Adenocarcinomic human alveolar basal epithelial cells constitute the A549 cell-line. A549 cells were cultured with media containing RPMI, 10% FBS, L-glutamine, and supplemented with penicillin and streptomycin. Cells were plated into TC-treated 96-well plates (Corning, Cat.#3997) at 50,000 cells per well and starved of serum for 18 hours before KLK5 challenge. Human KLK5 was first incubated with KLK5 inhibitors or starvation media for 1 hour at room temperature prior to addition to plate (200 nM in-well concentration) for 24 hr at 37° C. in a humid environment in the presence of 5% CO₂. Endotoxin inhibitor (1 μM) was also added to each well. After incubation, the cell supernatants were collected and either analyzed immediately or stored at −20° C. Cell supernatants were serially diluted in sample diluent (PBS/0.5% BSA/0.05% polysorbate-20/5 mM EDTA/0.25% CHAPS/0.2% BGG/10 ppM Proclin) for analysis in an IL-8 sandwich ELISA using a standard protocol with mouse anti-human IL-8 monoclonal antibody for capture (R&D Systems, Cat # MAB208) and biotinylated mouse anti-human IL-8 monoclonal antibody for detection (R&D Systems, Cat # BAF208). The cell stimulation activity of KLK5 was analyzed by normalizing the IL-8 concentrations to 100% for KLK5 treatment alone and to 0% for starvation media alone treatment. IC₅₀values were determined using a 4-parameter fit with GraphPad Prism software.

KLK5 and Fab Expression, Purification and Crystallization

Recombinant human KLK5 residues I67-S293 (SEQ ID NO:328) was expressed in a Baculovirus expression system as a C-terminal fusion of ubiquitin with an Enterokinase cleavage site engineered between ubiquitin and KLK5. Sf9 cells were coexpressed with EndoH with 1 mg/mL of Kifunensine. Protein was purified on a HiTrap™ Heparin column. The column was washed with 25 mM TRIS pH 7.5 for 5 CV (column volumes), and then eluted with 0-750 mM NaCl over a gradient of 20 CV. Resultant protein pool was then further purified over 5200 by SEC in 25 mM Tris pH 7.5, 300 mM NaCl. The Ubiquitin was then cleaved using Enterokinase, and sample further purified by SEC again. Mass spectrometry and SDS PAGE revealed a pure KLK5 sample, which was confirmed to be active. Fab fragments including heavy and light chains were expressed and purified as described. See Carter et al.,Biotechnology10(2), 163-167 (1992). KLK5 was then mixed with each of the Fabs separately, 10C5, 9H5, and 3-3F5, and the complex was purified by SEC in 25 mM HEPES pH 7.2, 100 mM NaCl. The crystallization conditions for the 3 Fab-KLK5 complexes were as follows: 3-3F5 complex—15% PEG 4K, 0.1 M MgCl2, 0.1 M Na Citrate pH 5.0; 10C5 Complex: 20% PEG4K, 0.2M Ammonium Sulfate, 25% Glycerol; 9H5 Complex: 15% PEG4K, 10% Isopropanol, 0.1M HEPES pH 7.5. Crystal for the 10C5 and 9H5 complexes were only obtained when the lysine residues in the protein complexes were methylated. See Walter et al.,Structure,14(11), 1617-1622 (2006).

Data Collection and Structure Solution

X-ray diffraction data was collected under cryo-cooled conditions at 100 Kelvin using various synchrotron X-ray radiation at the Advanced Light Source (Berkeley, Calif.) or Advanced Photon Source (Argonne, Ill.) according to standard methods. Diffraction images were processed and reduced using the data processing software XDS. See Kabsch W,Acta Crystallogr D Biol Crystallogr,66 (Pt 2), 125-132 (2010). Models were generated using the molecular replacement technique with the program PHASER. The structure of human TIGIT (see Debala et al.,J Mol Biol,373:1017-1031 (2007)) and Fab antibody model (See Nakamura et al.,Cell Host Microbe,14(1), 93-103 (2013)) were used as search models. The structures underwent iterative rounds of model adjustment using the program COOT and refinement using the Phenix.refine or BUSTER programs. Models were refined to acceptable R and R free values and Ramachandran statistics (calculated by Molprobity). The crystal structures of KLK5 complexed with each of the Fabs, 10C5, 9H5 and 3-3F5 as well as the details of interactions and epitopes can be found inFIGS. 18-20 and Tables 5-13.

Example 2—Humanization of Anti-KLK5 Antibodies

By immunization of animals with human KLK5 as described herein above, as set of 540 monoclonal anti-KLK5 antibodies was obtained. As this set contained anti-KLK5 antibodies with highly variable characteristics, the antibodies were screened for desired characteristics, such as a certain 1050 values and selectivity to human KLK5. This screening revealed a large number of antibodies with low affinity to human KLK5, no selectivity with respect to human KLK5, and/or insufficient functional activity. For example, some of the obtained anti-KLK5 antibodies were partial inhibitors, i.e. inhibition by ≤50% (e.g. clones 12B3, 1D10) or inhibition by ≤90% (e.g. clones 14C8, 14E12, 8E11). Some of the obtained anti-KLK5 antibodies inhibited human KLK5 only in one of the assays described herein (e.g. clones 9E3, 10D10). Only 13 anti-KLK5 antibodies were selected based on their characteristics (clones 8G10, 9B6, 2-3F4, 10C5, 2B11, 10H3, 9H3, 8B7, 9H5, 9F2, 10C8, 8F5, 3-3F5). The three anti-KLK5 antibodies with the highest inhibitory activities (clones 9H5, 10C5, 3-3F5) were then selected for humanization.

Rabbit monoclonal antibodies 9H5, 10C5, and 3-3F5 were humanized as described below. Residue numbers are according to Kabat et al., Sequences of proteins of immunological interest, 5th Ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991).

Variants constructed during the humanization of 9H5, 10C5, and 3-3F5 were assessed in the form of human IgG1. Hypervariable regions from each of the rabbit antibodies (namely positions 24-34 (L1), 50-56 (L2) and 89-97 (L3) in VL domain, and 26-35 (H1), 50-65 (H2) and 95-102 (H3) in VH domain) were grafted into various acceptor frameworks. Specifically, for 9H5, VL CDRs were grafted into KV1D-39*01 and VH CDRs were grafted into HV3-53*01. For 10C5, VL CDRs were grafted into KV1-8*01 and VH CDRs were grafted into HV3-64*01. For 3-3F5, VL CDRs were grafted into KV1-8*01 and VH CDRs were grafted into HV3-23*01. All VL and VH Vernier positions from rabbit antibodies were also grafted into their respective human germline frameworks. The grafts with all rabbit amino acids in Vernier positions are referred to as L1H1 (hu9H5.L1H1, hu10C5.L1H1 and hu3-3F5.L1H1) (FIGS. 14-16).

The binding affinity of the antibodies in this section was determined using BIAcore™ T200 as described herein above. The binding affinity of humanized 9H5, 10C5 and 3-3F5 version L1H1 (hu9H5.L1H1, hu10C5.L1H1 and hu3-3F5.L1H1) antibodies were compared to their chimeric parental clones. Rabbit Vernier positions of version L1H1 antibodies were converted back to human residues to evaluate the contribution of each rabbit Vernier positions to binding affinity to hKLK5.

For 9H5, three additional light chains (L2: L1+Ala43, L3: L1+Tyr49, and L4: L1+Ala43+Tyr49 (CDR graft)) and sixteen additional heavy chains (H2: H1+Ala24, H3: H1+Trp47, H4: H1+Val48, H5: H1+Ser49, H6: H1+Phe67, H7: H1+Asn73, H8: H1+Leu78, H9: H1+Tyr91, H10: H1+Gln105, H11: no rabbit residues in Vernier positions (CDR graft), H12: H1+Asp61+Ser62+Val63+Gly65, H13: CDR graft+Asp61+Ser62+Val63+Gly65, H14: CDR graft+Tyr47+Gly49, H15: H14+Gln2, H16: H14+Asn72+Thr73+Asn74+Leu75, and H17: H14+Phe62) were made (FIG. 15). Tyr47 and Gly49 on the heavy chain (H14) were determined to be the key rabbit Vernier residues based on binding affinity evaluation of the variant antibodies described above (data not shown). Chimeric 9H5 bound with a KD of 1.9E⁻¹° M, while hu9H5.L4H14, bound with a KD of 6.9E⁻¹⁰M.

For 10C5, four additional light chain variants L2-L5 (L2: L1+Ile2, L3: L1+Ala43, L4: L1+Ile2+Ala43 (CDR graft), L5: CDR graft+Ser77+Pro80, L6: CDR graft+Ser77+Pro80+Glu103+Val105+Val106) and twenty-seven additional heavy chain variants H2 to H28 (H2: H1+Ala24, H3: H1+Tyr47, H4: H1+Val48, H5: H1+Ser49, H6: H1+Phe67, H7: H1+Asn73, H8: H1+Leu78, H9: H1+Tyr91, H10: H1+Gln105, H11: H1+Asn61+Ser62+Val63+Gly65, H12: no rabbit residues in Vernier positions (CDR graft), H13: CDR graft+Asn61+Ser62+Val63+Gly65, H14: CDR graft+Trp47+Gly49, H15: H14+Gln2, H16: H14+Asn72+Leu73+Asn74+Thr75, H17: H14+Phe62, H18: H14+Asn72+Thr73+Asn74+Leu75, H19: H14+Asn72, H20: H14+Asn74, H21: H14+Asn72+Asn74, H22: H14+Ile48, H23: H14+Ser67, H24: H22+Ser67, H25: H14+Thr73, H26: H14+Thr78, H27: H25+Thr78, H28: H22+Ser67+Thr73+Thr78) were made (FIG. 14). Trp47, Ile48, Gly49, Ser67, Thr73, and Val78 on the heavy chain (H28) were determined to be the key rabbit Vernier residues based on binding affinity evaluation of the variant antibodies described above (data not shown). Chimeric 10C5 bound with a KD of 1.65E⁻¹¹M, while hu10C5.L5H28, bound with a KD of 5.70E″¹¹M.

For 3-3F5, four additional light chain variants L2-L5 (L2: L1+Ile2, L3: L1+Ala43, L4: L1+Ile2+Ala43 (CDR graft), L5: CDR graft+Ser77+Pro80) and twenty-six additional heavy chain variants H2 to H27 (H2: H1+Ala24, H3: H1+Val48, H4: H1+Ser49, H5: H1+Phe67, H6: H1+Asn73, H7: H1+Leu78, H8: H1+Tyr91, H9: H1+Arg105, H10: H1+Phe58, H11: H1+Asp61+Ser62+Val63, H12: CDR graft+Phe58, H13: CDR graft+Phe58+Asp61+Ser62+Val63, H14: CDR graft+Gly49, H15: H14+Phe58, H16: H14+Gln2, H17: H14+Asn72+Thr73+Asn74+Leu75, H18: H14+Phe62, H19: H18+Val24, H20: H18+Ile48, H21: H18+Ser67, H22: H18+Ile48+Ser67, H23: H18+Thr73, H24: H18+Val78, H25: H18+Thr73+Val78, H26: H18+Ile148+Ser67+Thr73+Val78, H27: CDRs graft+Ala24+Ile48+Gly49+Phe58+Phe62+Ser67, H28: H19+Phe58+Thr73+Thr78) were made (FIG. 16). Val24, Gly49, Thr73, and Val78 on the heavy chain (H28) were determined to be the key rabbit Vernier residues based on binding affinity evaluation of the variant antibodies described above (data not shown). Chimeric 3-3F5 bound with a KD of <1E⁻¹²M (KD is below the detection limit of 10E⁻⁶s⁻¹for the instrument), while hu3-3F5.L5H19 bound with a KD of 4.1E⁻¹²M and hu3-3F5.L5H25 bound with a KD of 9.1E⁻¹²M.

The hu9H5.L4H14, hu10C5.L5H28, hu3-3F5.L5H19, hu3-3F5.L5H25 and their chimeric counterparts were tested for their ability to bind human KLK5 as described herein above. Binding properties for the humanized antibodies are shown in Table 3.

TABLE 3

Ligand	Sample	ka (1/Ms)	kd (1/s)	KD (M)

human KLK5	9H5	7.05E⁺⁵	1.37E⁻⁴	1.93E⁻¹⁰
	hu9H5.L4H14	8.10E⁺⁵	5.62E⁻⁴	6.94E⁻¹⁰
human KLK5	10C5	1.78E⁺⁷	2.92E⁻⁴	1.65E⁻¹¹
	hu10C5.L5H28	1.90E⁺⁷	1.08E⁻³	5.70E⁻¹¹
human KLK5	3-3F5	2.93E⁺⁷	<1.00E⁻⁵	<1.00E⁻¹²
	hu3-3F5.L5H19	4.84E⁺⁷	2.01E⁻⁴	4.14E⁻¹²
	hu3-3F5.L5H25	2.57E⁺⁷	2.35E⁻⁴	9.14E⁻¹²

Example 3—Evaluation of IC₅₀Values and Specificity of Anti-KLK5 AntibodiesEvaluation of KLK5 Inhibitor IC₅₀Values Using Fluorescent Peptide Substrates

The ability of Spink9.SRE.Fc, mAb1108 or 12 selected antibodies to inhibit the proteolysis of the substrate, Boc-VPR-AMC, by human KLK5 was assessed using an enzymatic assay. In this assay the three-mer fluorogenic peptide substrate contains a highly fluorescent 7-amino4-methylcoumarin (AMC) group that is quenched by resonance energy transfer to the t-Butyloxycarbonyl (Boc). The cleavage of the peptide substrate by human KLK5 resulted in an increased fluorescent signal and the inhibition or absence of KLK5 resulted in a quenched fluorescent signal. The results were expressed as a percentage of maximum KLK5 activity (% control). The results of a single experiment run in duplicate are shown inFIG. 1. The calculated IC₅₀value for Spink9.SRE.Fc (FIG. 1A) was 1.23 nM and the range of IC₅₀values for the 12 selected antibodies (FIGS. 1 C-N) was 0.89 to 1.32 nM. Spink0.SRE.Fc as well as all 12 selected antibodies fully inhibited KLK5 activity, although mAb1108 (FIG. 1B) only demonstrated ˜20% inhibition of KLK5 activity. The IC₅₀values from the curve fittings are presented inFIG. 11 (Column 1).

Evaluation of KLK5 Inhibitor IC₅₀Values Using Coupled Macromolecular Substrate Activity

As demonstrated inFIG. 1, Spink9.SRE.Fc as well as the identified 12 anti-KLK5 antibodies are potent inhibitors of KLK5 activity as monitored using a peptide based substrate. To further evaluate the inhibitory profiles of these inhibitors, two assays were developed utilizing macromolecular substrates, pro-KLK7 (FIG. 2) and pro-KLK1 (FIG. 3), in combination with KLK specific fluorescent peptide substrates.

InFIG. 2, the ability of Spink9.SRE.Fc, mAb1108 or 12 selected anti-KLK5 antibodies to inhibit KLK5 mediated activation of pro-KLK7 was assessed using a coupled enzymatic assay. In this assay, human KLK5 is incubated with human pro-KLK7 resulting in cleavage, release of the KLK7 pro-domain and activation of KLK7. Activated human KLK7 can proteolyze a KLK7 specific substrate, Suc-LLVY-AMC, resulting in an increased fluorescent signal. The cleavage of pro-KLK7 by human KLK5 results in active KLK7 and an increased fluorescent signal whereas the inhibition or absence of KLK5 resulted in a quenched fluorescent signal. The results were expressed as a percentage of maximum human KLK5 activity (% control). The results of a single experiment run in duplicate are shown inFIG. 2.

InFIG. 3, the ability of Spink9.SRE.Fc, mAb1108 or 12 selected anti-KLK5 antibodies to inhibit KLK5 mediated activation of pro-KLK1 was assessed using a coupled enzymatic assay. In this assay, human KLK5 is incubated with human pro-KLK1 resulting in cleavage, release of the KLK7 pro-domain and activation of KLK1. Activated human KLK1 can proteolyze a KLK1 specific substrate, PFR-AMC, resulting in an increased fluorescent signal. The cleavage of pro-KLK1 by human KLK5 results in active KLK1 and an increased fluorescent signal whereas the inhibition or absence of KLK5 resulted in a quenched fluorescent signal. The results were expressed as a percentage of maximum human KLK5 activity (% control). The results of a single experiment run in duplicate are shown inFIG. 3. The IC₅₀value for Spink9. SRE.Fc (FIG. 3A) was 0.325 nM and the range of IC₅₀for the 12 selected anti-KLK5 antibodies (FIGS. 2 C-N) was 0.074 to 0.151 nM. Spink0.SRE.Fc as well as all 12 selected anti-KLK5 antibodies fully inhibited KLK5 activity, although mAb1108 (FIG. 1B) only demonstrated ˜40% inhibition of KLK5 activity. The IC₅₀values from the curve fittings are presented inFIG. 11 (Column 3).

KLK5-Derived Cleavage Peptide Detection by LC/MS for IC₅₀Value Determination

The ability of Spink9.SRE.Fc, mAb1108 or 12 selected anti-KLK5 antibodies to inhibit proteolysis of pro-KLK7 or pro-KLK1 by recombinant KLK5 was assessed using an LC/MS assay that monitors the KLK5-derived cleavage product peptides. For both assays, the cleavage of the pro-peptide KLK7 or KLK1 by human KLK5 results in a specific MS signal and the inhibition of KLK5 activity results in a measurable decrease of the peptide signal. The results of a single experiment for pro-KLK7 are shown inFIG. 4 and they are expressed as area of pro-peptide KLK7. The calculated IC₅₀value for Spink9.SRE.Fc (FIG. 4A) was 1.13 nM, for MAb1108 (FIG. 4B) was 1.86 nM and the range of IC₅₀values for the 12 selected anti-KLK5 antibodies (FIG. 4 C-N) was 0.31 to 1.72 nM. Spink9.SRE.Fc as well as all 12 selected anti-KLK5 antibodies fully inhibited KLK5 activity, and mAb1108 (FIG. 4B) demonstrated ˜80% inhibition of KLK5 activity. The IC₅₀values from the curve fittings are presented inFIG. 11 (Column 4).FIG. 5 shows the results of three experiments for pro-KLK1 and they are expressed as area of pro-peptide KLK1. The IC₅₀value for Spink9.SRE.Fc (FIG. 5A) was 0.58 nM, for MAb1108 (FIG. 5B) was 0.34 nM and the range of IC₅₀values for the 12 selected anti-KLK5 antibodies (FIG. 5 C-N) was 0.08 to 0.48 nM. Spink9.SRE.Fc as well as all 12 selected anti-KLK5 antibodies fully inhibited KLK5 activity, although mAb1108 (FIG. 5B) demonstrated ˜40% inhibition of KLK5 activity. The ICso values from the curve fittings are presented inFIG. 11 (Column 5).

Specificity of KLK5 Antibodies

To evaluate the specificity the anti-KLK5 antibodies characterized inFIGS. 1-5, the 12 anti-KLK5 antibodies were assayed against activated human KLK7 (FIG. 6), human KLK1 (FIG. 7), human KLK4 (FIG. 8) and trypsin (FIG. 9) monitored by the cleavage of specific fluorescent peptide substrates. As these 12 anti-KLK5 antibodies were generated to selectively interact with KLK5, it was anticipated that these molecules should not inhibit other KLKs (FIGS. 6-9) or trypsin (FIG. 9).

InFIG. 6, the ability of Spink9.SRE.Fc, mAb1108 or 12 selected anti-KLK5 antibodies to inhibit the proteolysis of the substrate, Suc-LLVY-AMC, by human KLK7 was assessed using an enzymatic assay. The cleavage of the peptide substrate by human KLK7 resulted in an increased fluorescent signal and the inhibition or absence of KLK7 resulted in a quenched fluorescent signal. The results were expressed as a percentage of maximum KLK7 activity (% control). The results of a single experiment run in duplicate are shown inFIG. 6. Spink9.SRE.Fc (FIG. 6A) and mAb1108 (FIG. 6B) did not inhibit KLK7 up to 100 nM. As seen inFIG. 6, the 12 selected anti-KLK5 antibodies (FIGS. 6C-N) also do not inhibit KLK7 activity up to 100 nM. The IC₅₀values from the curve fittings are presented inFIG. 11 (Column 6).

InFIG. 7, the ability of Spink9.SRE.Fc, mAb1108 or 12 selected anti-KLK5 antibodies to inhibit the proteolysis of the substrate, PFR-AMC, by human KLK1 was assessed using an enzymatic assay. The cleavage of the peptide substrate by human KLK1 resulted in an increased fluorescent signal and the inhibition or absence of KLK1 resulted in a quenched fluorescent signal. The results were expressed as a percentage of maximum KLK1 activity (% control). The results of a single experiment run in duplicate are shown inFIG. 7. Spink9.SRE.Fc (FIG. 7A) and mAb1108 (FIG. 7B) did not inhibit KLK1 up to 100 nM. As seen inFIG. 7, the 12 selected anti-KLK5 antibodies (FIGS. 7C-N) also do not inhibit KLK1 activity up to 100 nM. The IC₅₀values from the curve fittings are presented inFIG. 11 (Column 7).

InFIG. 8, the ability of Spink9.SRE.Fc, mAb1108 or 12 selected anti-KLK5 antibodies to inhibit the proteolysis of the substrate, Boc-VPR-AMC, by human KLK4 was assessed using an enzymatic assay. The cleavage of the peptide substrate by human KLK4 resulted in an increased fluorescent signal and the inhibition or absence of KLK4 resulted in a quenched fluorescent signal. The results were expressed as a percentage of maximum KLK4 activity (% control). The results of a single experiment run in duplicate are shown inFIG. 8. Spink9.SRE.Fc (FIG. 8A) and mAb1108 (FIG. 8B) did not inhibit KLK4 up to 100 nM. As seen inFIG. 8, the 12 selected anti-KLK5 antibodies (FIGS. 8C-N) also do not inhibit KLK4 activity up to 100 nM. The IC₅₀values from the curve fittings are presented inFIG. 11 (Column 8).

InFIG. 9, the ability of Spink9.SRE.Fc, mAb1108 or 12 selected antibodies to inhibit the proteolysis of the substrate, Boc-VPR-AMC, by bovine trypsin was assessed using an enzymatic assay. The cleavage of the peptide substrate by trypsin resulted in an increased fluorescent signal and the inhibition or absence of trypsin resulted in a quenched fluorescent signal. The results were expressed as a percentage of maximum trypsin activity (% control). The results of a single experiment run in duplicate are shown inFIG. 9. Spink9.SRE.Fc (FIG. 9A) and mAb1108 (FIG. 9B) did not inhibit trypsin up to 100 nM. As seen inFIG. 9, the 12 selected antibodies (FIG. 9C-N) also do not inhibit trypsin activity up to 100 nM. The IC₅₀values from the curve fittings are presented inFIG. 11 (Column 9).

Taken together, these studies using KLK7 (FIG. 6 and Table 6), KLK1 (FIG. 7 and Table 7), KLK4 (FIG. 8 and Table 8) and trypsin (FIG. 9 and Table 9) show that Spink9.SRE.Fc, mAb1108 or the 12 selected antibodies specifically interact and inhibit only KLK5 activity.

Ranking of Antibodies by Ki_app

In characterizing the 12 selected antibodies in either the direct (FIG. 1) or coupled assays (FIGS. 2-5), it was observed that the selected antibodies have similar or greater inhibitory potency than Spink9.SRE.Fc for KLK5. However, several of the antibodies have similar IC₅₀values in each of the assays (Tables 1-5) making it difficult to rank the potency of the antibodies.

InFIG. 10, the ability of Spink9.SRE.Fc, mAb1108 or 12 selected antibodies to inhibit the proteolysis of the substrate, z-VPR-pNA, by human KLK5 at various concentrations was assessed using an enzymatic assay. In this assay the three-mer chromogenic peptide substrate contains a p-nitroanilide (pNA) group that is quenched by the terminal amino acid. The cleavage of the chromogenic peptide substrate by KLK5 resulted in an increased absorbance at 405 nm and the inhibition or absence of KLK5 resulted in a low absorbance 405 nm. The results were expressed as a percentage of maximum KLK5 activity (% control).

The IC₅₀values of Spink9.SRE.Fc at various KLK5 concentrations (FIG. 10A) is determined and plotted as a function of KLK5 concentration (FIG. 10B) where the Ki_appvalue is determined as the y-intercept. From this analysis, the Ki_appvalue for Spink9.SRE.Fc is 1.28 nM. This analysis was also performed for mAb1108 (FIGS. 10 C-D) that has a Ki_appvalue of 1.53 nM as well as the 12 selected antibodies (FIGS. 10 E-AB), which have a range of Ki_appvalues of less than 0.01 nM to 6.35 nM. The Ki_appvalues from this analysis are presented inFIG. 11 (Column 10).

Example 4—Kinetic Analysis and Epitope Binning with Wasatch

The results of the epitope binning and off-rates against human KLK5 for a subset of the most potent antibodies are shown in Table 4. Variable levels of binding were observed to mouse and cyno KLK5. Importantly, no binding was observed to human KLK1, human KLK4, or human KLK7, confirming that these antibodies are specific. Most clones, except for 8E11 and 8G10, compete with SPINK9 for binding to human KLK5, suggesting that they either bind the same epitope (i.e., the active site) at SPINK9 or allosterically alter human KLK5 so that SPINK9 can no longer bind.

TABLE 4

Clone ID	SPINK9 competition (Y/N)	human KLK5 kd (1/s)

14C8	Y	3.76E⁻⁰⁴
14E12	Y	4.14E⁻⁰⁴
2B11	Y	5.74E⁻⁰⁴
8B7	Y	5.47E⁻⁰⁴
8E11	N	2.02E⁻⁰⁴
8F5	Y	3.16E⁻⁰⁴
8G10	N	2.45E⁻⁰⁴
9B6	Y	1.78E⁻⁰⁴
9F2	Y	3.39E⁻⁰⁴
9H3	Y	1.43E⁻⁰⁴
9H5	Y	3.67E⁻⁰⁴
10C5	Y	1.26E⁻⁰⁴
10C8	Y	6.16E⁻⁰⁵
10H3	Y	5.89E⁻⁰⁴
2.3F4	Y	1.84E⁻⁰⁴
SPINK9-SRE-Fc	Y	4.70E⁻⁰⁴

Example 5—Epitope Mapping by Hydrogen Exchange Mass Spectrometry

Hydrogen exchange measurements as completed herein measure the exchange of protons bound to backbone amide residues with those bound to molecules of the solvent. When a protiated (¹H) sample is diluted into deuterated solvent, difference in mass between a proton and deuteron can be measured by mass spectrometry. Upon a series of increasing incubation times in deuterated solvent (²H₂O), rate of exchange can be measured. In this way, KLK 5 (SEQ ID NO:353) complexed to one of three anti-KLK5 antibodies (10C5, 10H3 and 9H5) over three separate experiments was measured and then compared to results obtained from performing the experiment on KLK5 alone. A differential analysis of mass differences was then performed and overlapping peptides utilized to narrow in on a common thermodynamic epitope shared between all three anti-KLK5 antibodies (10C5, 10H3 and 9H5) (FIG. 12 A). The term “thermodynamic epitope” refers to those portions of a protein whose backbone structural dynamics, or local free energy of unfolding is altered in response to a specific binding event such as becoming bound by an antibody. The structural epitope may be contained within the thermodynamic epitope.

Interpretation of data used the rule of N-2 whereby each peptide cannot carry deuterium on the first two sites due to back exchange. In addition, when there are many unique overlapping peptides, this information may be used to narrow in on those affected residues within each peptide. The four sequence regions of KLK5 identified to comprise a common thermodynamic epitope between are LRPNQL (FIG. 12 B, Region 1), QGVKSI (FIG. 12 B, Region 2), KRCEDAYPRQIDDT (FIG. 12 B, Region 3), and DYPCARPNRPGVY (FIG. 12 B, Region 4), a common structural epitope between all three antibodies tested is contained within these regions.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, the descriptions and examples should not be construed as limiting the scope of the invention. The disclosures of all patent and scientific literature cited herein are expressly incorporated in their entirety by reference.

Example 6—Evaluation of KLK5 Inhibitor IC₅₀Values in a Cell-Based IL-8 Secretion Assay

KLK5 stimulates A549 cells to secrete IL-8. The ability of Spink5.Fc, Spink9.SRE.Fc, or humanized anti-KLK5 antibodies 3-3F5, 9H5, or 10C5, to inhibit KLK5-induced IL-8 secretion was evaluated in the A549 cell-based IL-8 secretion assay. In this assay, serum-starved A549 cells were stimulated with 200 nM KLK5 for 24 hr (KLK5 alone or KLK5 pre-incubated with inhibitors for 1 hour). The IL-8 concentration was measured with a sandwich ELISA and IC₅₀s of the inhibitors were determined. The results were expressed as a percentage of maximum KLK5 activity and the averages±standard deviations of at least three independent experiments are shown inFIG. 17. All inhibitors fully inhibited KLK5-induced IL-8 secretion to within 5% of the level of buffer alone (starvation media), which was within the error of the assay. All inhibitors showed potent inhibition of KLK5-induced IL-8 secretion and the average IC₅₀s for at least three independent experiments were as follows: Spink5.Fc (21 nM); 10C5 (28 nM); 9H5 (15 nM); 3-3F5 (1.2 nM). The residual activity observed when KLK5 is incubated with 360 nM Spink9.SRE.Fc is 2% (data not shown).

Example 7—Structure of 10C5, 9H5 and 3-3F5 Bound to Human KLK5

For crystal structure experiments described herein, human KLK5 residues I67-S293 (SEQ ID NO:328) were used. The numbering of the amino acid residues of human KLK5 used in this Example 7 and as shown in correspondingFIGS. 18-20 and Tables 5-13 is based on the standard numbering for proteases. See Debela et al.,J Mol Biol,373, 1017-1031 (2007). The numbering of the amino acid residues of the Fab fragments used in this Example 7 and as shown in correspondingFIGS. 18-20 and Tables 5-13 is based on Kabat.

The Structure of 10C5 Bound to Human KLK5

The 10C5 Fab/KLK5 complex structure shows that the binding of 10C5 to KLK5 results in conformational changes that allosterically result in disruption of the substrate binding site as well as the active site of KLK5, including the catalytic triad, rendering the protease unable to bind substrates and losing activity. The most distinct element of KLK5 that is recognized by the 10C5 fab is the helix encompassing residues 163-174A. The loop/turn immediately following the helix, made up by the residues 173-174A is flipped up by the antibody binding which results in a steric clash with residues in the 220s loop as well as the 90s loop (standard protease convention), that are important for substrate binding as well as positioning of the catalytic triad in the active site that cleaves peptides (FIG. 18A).

The buried surface area between KLK5 and 10C5 Fab is ˜860 Å². In the 10C5 fab light chain, CDR-L1, residues Q24-S34 contact residues 5131, A132, 5164 and R167 in KLK5; Y50 from CDR-L2 contacts R167 in KLK5; CDR-L3 contacts A132, L163, 5164, Q165, K166, E169, I176, D177 and D178 in KLK5. In the 10C5 heavy chain, CDRH1, residues S31-T35 contact only D170 in KLK5; CDRH2, residues Y50-A63, contacts residues K166, E169, D170, A171, Y172, P173, R174, Q174A and 1176 in KLK5; CDRH3, E95-Y100c contacts residues 5164, K166, R167 and D170 in KLK5 (Tables 5-7,FIG. 18B).

The sequences of the 10C5 Fab HC and LC used for the crystallization with human KLK5 is depicted in SEQ ID NO:322 and SEQ ID NO:323, respectively.

TABLE 5

	Interface		Interface
	residues in		residues
	KLK5		in KLK5
Interface residues in	(Standard	Interface residues in	(Standard
10C5 Heavy Chain	Protease	10C5 Light Chain	Protease
(Kabat Numbering)	Numbering)	(Kabat Numbering)	Numbering)

Ser 31	Ser 164	Glu 27	Pro 130
Gly 33	Lys 166	Ser 28	Ser 131
Tyr 50	Arg 167	Ser 30	Ala 132
Thr 52	Glu 169	Glu 32	Val 162
Ser 52A	Asp 170	Tyr 50	Leu 163
Asn 53	Ala 171	Gly 91	Ser 164
Tyr 54	Tyr 172	Phe 92	Gln 165
Val 56	Pro 173	Gly 93	Lys 166
Ser 57	Arg 174	Ser 94	Arg 167
Tyr 58	Gln 174A	Ser	95	Glu 169
Tyr 59	Ile 176	Val 97	Gln 174A
Lys 64	Arg 224		Ile 176
Glu 95			Asp 177
Pro 97			Asp 178
Gly 100			Lys 233
Tyr 100A
Tyr 100C

TABLE 6

Hydrogen Bonds

	Bond			Bond
Heavy Chain	Length		Light Chain	Length
Residue	(Angstrom)	KLK5 residue	Residue	(Angstrom)	KLK5 residue

Tyr 50 [OH]	2.8	Glu 169 [OE2]	Tyr 50 [OH]	2.6	Arg 167 [NH1]
Ser 52A [OG]	2.6	Asp 170 [OD1]	Phe 92 [O]	2.9	Gln 165 [N]
Ser 52A [N]	3.4	Asp 170 [OD2]	Phe 92 [O]	3.2	Lys 166 [N]
Tyr 58 [OH]	3.8	Arg 174 [O]	Ser 95 [OG]	3.7	Asp 178 [N]
Ser 57 [O]	2.6	Gln 174A	Ser 94 [N]	2.7	Glu 169 [OE1]
		[NE2]
Tyr 58 [OH]	3.0	Ile 176 [N]

TABLE 7

Salt Bridges

	Bond
Heavy Chain	Length
Residue	(Angstrom)	KLK5 residue

Glu 95 [OE1]	2.3	Lys 166 [NZ]
Glu 95 [OE1]	3.4	Lys 166 [NZ]

The Structure of 9H5 Bound to Human KLK5

The 9H5 Fab/KLK5 complex structure shows that the binding of 9H5 to KLK5 results in conformational changes, similar to 10C5 fab, result in allosteric disruption of the substrate binding site as well as the active site of KLK5, including the catalytic triad, rendering the protease unable to bind substrates and losing activity. The most distinct element of KLK5 that is recognized by the 9H5 fab is the helix encompassing residues 163-174A. The loop/turn immediately following the helix, made up by the residues 173-174A is flipped up by the antibody binding which results in a steric clash with residues in the 220s loop as well as the 90s loop (standard protease convention), that are important for substrate binding as well as positioning of the catalytic triad in the active site that cleaves peptides. Overall, more of the KLK5 protein is disordered in the 9H5:KLK5 complex crystal structure, compared to 10C5 bound KLK5, and is likely a direct result of the Fab binding and the induced conformational changes (FIG. 19A).

The buried surface area between KLK5 and 9H5 Fab is 805 Å². In the 9H5 light chain, CDRL1, residues Q24-S34 contacts residues 5131, A132, G133, L163, 5164, R167 in KLK5; CDRL2, residues S50-S56, does not contact any residues in KLK5; CDRL3, residues H89-T97 contact residues A132, 5164, Q165, K166, E169, Q174A, 1176 and D177 in KLK5. In the 9H5 heavy chain, CDRH1, residues S31-S35 do not contact KLK5; CDRH2, residues F50-A63 contacts residues K166, E169, D170, Y172, P173, R174, Q174A and 1176 in KLK5; CDRH3, residues D95-1102 contacts residues K166, R167 and D170 in KLK5 (Tables 8-10,FIG. 19B).

The sequences of the 9H5 Fab HC and LC used for the crystallization with human KLK5 is depicted in SEQ ID NO:324 and SEQ ID NO:325, respectively.

TABLE 8

	Interface		Interface
	residues		residues
	in KLK5		in KLK5
Interface residues in	(Standard	Interface residues	(Standard
9H5 Heavy Chain	Protease	in 9H5 Light Chain	Protease
(Kabat Numbering)	Numbering)	(Kabat Numbering)	Numbering)

Ser 31	Ser 164	Gln 27	Pro 130
Gly 33	Lys 166	Ser 28	Ser 131
Ser 35	Arg 167	Ser 30	Ala 132
Phe 50	Glu 169	Tyr 32	Gly 133
Gly 52	Asp 170	His 89	Val 162
Ser 53	Ala 171	Gln 90	Leu 163
Gly 54	Tyr 172	Asp 91	Ser 164
Phe 56	Pro 173	Tyr 92	Gln 165
Tyr 58	Arg 174	Thr 93	Lys 166
Lys 64	Gln 174A	Ser	94	Arg 167
Asp 95	Ile 176	Ser 95	Glu 169
Val 97	Asp 177	Asn 95A	Gln 174A
Gly 98		Thr 97	Ile 176
Ser 100B			Asp 177
Leu 100C			Lys 233

TABLE 9

Hydrogen Bonds

Ser 53 [N]	2.3	Asp 170 [OD2]	Tyr 92 [O]	3.2	Gln 165 [N]
Ser 53 [N]	3.5	Asp 170 [O]	Tyr 92 [O]	2.8	Lys 166 [N]
Ser 53 [OG]	2.2	Asp 170 [OD2]	Ser 30 [OG]	3.1	Ala 132 [O]
Ser 53 [OG]	3.7	Asp 170 [O]	Thr 93 [OG1]	2.9	Glu 169 [OE1]
Gly 54 [N]	3.5	Asp 170 [OD2]	Ser 95 [OG]	3.4	Glu 169 [OE1]
Gly 54 [N]	2.8	Asp 170 [O]	Ser 94 [N]	3.0	Glu 169 [OE2]
Tyr 58 [OH]	3.1	Ile 176 [O]	Ser 95 [OG]	3.6	Ile 176 [O]
Gly 98 [O]	3.6	Arg 167 [NH2]	Asn 95A	2.5	Asp 177 [OD1]
			[ND2]
Tyr 58 [OH]	2.7	Ile 176 [N]

TABLE 10

Salt Bridges

	Bond
Heavy Chain	Length
Residue	(Angstrom)	KLK5 residue

Asp 95 [OD1]	2.5	Lys 166 [NZ]
Asp 95 [OD2]	3.7	Lys 166 [NZ]

The Structure of 3F5.5 Fab Bound to Human KLK5

The 3-3F5 Fab/KLK5 complex structure shows that the binding of the 3-3F5 to KLK5 results in slight conformational changes, although not as drastic as observed with the 10C5 or the 9H5 complexes with KLK5. The substrate recognition pocket is altered, where the Asp 189 in KLK5, (which forms a salt bridge and thereby recognizing positively charged P1-residue (Arg/Lys) before proteolysis) becomes disordered. The catalytic triad in KLK5 appears intact, although the fab binding renders the catalytic pocket more open, resulting in KLK5 losing catalytic activity. The 140s loop and 70s loop are disordered in the crystal structure (FIG. 20A).

The buried surface area between KLK5 and 3F5.5 Fab is 956 Å². In the 3-3F5 light chain, CDRL1, residues Q24-A34 contact 5131, A132 and G133 in KLK5; CDRL2, residues D50-S56 does not contact any residues in KLK5; CDRL3, residues Q89-I97 contact residues S164, Q165, K166 and E169 in KLK5. In the 3F5.5 heavy chain, CDRH1 residues D31-E46 does not interact with KLK5 at all, neither does CDRH2; CDRH3, residues D95-G100i contact residues L163, 5164, K166, R167, D170, G184, D185, K186, A187, N224, R225 and P225 in KLK5 (Tables 11-13,FIG. 20B).

The sequences of the 3-3F5 Fab HC and LC used for the crystallization with human KLK5 is depicted in SEQ ID NO:326 and SEQ ID NO:327, respectively.

TABLE 11

	Interface		Interface
	residues		residues
	in KLK5		in KLK5
Interface residues in	(Standard	Interface residues in	(Standard
3-3F5 Heavy Chain	Protease	3-3F5 Light Chain	Protease
(Kabat Numbering)	Numbering)	(Kabat Numbering)	Numbering)

Asp 31	Leu 163	Ile2	Ser 131
Trp 47	Ser 164	Ser 28	Ala 132
Gly 52	Lys 166	Ile 29	Gly 133
Ser 53	Arg 167	Gly 30	Ser 164
Ser 54	Glu 169	Asn 31	Gln 165
Val 56	Asp 170	Ala 32	Lys 166
Trp 58	Ala 171	Asp 50	Arg 167
Asp 95	Pro 173	Gly 68	Glu 169
Arg 96	Arg 174	Gln 89	Asp 170
Asp 97	Gly 184	Gln 90
Tyr 98	Asp 185	Gly 91
Gly 99	Lys 186	Asp 92
Tyr 100	Ala 186A	Ser 93
Arg 100A	Arg 188	His 94
Ala 100B	Asn 223	Asn 95
Asp 100C	Arg 224	Ile 97
Ala 100E	Pro 225
Thr 100F
Ser 100G
Met 100I

TABLE 12

Hydrogen Bonds

	Bond			Bond
Heavy Chain	Length		Light Chain	Length	KLK5
Residue	(Angstrom)	KLK5 residue	Residue	(Angstrom)	residue

Ser 53 [N]	3.0	Asp 170 [OD1]	Ser 28 [OG]	2.9	Ser 131 [OG]
Ser 54 [N]	3.0	Asp 170 [OD1]	Asp 92 [OD1]	3.7	Gln 165 [N]
Ser 54 [OG]	2.8	Asp 170 [OD1]	Asp 92 [O]	3.1	Gln 165 [N]
Gly 99 [N]	3.1	Asp 170 [OD2]	Asp 92 [O]	3.0	Lys 166 [N]
Ser 53 [N]	3.1	Asp 170 [OD2]	Asn 31 [N]	3.6	Ala 132 [O]
Ser 53 [OG]	3.0	Asp 170 [OD2]	Asn 95 [ND2]	3.1	Gln 165 [OE]
Ala 100B [N]	2.8	Asn 223 [OD1]
Thr 100F [O]	3.9	Arg 167 [NH1]
Arg 96 [O]	2.8	Arg 167 [NH1]
Ser 100G [OG]	2.8	Arg 167 [NH2]
Tyr 100 [OH]	2.9	Asp 185 [N]
Tyr 100 [OH]	3.7	Lys 186 [N]
Arg 100A [O]	2.8	Lys 186 [NZ]
Tyr 100 [O]	3.0	Asn 223 [ND2]

TABLE 13

Salt Bridges

	Bond
Heavy Chain	Length
Residue	(Angstrom)	KLK5 residue

His 94 [NE2]	2.8	Glu 169 [OE1]
His 94 [NE2]	3.9	Glu 169 [OE2]

Table of Sequences

		SEQ
NAME	SEQUENCE	ID NO

Human KLK5	MATARPPWMWVLCALITALLLGVTEHVLANNDVSCDHPSNTVPSGSNQDLGAGAGE		1
Q9Y337	DARSDDSSSRIINGSDCDMHTQPWQAALLLRPNQLYCGAVLVHPQWLLTAAHCRKK
G55, D153	VFRVRLGHYSLSPVYESGQQMFQGVKSIPHPGYSHPGHSNDLMLIKLNRRIRPTKD
(incl. signal	VRPINVSSHCPSAGTKCLVSGWGTTKSPQVHFPKVLQCLNISVLSQKRCEDAYPRQ
peptide	IDDTMFCAGDKAGRDSCQGDSGGPVVCNGSLQGLVSWGDYPCARPNRPGVYTNLCK
(underlined))	FTKWIQETIQANS

Human KLK5		2
G55, D153	PWQAALLLRPNQLYCGAVLVHPQWLLTAAHCRKKVFRVRLGHYSLSPVYESGQQMF
(mature form)
	GTTKSPQVHFPKVLQCLNISVLSQKRCEDAYPRQIDDTMFCAGDKAGRDSCQGDSG
	GPVVCNGSLQGLVSWGDYPCARPNRPGVYTNLCKFTKWIQETIQANS

Human KLK5		3
G55, N153	DARSDDSSSRIINGSDCDMHTQPWQAALLLRPNQLYCGAVLVHPQWLLTAAHCRKK
(incl. signal
peptide (under	VRPINVSSHCPSAGTKCLVSGWGTTKSPQVHFPKVLQCLNISVLSQKRCEDAYPRQ
lined))	IDDTMFCAGDKAGRDSCQGDSGGPVVCNGSLQGLVSWGDYPCARPNRPGVYTNLCK
	FTKWIQETIQANS

Human KLK5		4
G55, N153	PWQAALLLRPNQLYCGAVLVHPQWLLTAAHCRKKVFRVRLGHYSLSPVYESGQQMF
(mature form)
	GTTKSPQVHFPKVLQCLNISVLSQKRCEDAYPRQIDDTMFCAGDKAGRDSCQGDSG
	GPVVCNGSLQGLVSWGDYPCARPNRPGVYTNLCKFTKWIQETIQANS

Human KLK5		5
R55, N153	DARSDDSSSRIINGSDCDMHTQPWQAALLLRPNQLYCGAVLVHPQWLLTAAHCRKK
(incl. signal
peptide (under	VRPINVSSHCPSAGTKCLVSGWGTTKSPQVHFPKVLQCLNISVLSQKRCEDAYPRQ
lined))	IDDTMFCAGDKAGRDSCQGDSGGPVVCNGSLQGLVSWGDYPCARPNRPGVYTNLCK
	FTKWIQETIQANS

Human KLK5		6
R55, N153	PWQAALLLRPNQLYCGAVLVHPQWLLTAAHCRKKVFRVRLGHYSLSPVYESGQQMF
(mature form)
	GTTKSPQVHFPKVLQCLNISVLSQKRCEDAYPRQIDDTMFCAGDKAGRDSCQGDSG
	GPVVCNGSLQGLVSWGDYPCARPNRPGVYTNLCKFTKWIQETIQANS

Human KLK5		7
R55, D153	DARSDDSSSRIINGSDCDMHTQPWQAALLLRPNQLYCGAVLVHPQWLLTAAHCRKK
(incl. signal
peptide (under	VRPINVSSHCPSAGTKCLVSGWGTTKSPQVHFPKVLQCLNISVLSQKRCEDAYPRQ
lined))	IDDTMFCAGDKAGRDSCQGDSGGPVVCNGSLQGLVSWGDYPCARPNRPGVYTNLCK
	FTKWIQETIQANS

Human KLK5		8
R55, D153	PWQAALLLRPNQLYCGAVLVHPQWLLTAAHCRKKVFRVRLGHYSLSPVYESGQQMF
(mature form)
	GTTKSPQVHFPKVLQCLNISVLSQKRCEDAYPRQIDDTMFCAGDKAGRDSCQGDSG
	GPVVCNGSLQGLVSWGDYPCARPNRPGVYTNLCKFTKWIQETIQANS

Human SPINK5	MKIATVSVLLPLALCLIQDAASKNEDQEMCHEFQAFMKNGKLFCPQDKKFFQSLDG		9
Q9NQ38	IMFINKCATCKMILEKEAKSQKRARHLARAPKATAPTELNCDDFKKGERDGDFICP
(incl. signal	DYYEAVCGTDGKTYDNRCALCAENAKTGSQIGVKSEGECKSSNPEQDVCSAFRPFV
peptide	RDGRLGCTRENDPVLGPDGKTHGNKCAMCAELFLKEAENAKREGETRIRRNAEKDF
(underlined))	CKEYEKQVRNGRLFCTRESDPVRGPDGRMHGNKCALCAEIFKQRFSEENSKTDQNL
	GKAEEKTKVKREIVKLCSQYQNQAKNGILFCTRENDPIRGPDGKMHGNLCSMCQAY
	FQAENEEKKKAEARARNKRESGKATSYAELCSEYRKLVRNGKLACTRENDPIQGPD
	GKVHGNTCSMCEVFFQAEEEEKKKKEGKSRNKRQSKSTASFEELCSEYRKSRKNGR
	LFCTRENDPIQGPDGKMHGNTCSMCEAFFQQEERARAKAKREAAKEICSEFRDQVR
	NGTLICTREHNPVRGPDGKMHGNKCAMCASVFKLEEEEKKNDKEEKGKVEAEKVKR
	EAVQELCSEYRHYVRNGRLPCTRENDPIEGLDGKIHGNTCSMCEAFFQQEAKEKER
	AEPRAKVKREAEKETCDEFRRLLQNGKLFCTRENDPVRGPDGKTHGNKCAMCKAVF
	QKENEERKRKEEEDQRNAAGHGSSGGGGGNTQDECAEYREQMKNGRLSCTRESDPV
	RDADGKSYNNQCTMCKAKLEREAERKNEYSRSRSNGTGSESGKDTCDEFRSQMKNG
	KLICTRESDPVRGPDGKTHGNKCTMCKEKLEREAAEKKKKEDEDRSNTGERSNTGE
	RSNDKEDLCREFRSMQRNGKLICTRENNPVRGPYGKMHINKCAMCQSIFDREANER
	KKKDEEKSSSKPSNNAKDECSEFRNYIRNNELICPRENDPVHGADGKFYTNKCYMC
	RAVFLTEALERAKLQEKPSHVRASQEEDSPDSFSSLDSEMCKDYRVLPRIGYLCPK
	DLKPVCGDDGQTYNNPCMLCHENLIRQTNTHIRSTGKCEESSTPGTTAASMPPSDE

Human SPINK5	KNEDQEMCHEFQAFMKNGKLFCPQDKKFFQSLDGIMFINKCATCKMILEKEAKSQK	10
(mature form)	RARHLARAPKATAPTELNCDDFKKGERDGDFICPDYYEAVCGTDGKTYDNRCALCA
	ENAKTGSQIGVKSEGECKSSNPEQDVCSAFRPFVRDGRLGCTRENDPVLGPDGKTH
	GNKCAMCAELFLKEAENAKREGETRIRRNAEKDFCKEYEKQVRNGRLFCTRESDPV
	RGPDGRMHGNKCALCAEIFKQRFSEENSKTDQNLGKAEEKTKVKREIVKLCSQYQN
	QAKNGILFCTRENDPIRGPDGKMHGNLCSMCQAYFQAENEEKKKAEARARNKRESG
	KATSYAELCSEYRKLVRNGKLACTRENDPIQGPDGKVHGNTCSMCEVFFQAEEEEK
	KKKEGKSRNKRQSKSTASFEELCSEYRKSRKNGRLFCTRENDPIQGPDGKMHGNTC
	SMCEAFFQQEERARAKAKREAAKEICSEFRDQVRNGTLICTREHNPVRGPDGKMHG
	NKCAMCASVFKLEEEEKKNDKEEKGKVEAEKVKREAVQELCSEYRHYVRNGRLPCT
	RENDPIEGLDGKIHGNTCSMCEAFFQQEAKEKERAEPRAKVKREAEKETCDEFRRL
	LQNGKLFCTRENDPVRGPDGKTHGNKCAMCKAVFQKENEERKRKEEEDQRNAAGHG
	SSGGGGGNTQDECAEYREQMKNGRLSCTRESDPVRDADGKSYNNQCTMCKAKLERE
	AERKNEYSRSRSNGTGSESGKDTCDEFRSQMKNGKLICTRESDPVRGPDGKTHGNK
	CTMCKEKLEREAAEKKKKEDEDRSNTGERSNTGERSNDKEDLCREFRSMQRNGKLI
	CTRENNPVRGPYGKMHINKCAMCQSIFDREANERKKKDEEKSSSKPSNNAKDECSE
	FRNYIRNNELICPRENDPVHGADGKFYTNKCYMCRAVFLTEALERAKLQEKPSHVR
	ASQEEDSPDSFSSLDSEMCKDYRVLPRIGYLCPKDLKPVCGDDGQTYNNPCMLCHE
	NLIRQTNTHIRSTGKCEESSTPGTTAASMPPSDE

HVR-H1 Sequences

HVR-H1	DYNMA	11
14C8

HVR-H1	DYYMA	12
14E12

HVR-H1	SSYWIC	13
8E11

HVR-H1	TSYWIC	14
8G10

HVR-H1	NYGVT	15
9B6

HVR-H1	NYGVS	16
2.3F4

HVR-H1	SYGVT	17
10C5,
hu10C5-H1 to
hu10C5-H28

HVR-H1	NYGVS	18
2B11

HVR-H1	TFAIN	19
10H3

HVR-H1	GYGVS	20
9H3

HVR-H1	NYGVT	21
8B7

HVR-H1	SYGVS	22
9F2,
10C8,
9H5,
hu9H5-H1 to
hu9H5-H17

HVR-H1	SYPIS	23
8F5

HVR-H1	DYGVS	24
3-3F5,
hu3-3F5-H1 to
hu3-3F5-H27

HVR-H1	NNYVNFVMC	25
9E3

HVR-H1	DNYVMS	26
10D10

HVR-H1	GGGIY	27
12B3,
1D10

HVR-H1	X₁YGVX₂ wherein X₁ is S or D, X₂ is T or S	28
10C5,
hu10C5-H1 to
hu10C5-H28,
9H5,
hu9H5-H1 to
hu9H5-H17,
3-3F5,
hu3-3F5-H1 to
hu3-3F5-H27
(consensus)

HVR-H2 Sequences

HVR-H2	TISYDAGRTYYRDSVKG	29
14C8

HVR-H2	SISYDGDTTYYRDSVKG	30
14E12

HVR-H2	CVYGLDVNIYYASWTK	31
8E11

HVR-H2	CVYGLDVNIYYASWTE	32
8G10

HVR-H2	FIGSGGSAYYASWAKS	33
9B6,
9H3

HVR-H2	FIGYGGSTYYASWAKS	34
2.3F4

HVR-H2	YITSNYGVSYYASWAKS	35
10C5,
hu10C5-H1 to
hu10C5-H10,
hu10C5-H12,
hu10C5-H14 to
hu10C5-H16,
hu10C5-H18 to
hu10C5-H28

HVR-H2	YITSNYGVSYYANSVKG	36
hu10C5-H11,
hu10C5-H13

HVR-H2	YITSNYGVSYYASFAKS	37
hu10C5-H17

HVR-H2	YITSNYGVSYYAX₁X₂X₃KX₄ wherein X₁ is S or N, X₂ is W, S or	38
hu10C5-H1 to	F, X₃ is A or V, X₄ is S or G
hu10C5-H28
(consensus)

HVR-H2	YIGSAGSTYYATWAKS	39
2B11

HVR-H2	AIGRGGSAYYASWAKS	40
10H3

HVR-H2	FIGSSGSAYYASWAKS	41
8B7

HVR-H2	FIGSGGFAYYASWAKS	42
10C8,
9H5,
hu9H5-H1 to
hu9H5-H10,
hu9H5-H12,
hu9H5-H14 to
hu9H5-H16

HVR-H2	FIGSGGFAYYADSVKG	43
hu9H5-H11,
hu9H5-H13

HVR-H2	FIGSGGFAYYASFAKS	44
hu9H5-H17

HVR-H2	FIGSGGFAYYAX₁X₂X₃KX₄ wherein X₁ is S or D, X₂ is W, S or	45
hu9H5-H1 to	F, X₃ is A or V, X₄ is S or G
hu9H5-H17
(consensus)

HVR-H2	FIGSGGSPYYASWAKS	46
9F2

HVR-H2	YITSEYGVAYYATWAES	47
8F5

HVR-H2	AIGSSGVAWYANWAKG	48
3-3F5,
hu3-3F5-H1 to
hu3-3F5-H9,
hu3-3F5-H14,
hu3-3F5-H16,
hu3-3F5-H17

HVR-H2	AIGSSGVAFYANWAKG	49
hu3-3F5-H10,
hu3-3F5-H12,
hu3-3F5-H15

HVR-H2	AIGSSGVAWYADSVKG	50
hu3-3F5-H11,

HVR-H2	AIGSSGVAFYADSVKG	51
hu3-3F5-H13

HVR-H2	AIGSSGVAWYANFAKG	52
hu3-3F5-H18
to
hu3-3F5-H26

HVR-H2	AIGSSGVAFYANFAKG	53
hu3-3F5-H27

HVR-H2	AIGSSGVAX₁YAX₂X₃X₄KG wherein X₁ is W or F, X₂ is N or D, X₃	54
hu3-3F5-H1 to	is W, S or F, X₄ is A or V
hu3-3F5-H27
(consensus)

HVR-H2	SIDPGDDSTDYASWAT	55
9E3

HVR-H2	CIDPGDDSTYYASWAT	56
10D10

HVR-H2	SIYPDHGSVDYANWVNG	57
12B3

HVR-H2	YIYPDHGSADYATWVNG	58
1D10

HVR-H2	X₁IGSX₂GX₃AX₄YAX₅X₆X₇KX₈ wherein X₁ is F or A, X₂ is G or S,	59
9H5,	X₃ is F or V, X₄ is Y, W, or F, X₅ is S, D, or N, X₆ is W,
hu9H5-H1 to	S, or F, X₇ is A or V, X₈ is S or G
hu9H5-H17,
3-3F5,
hu3-3F5-H1 to
hu3-3F5-H27
(consensus)

HVR-H3 Sequences

HVR-H3	GIFNYGTDYFDY	60
14C8

HVR-H3	DGTIPAGSWFAY	61
14E12

HVR-H3	GGGSADFGFDL	62
8E11,
8G10

HVR-H3	DDVGGGKSLDI	63
9B6

HVR-H3	LCGVDCADALDS	64
2.3F4

HVR-H3	ENPDYGYAYDA	65
10C5,
hu10C5-H1 to
hu10C5-H28

HVR-H3	AAYSAGSADAEDI	66
2B11

HVR-H3	ENAGSGWGELDI	67
10H3

HVR-H3	DNVGGDMSLDI	68
9H3

HVR-H3	DDVGGGKSLDI	69
8B7,
9F2,
9H5,
hu9H5-H1 to
hu9H5-H17

HVR-H3	DDVGGGRSLDI	70
10C8

HVR-H3	ENPTYGYAYDA	71
8F5

HVR-H3	DRDYGYRADDATSGMDL	72
3-3F5,
hu3-3F5-H1 to
hu3-3F5-H27

HVR-H3	GDAGTSYSFNF	73
9E3

HVR-H3	GDAAASYSFNF	74
10D10

HVR-H3	ESGGSYYDL	75
12B3

HVR-H3	ETGGSWYDL	76
1D10

HVR-Ll Sequences

HVR-L1	RASEDIYSGLA	77
14C8

HVR-L1	LASKNIYRNLA	78
14E12

HVR-L1	QASENIYSLLA	79
8E11,
8G10

HVR-L1	QASQNIGDYLS	80
9B6

HVR-L1	QASEDIGSYCS	81
2.3F4

HVR-Ll	QASESISNELS	82
10C5,
hu10C5-L1 to
hu10C5-L6

HVR-Ll	QASQSISNYVA	83
2B11

HVR-L1	QASESISSDLA	84
10H3

HVR-L1	QASQNINNYLS	85
9H3

HVR-L1	QASQSIGSYLS	86
8B7

HVR-L1	QASQSISSYLS		87
9H5,
hu9H5-L1 to
hu9H5-L4

HVR-L1	QASQSISNYLS		88
9F2

HVR-L1	QASQSISTYLS		89
10C8

HVR-L1	QASESIGNELS	90
8F5

HVR-L1	QASESIGNALA	91
3-3F5,
hu3-3F5-L1 to
hu3-3F5-L5

HVR-L1	QASESISRYLS	92
9E3

HVR-L1	QASESISTYLS	93
10D10

HVR-L1	QASQSISTYLA	94
12B3

HVR-L1	QASQSISSYLA	95
1D10

HVR-L1	QASX₁SIX₂X₃X₄LX₅ wherein X₁ is E or Q, X₂ is S or G, X₃ is	96
10C5,	N or S, X₄ is E, Y or A, X₅ is S or A
hu10C5-L1 to
hu10C5-L6,
9H5,
hu9H5-L1 to
hu9H5-L4,
3-3F5,
hu3-3F5-L1 to
hu3-3F5-L5
(consensus)

HVR-L2 Sequences

HVR-L2	GATTLHD	97
14C8

HVR-L2	DASRLQD	98
14E12

HVR-L2	DASDLAS	99
8E11,
8G10,
2.3F4,
9E3,
10D10,
3-3F5,
hu3-3F5-L1 to
hu3-3F5-L5

HVR-L2	SASTLAS		100
9B6

HVR-L2	YASTLAS	101
10C5,
hu10C5-L1 to
hu10C5-L6

HVR-L2	RASTLAS	102
2B11

HVR-L2	AASTLAS	103
10H3,
9H3

HVR-L2	DASNLAS	104
8B7

HVR-L2	SASTLAS	105
9F2
10C8
9H5,
hu9H5-L1 to
hu9H5-L4

HVR-L2	QASTLAS	106
8F5

HVR-L2	KTSTLAS	107
12B3

HVR-L2	KASTLAS	108
1D10

HVR-L2	X₁ASX₂LAS wherein X₁ is Y, S or D, X₂ is T or D	109
10C5,
hu10C5-L1 to
hu10C5-L6
9H5,
hu9H5-L1 to
hu9H5-L4,
3-3F5,
hu3-3F5-L1 to
hu3-3F5-L5
(consensus)

HVR-L3 Sequences

HVR-L3	HQGLSFPYT	110
14C8

HVR-L3	QQYHDYPYT	111
14E12

HVR-L3	QATAYGSSGNA	112
8E11,
8G10

HVR-L3	HQDYTSNDVENT	113
9B6

HVR-L3	QQDYTGNNVDNT	114
2.3F4

HVR-L3	AQGFGSSGVENV	115
10C5,
hu10C5-L1 to
hu10C5-L6

HVR-L3	HQGYSSSNVDNI	116
2B11

HVR-L3	QQGYTWNNVDNV	117
10H3

HVR-L3	HQDYTSNNVDNT	118
9H3,
8B7,
10C8

HVR-L3	HQDYTSSNVDNT	119
9H5,
hu9H5-L1 to
hu9H5-L4

HVR-L3	HQDYTSNSVDNT	120
9F2

HVR-L3	AQGFSSSGVENV	121
8F5

HVR-L3	QQGDSHNNVDNI	122
3-3F5,
hu3-3F5-L1 to
hu3-3F5-L5

HVR-L3	QQDYSRSNIVNS	123
9E3

HVR-L3	QQDYSSSNIVNS	124
10D10

HVR-L3	QQGYSGSSVENT	125
12B3

HVR-L3	QQGYSGSNVENT	126
1D10

HVR-L3	X₁QX₂X₃X₄X₅X₆X₇VX₈NX₉ wherein X₁ is A, H or Q, X₂ is G or D,	127
10C5,	X₃ is F, Y or D, X₄ is G, T or S, X₅ is S or H, X₆ is S
hu10C5-L1 to	or N, X₇ is G or N, X₈ is E or D, X₉ is V, T or I
hu10C5-L6
9H5,
hu9H5-L1 to
hu9H5-L4,
3-3F5,
hu3-3F5-L1 to
hu3-3F5-L5
(consensus)

VL Sequences (HVRs underlined)

VL	DIQMTQSPASLSASLGETVTIQCRASEDIYSGLAWYQQKPGKSPQLLIYGATTLHD	128
14C8	GVPSRFSGSGSGTQYSLKISSMHSEDEGIYFCHQGLSFPYTFGAGTKLELK

VL	DIQMTQSPASLSASLGETVTIECLASKNIYRNLAWYQQKPGKSPQFLISDASRLQD	129
14E12	GVPSRFTGSDSGSQYSLKINSLQSEDVATYFCQQYHDYPYTFGAGTKLELK

VL	DVVMTQTASPVSAAVGGTVTIKCQASENIYSLLAWYQQKPGQPPKVLIYDASDLAS	130
8E11	GVPSRFKGSGSGTQFTLTISDLECADAATYYCQATAYGSSGNAFGGGTEVVVK

VL	DVVMTQTPASVSEPVGGTVTIKCQASENIYSLLAWYQQKPGQPPKVLIYDASDLAS	131
8G10	GVPSRFKGSGSGTQFTLTISDLECADAATYYCQATAYGSSGNAFGGGTEVVVK

VL	NIVMTQTPASVEVAVGGTVVIKCQASQNIGDYLSWYQQKPGQRPKLLIYSASTLAS	132
9B6	GVPSRFKGSGSGTQFTLTISDLECADAATYYCHQDYTSNDVENTFGGGTEVVVK

VL	AYYMTQTPASVEVAVGGTVTIKCQASEDIGSYCSWYQQKPGQPPKLLIYDASDLAS	133
2.3F4	GVPSRFKGSGSGTDFTLTISGVQCDDAATYYCQQDYTGNNVDNTFGGGSEVVVK

VL	AYDMTQTPASLEAAVGGTVTINCQASESISNELSWYQQKPGQPPDLLIYYASTLAS	134
10C5	GVPSRFKGSGSGTEFTLTISDLECADAATYYCAQGFGSSGVENVFGGGTEVVVK

VL	AYRMTQSPSSFSASTGDRVTITCQASESISNELSWYQQKPGKPPKLLIYYASTLAS	135
hu10C5-L1	GVPSRFSGSGSGTDFTLTISCLQSEDFATYYCAQGFGSSGVENVFGGGTKVEIK

VL	AIRMTQSPSSFSASTGDRVTITCQASESISNELSWYQQKPGKPPKLLIYYASTLAS	136
hu10C5-L2	GVPSRFSGSGSGTDFTLTISCLQSEDFATYYCAQGFGSSGVENVFGGGTKVEIK

VL	AYRMTQSPSSFSASTGDRVTITCQASESISNELSWYQQKPGKAPKLLIYYASTLAS	137
hu10C5-L3	GVPSRFSGSGSGTDFTLTISCLQSEDFATYYCAQGFGSSGVENVFGGGTKVEIK

VL	AIRMTQSPSSFSASTGDRVTITCQASESISNELSWYQQKPGKAPKLLIYYASTLAS	138
hu10C5-L4	GVPSRFSGSGSGTDFTLTISCLQSEDFATYYCAQGFGSSGVENVFGGGTKVEIK

VL	AIRMTQSPSSFSASTGDRVTITCQASESISNELSWYQQKPGKAPKLLIYYASTLAS	139
hu10C5-L5	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCAQGFGSSGVENVFGGGTKVEIK

VL	AX₁RMTQSPSSFSASTGDRVTITCQASESISNELSWYQQKPGKX₂PKLLIYYASTLA	140
10C5,	SGVPSRFSGSGSGTDFTLTISX₃LQX₄EDFATYYCAQGFGSSGVENVFGGGTX₅VX₆
hu10C5-L1 to	X₇K
hu10C5-L6	wherein X₁ is Y or I, X₂ is P or A, X₃ is C or S, X₄ is S
(consensus)	or P, X₅ is E or K, X₆ is E or V, X₇ is I or V

VL	AYYMTQTPASVEAAVGGTVTIKCQASQSISNYVAWYQQKPGQPPKLLIYRASTLAS	141
2B11	GVSSRFSGSGSGTEFTLTISDLECADAATYYCHQGYSSSNVDNIFGGGTEVVVK

VL	AYEMTQTPASVEVAVGGTVTINCQASESISSDLAWYQQKPGQRPKLLIYAASTLAS	142
10H3	GVPSRFKGSGSGTEFTLSISGVQCADAATYYCQQGYTWNNVDNVFGGGTEVVVK

VL	DIVMTQTPASVSEPVGGTVTIKCQASQNINNYLSWYQQKPGQPPKQLIYAASTLAS	143
9H3	GVPSRFKGSGSGTQFTLTISDLECADAATYYCHQDYTSNNVDNTFGGGTEVVVK

VL	NIVMTQTPASVEVAVGGTVTIKCQASQSIGSYLSWYQQKPGQPPKLLIYDASNLAS	144
8B7	GVPSRFKGSGSGTQFTLSISDLECADAATYYCHQDYTSNNVDNTFGGGTEVVIK

VL	NIVMTQTPASVEAAVGGTVTINCQASQSISSYLSWYQQKSGQRPKLLIFSASTLAS	145
9H5	GVPSRFTGSGSGTQFTLTISDLQCADAATYYCHQDYTSSNVDNTFGGGTEVVVK

VL	DIQMTQSPSSLSASVGDRVTITCQASQSISSYLSWYQQKPGKRPKLLIFSASTLAS	146
hu9H5-L1	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQDYTSSNVDNTFGGGTKVEIK

VL	DIQMTQSPSSLSASVGDRVTITCQASQSISSYLSWYQQKPGKAPKLLIFSASTLAS	147
hu9H5-L2	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQDYTSSNVDNTFGGGTKVEIK

VL	DIQMTQSPSSLSASVGDRVTITCQASQSISSYLSWYQQKPGKRPKLLIYSASTLAS	148
hu9H5-L3	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQDYTSSNVDNTFGGGTKVEIK

VL	DIQMTQSPSSLSASVGDRVTITCQASQSISSYLSWYQQKPGKAPKLLIYSASTLAS	149
hu9H5-L4	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQDYTSSNVDNTFGGGTKVEIK

VL	DIQMTQSPSSLSASVGDRVTITCQASQSISSYLSWYQQKPGKAPKLLIYSASTLAS	150
hu9H5-L5	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQDYTSSNVDNTFGGGTEVVVK

VL	DIQMTQSPSSLSASVGDRVTITCQASQSISSYLSWYQQKPGKX₁PKLLIX₂SASTLA	151
9H5,	SGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQDYTSSNVDNTFGGGTX₃VX₄X₅
hu9H5-L1 to	K
hu9H5-L5	wherein X₁ is R or A, X₂ is F or Y, X₃ is E or K, X₄ is E
(consensus)	or V, X₅ is V or I

VL	NIVMTQTPASVEVAVGGTVIIKCQASQSISNYLSWYHQKSGQRPRLLIYSASTLAS	152
9F2	GVPSRFKGSGSGTQFTLTISDLECADAATYYCHQDYTSNSVDNTFGGGTEVVVK

VL	NIVMTQTPASVEVAMGGTVIIKCQASQSISTYLSWYQQKPGQPPKLLIYSASTLAS	153
10C8	GVSSRFEGSGSGTQFTLTISGVQCADAATYYCHQDYTSNNVDNTFGGGTEVVVK

VL	AYDLTQTPASVEAAVGGTVTINCQASESIGNELSWYQQKSGQPPKLLIYQASTLAS	154
8F5	GVPSRFKGSGSGTDFTLTISDLECADAATYYCAQGFSSSGVENVFGGGTEVVVK

VL	AYDMTQTPASVEAAVGGTVTIKCQASESIGNALAWYQQKPGQPPKLLIYDASDLAS	155
3-3F5	GVPSRFKGSGSGTQFTLTISGVECADAATYYCQQGDSHNNVDNIFGGGTEVVVK

VL	AYRMTQSPSSFSASTGDRVTITCQASESIGNALAWYQQKPGKPPKLLIYDASDLAS	156
hu3-3F5-L1	GVPSRFSGSGSGTDFTLTISCLQSEDFATYYCQQGDSHNNVDNIFGGGTKVEIK

VL	AIRMTQSPSSFSASTGDRVTITCQASESIGNALAWYQQKPGKPPKLLIYDASDLAS	157
hu3-3F5-L2	GVPSRFSGSGSGTDFTLTISCLQSEDFATYYCQQGDSHNNVDNIFGGGTKVEIK

VL	AYRMTQSPSSFSASTGDRVTITCQASESIGNALAWYQQKPGKAPKLLIYDASDLAS	158
hu3-3F5-L3	GVPSRFSGSGSGTDFTLTISCLQSEDFATYYCQQGDSHNNVDNIFGGGTKVEIK

VL	AIRMTQSPSSFSASTGDRVTITCQASESIGNALAWYQQKPGKAPKLLIYDASDLAS	159
hu3-3F5-L4	GVPSRFSGSGSGTDFTLTISCLQSEDFATYYCQQGDSHNNVDNIFGGGTKVEIK

VL	AIRMTQSPSSFSASTGDRVTITCQASESIGNALAWYQQKPGKAPKLLIYDASDLAS	160
hu3-3F5-L5	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDSHNNVDNIFGGGTKVEIK

VL	AIRMTQSPSSFSASTGDRVTITCQASESIGNALAWYQQKPGKAPKLLIYDASDLAS	161
hu3-3F5-L6	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDSHNNVDNIFGGGTEVVVK

VL	AX₁RMTQSPSSFSASTGDRVTITCQASESIGNALAWYQQKPGKX₂PKLLIYDASDLA	162
3-3F5,	SGVPSRFSGSGSGTDFTLTISX₃LQX₄EDFATYYCQQGDSHNNVDNIFGGGTX₅VX₆
hu3-3F5-L1 to	X₇K
hu3-3F5-L6	wherein X₁ is Y or I, X₂ is P or A, X₃ is C or S, X₄ is S
(consensus)	or P
	X₅ is E or K, X₆ is E or V, X₇ is V or I

VL	AIEMTQTPSSASEPVGGTVTIKCQASESISRYLSWYQQKPGQPPKLLIYDASDLAS	163
9E3	GVSSRFKGSGSGTQFTLIISDVECADAATYYCQQDYSRSNIVNSFGGGTEVVVK

VL	AYDMTQTPSSASEPVGGTVTIKCQASESISTYLSWYQQKPGQPPKLLIYDASDLAS	164
10D10	GVSSRFKGSGSGTQFTLTISDVECADAATYYCQQDYSSSNIVNSFGGGTEVVVK

VL	AYDMTQTPASVEVAVGGTVTIKCQASQSISTYLAWYQQKPGQRPNLLIYKTSTLAS	165
12B3	GVPSRFRGSGSGTQFTLTISGVECADAATYYCQQGYSGSSVENTFGGGTEVVVK

VL	AYDMTQTPVSVEAAVGGTVTIKCQASQSISSYLAWYQQKPGQPPKLLIYKASTLAS	166
1D10	GVSSRFKGSGSGTEFTLTISDLECADAATYYCQQGYSGSNVENTFGGGTEVVVK

VH Sequences (HVRs underlined)

VH	EVQLVESGGGLVQPGRSLKLSCTASGFTFSDYNMAWVRQAPKGGLEWVTTISYDAG	167
14C8	RTYYRDSVKGRFTISRDNAKRTLSLQMDSLRSEDTATYYCATGIFNYGTDYFDYWG
	QGVMVTVSS

VH	EVQLVESGGGLVRPGRSLRLSCAASGFTFSDYYMAWVRQAPTKGLEWVASISYDGD	168
14E12	TTYYRDSVKGRFTISRDNARSSLYLQMDSLRSDDTANYFCTTDGTIPAGSWFAYWG
	QGTLVTVSS

VH	QEQLEESGGDLVKPEGSLTLTCTASGFSFSSSYWICWVRQAPGKGLEWIACVYGLD	169
8E11	VNIYYASWTKGRFTISKTSSTTVTLQMTSLTAADTATYFCARGGGSADEGFDLWGP
	GTLVTVSS

VH	QSLEESGGDLVKPEGSLTLTCTASGFSFSTSYWICWVRQAPGKGLEWIACVYGLDV	170
8G10	NIYYASWTEGRFTISKTSSTTVTLQVTSLTAADTATYFCARGGGSADFGFDLWGPG
	TLVTVSS

VH	QSVKESEGGLFKPTDNLTLTCTVSGFSLSNYGVTWVRQAPGNGLEYIGFIGSGGSA	171
9B6	YYASWAKSRSTITRNTNLNTVTLKMTSLTAADTATYFCARDDVGGGKSLDIWGPGT
	LVTVSS

VH	QSVEESRGGLIKPTDTLTLTCTASGFSLSNYGVSWVRQAPGNGLEYIGFIGYGGST	172
2.3F4	YYASWAKSRSTITRNTNLNTVTLQMTSLTAADTATYFCARLCGVDCADALDSWGPG
	TLVTVSS

VH	QSLEESGGGLVKPTDTLTLTCTVSGFSLSSYGVTWVRQAPGRGLEWIGYITSNYGV	173
10C5	SYYASWAKSRSTITRNTNLNTVTLKMTSLTAADTATYFCARENPDYGYAYDAWGPG
	TLVTVSV

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLSSYGVTWVRQAPGKGLEWIGYITSNYG	174
hu10C5-H1	VSYYASWAKSRSTISRDTSKNTVYLQMGSLRAEDMAVYFCARENPDYGYAYDAWGP
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWIGYITSNYG	175
hu10C5-H2	VSYYASWAKSRSTISRDTSKNTVYLQMGSLRAEDMAVYFCARENPDYGYAYDAWGP
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLSSYGVTWVRQAPGKGLEYIGYITSNYG	176
hu10C5-H3	VSYYASWAKSRSTISRDTSKNTVYLQMGSLRAEDMAVYFCARENPDYGYAYDAWGP
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLSSYGVTWVRQAPGKGLEWVGYITSNYG	177
hu10C5-H4	VSYYASWAKSRSTISRDTSKNTVYLQMGSLRAEDMAVYFCARENPDYGYAYDAWGP
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLSSYGVTWVRQAPGKGLEWISYITSNYG	178
hu10C5-H5	VSYYASWAKSRSTISRDTSKNTVYLQMGSLRAEDMAVYFCARENPDYGYAYDAWGP
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLSSYGVTWVRQAPGKGLEWIGYITSNYG	179
hu10C5-H6	VSYYASWAKSRFTISRDTSKNTVYLQMGSLRAEDMAVYFCARENPDYGYAYDAWGP
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLSSYGVTWVRQAPGKGLEWIGYITSNYG	180
hu10C5-H7	VSYYASWAKSRSTISRDNSKNTVYLQMGSLRAEDMAVYFCARENPDYGYAYDAWGP
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLSSYGVTWVRQAPGKGLEWIGYITSNYG	181
hu10C5-H8	VSYYASWAKSRSTISRDTSKNTLYLQMGSLRAEDMAVYFCARENPDYGYAYDAWGP
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLSSYGVTWVRQAPGKGLEWIGYITSNYG	182
hu10C5-H9	VSYYASWAKSRSTISRDTSKNTVYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGP
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLSSYGVTWVRQAPGKGLEWIGYITSNYG	183
hu10C5-H10	VSYYASWAKSRSTISRDTSKNTVYLQMGSLRAEDMAVYFCARENPDYGYAYDAWGQ
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLSSYGVTWVRQAPGKGLEWIGYITSNYG	184
hu10C5-H11	VSYYANSVKGRSTISRDTSKNTVYLQMGSLRAEDMAVYFCARENPDYGYAYDAWGP
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEYVSYITSNYG	185
hu10C5-H12	VSYYASWAKSRFTISRDNSKNTLYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEYVSYITSNYG	186
hu10C5-H13	VSYYANSVKGRFTISRDNSKNTLYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWVGYITSNYG	187
hu10C5-H14	VSYYASWAKSRFTISRDNSKNTLYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
	GTTVTVSS

VH	EQQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWVGYITSNYG	188
hu10C5-H15	VSYYASWAKSRFTISRDNSKNTLYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWVGYITSNYG	189
hu10C5-H16	VSYYASWAKSRFTISRNLNTNTLYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWVGYITSNYG	190
hu10C5-H17	VSYYASFAKSRFTISRDNSKNTLYLQMGSLRAEDMAVYYCARENPDYCYAYDAWGQ
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWVGYITSNYG	191
hu10C5-H18	VSYYASWAKSRFTISRNTNLNTLYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWVGYITSNYG	192
hu10C5-H19	VSYYASWAKSRFTISRNNSKNTLYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWVGYITSNYG	193
hu10C5-H20	VSYYASWAKSRFTISRDNNKNTLYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWVGYITSNYG	194
hu10C5-H21	VSYYASWAKSRFTISRNNNKNTLYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWIGYITSNYG	195
hu10C5-H22	VSYYASWAKSRFTISRDNSKNTLYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWVGYITSNYG	196
hu10C5-H23	VSYYASWAKSRSTISRDNSKNTLYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWIGYITSNYG	197
hu10C5-H24	VSYYASWAKSRSTISRDNSKNTLYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWVGYITSNYG	198
hu10C5-H25	VSYYASWAKSRFTISRDTSKNTLYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWVGYITSNYG	199
hu10C5-H26	VSYYASWAKSRFTISRDNSKNTVYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWIGYITSNYG	200
hu10C5-H27	VSYYASWAKSRSTISRDNSKNTVYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
	GTTVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWIGYITSNYG	201
hu10C5-H28	VSYYASWAKSRSTISRDTSKNTVYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
	GTTVTVSS

VH	EX₁QLVESGGGLVQPGGSLRLSCAX₂SGFSLSSYGVTWVRQAPGKGLEX₃X₄X₅YITS	202
10C5,	NYGVSYYAX₆X₇X₈KX₉RX₁₀TISRX₁₁X₁₂X₁₃X₁₄NTX₁₅YLQMGSLRAEDMAVYX₁₆CA
hu10C5-H1 to	RENPDYGYAYDAWGX₁₇GTTVTVSS
hu10C5-H28	wherein X₁ is V or Q, X₂ is V or A, X₃ is W or Y, X₄ is I
(consensus)	or V, X₅ is G or S, X₆ is S or N, X₇ is W, S or F, X₈ is
	A or V, X₉ is S or G, X₁₀ is S or F, X₁₁ is D or N, X₁₂ is
	T, L or N, X₁₃ is S or N, X₁₄ is K, T or L, X₁₅ is V or L,
	X₁₆, is F or Y, X₁₇ is P or Q

VH	QSVKESEGGLFKPTDTLTLTCTVSGFSLINYGVSWVRQAPGKGLEWIGYIGSAGST	203
2B11	YYATWAKSRATITRNTNLNTVTLKMTSLTAADTATYFCARAAYSAGSADAEDIWGP
	GTLVTVSS

VH	QSVKESEGGLIKPTDTLTLTCTVSGFSLSTFAINWVRQAPGNGLEWIGAIGRGGSA	204
10H3	YYASWAKSRSTITKNTNLNTVTLKMTRPTAADTATYFCARENAGSGWGELDIWGPG
	TLVTVSS

VH	QSVKESEGGLFKPTDTLTLTCTVSGFSLSGYGVSWVRQAPGKGLEYIGFIGSGGSA	205
9H3	YYASWAKSRSTITRNTNLNTVTLKMTRLTAADTATYFCARDNVGGDMSLDIWGPGT
	LVTVSS

VH	QSVKESEGGLFKPTDNLTLTCTVSGFSLSNYGVTWVRQAPGNGLEYIGFIGSSGSA	206
8B7	YYASWAKSRSTITRNTNLNTVTLKMTSLTAADTATYFCARDDVGGGKSLDIWGPGT
	LVTVSS

VH	QSVKESEGGLFKPTDNLTLTCTVSGFSLSSYGVSWVRQAPGNGLEYIGFIGSGGFA	207
9H5	YYASWAKSRSTITRNTNLNTVTLKMTSLTAADTATYFCARDDVGGGKSLDIWGPGT
	VVTVSV

VH	EVQLVESGGGLIQPGGSLRLSCAVSGFSLSSYGVSWVRQAPGKGLEYIGFIGSGGF	208
hu9H5-H1	AYYASWAKSRSTISRDTSKNTVYLQMNSLRAEDTAVYFCARDDVGGGKSLDIWGPG
	TLVTVSS

VH	EVQLVESGGGLIQPGGSLRLSCAASGFSLSSYGVSWVRQAPGKGLEYIGFIGSGGF	209
hu9H5-H2	AYYASWAKSRSTISRDTSKNTVYLQMNSLRAEDTAVYFCARDDVGGGKSLDIWGPG
	TLVTVSS

VH	EVQLVESGGGLIQPGGSLRLSCAVSGFSLSSYGVSWVRQAPGKGLEWIGFIGSGGF	210
hu9H5-H3	AYYASWAKSRSTISRDTSKNTVYLQMNSLRAEDTAVYFCARDDVGGGKSLDIWGPG
	TLVTVSS

VH	EVQLVESGGGLIQPGGSLRLSCAVSGFSLSSYGVSWVRQAPGKGLEYVGFIGSGGF	211
hu9H5-H4	AYYASWAKSRSTISRDTSKNTVYLQMNSLRAEDTAVYFCARDDVGGGKSLDIWGPG
	TLVTVSS

VH	EVQLVESGGGLIQPGGSLRLSCAVSGFSLSSYGVSWVRQAPGKGLEYISFIGSGGF	212
hu9H5-H5	AYYASWAKSRSTISRDTSKNTVYLQMNSLRAEDTAVYFCARDDVGGGKSLDIWGPG
	TLVTVSS

VH	EVQLVESGGGLIQPGGSLRLSCAVSGFSLSSYGVSWVRQAPGKGLEYIGFIGSGGF	213
hu9H5-H6	AYYASWAKSRFTISRDTSKNTVYLQMNSLRAEDTAVYFCARDDVGGGKSLDIWGPG
	TLVTVSS

VH	EVQLVESGGGLIQPGGSLRLSCAVSGFSLSSYGVSWVRQAPGKGLEYIGFIGSGGF	214
hu9H5-H7	AYYASWAKSRSTISRDNSKNTVYLQMNSLRAEDTAVYFCARDDVGGGKSLDIWGPG
	TLVTVSS

VH	EVQLVESGGGLIQPGGSLRLSCAVSGFSLSSYGVSWVRQAPGKGLEYIGFIGSGGF	215
hu9H5-H8	AYYASWAKSRSTISRDTSKNTLYLQMNSLRAEDTAVYFCARDDVGGGKSLDIWGPG
	TLVTVSS

VH	EVQLVESGGGLIQPGGSLRLSCAVSGFSLSSYGVSWVRQAPGKGLEYIGFIGSGGF	216
hu9H5-H9	AYYASWAKSRSTISRDTSKNTVYLQMNSLRAEDTAVYYCARDDVGGGKSLDIWGPG
	TLVTVSS

VH	EVQLVESGGGLIQPGGSLRLSCAVSGFSLSSYGVSWVRQAPGKGLEYIGFIGSGGF	217
hu9H5-H10	AYYASWAKSRSTISRDTSKNTVYLQMNSLRAEDTAVYFCARDDVGGGKSLDIWGQG
	TLVTVSS

VH	EVQLVESGGGLIQPGGSLRLSCAVSGFSLSSYGVSWVRQAPGKGLEYIGFIGSGGF	218
hu9H5-H11	AYYADSVKGRSTISRDTSKNTVYLQMNSLRAEDTAVYFCARDDVGGGKSLDIWGPG
	TLVTVSS

VH	EVQLVESGGGLIQPGGSLRLSCAASGFSLSSYGVSWVRQAPGKGLEWVSFIGSGGF	219
hu9H5-H12	AYYASWAKSRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDVGGGKSLDIWGQG
	TLVTVSS

VH	EVQLVESGGGLIQPGGSLRLSCAASGFSLSSYGVSWVRQAPGKGLEWVSFIGSGGF	220
hu9H5-H13	AYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDVGGGKSLDIWGQG
	TLVTVSS

VH	EVQLVESGGGLIQPGGSLRLSCAASGFSLSSYGVSWVRQAPGKGLEYVGFIGSGGF	221
hu9H5-H14	AYYASWAKSRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDVGGGKSLDIWGQG
	TLVTVSS

VH	EQQLVESGGGLIQPGGSLRLSCAASGFSLSSYGVSWVRQAPGKGLEYVGFIGSGGF	222
hu9H5-H15	AYYASWAKSRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDVGGGKSLDIWGQG
	TLVTVSS

VH	EVQLVESGGGLIQPGGSLRLSCAASGFSLSSYGVSWVRQAPGKGLEYVGFIGSGGF	223
hu9H5-H16	AYYASWAKSRFTISRNTNLNTLYLQMNSLRAEDTAVYYCARDDVGGGKSLDIWGQG
	TLVTVSS

VH	EVQLVESGGGLIQPGGSLRLSCAASGFSLSSYGVSWVRQAPGKGLEYVGFIGSGGF	224
hu9H5-H17	AYYASFAKSRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDVGGGKSLDIWGQG
	TLVTVSS

VH	EX₁QLVESGGGLIQPGGSLRLSCAX₂SGFSLSSYGVSWVRQAPGKGLEX₃X₄X₅FIGS	225
9H5,	GGFAYYAX₆X₇X₈KX₉RX₁₀TISRX₁₁X₁₂X₁₃X₁₄NTX₁₅YLQMNSLRAEDTAVYX₁₆CAR
hu9H5-H1 to	DDVGGGKSLDIWGX₁₇GTLVTVSS
hu9H5-H17	wherein X₁ is V or Q, X₂ is V or A, X₃ is Y or W, X₄ is I
(consensus)	or V, X₅ is G or S, X₆ is S or D, X₇ is W, S or F, X₈ is
	A or V, X₉ is S or G, X₁₀ is S or F, X₁₁ is D or N, X₁₂ is
	T or N, X₁₃ is S or N, X₁₄ is K or L, X₁₅ is V or L, X₁₆ is
	F or Y, X₁₇ is P or Q

VH	QSVKESEGGLFKPTDNLTLTCTVSGFSLSSYGVSWVRQAPGNGLEYIGFIGSGGSP	226
9F2	YYASWAKSRSTITRNTNLNTVTLKMTSLTAADTATYFCARDDVGGGKSLDIWGPGT
	LVTVSS

VH	QSVKESEGGLFKPTDNLTLTCTVSGFSLSSYGVSWVRQAPGNGLEYIGFIGSGGFA	227
10C8	YYASWAKSRSTITRNTNLNTVTLKMTSLTAADTATYFCARDDVGGGRSLDIWGPGT
	VVTVSS

VH	QSVKESEGGLFKPTDTLTLTCTVSGFSLSSYPISWVRQAPGNGLEWIGYITSEYGV	228
8F5	AYYATWAESRSTITRNTNLNTVTLKMTSLTAADTATYFCVRENPTYGYAYDAWGPG
	TLVTVSS

VH	QSVKESEGGLFKPTDTLTLTCTVSGFSLNDYGVSWVRQAPGNGLEWIGAIGSSGVA	229
3-3F5	WYANWAKGRSTITRNTNLNTVTLKMASLTAADTATYFCARDRDYGYRADDATSGMD
	LWGPGTLVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLNDYGVSWVRQAPGKGLEWIGAIGSSGV	230
hu3-3F5-H1	AWYANWAKGRSTISRHTSKNTVYLQMNSLRAEDTAVYFCARDRDYGYRADDATSGM
	DLWGPGTLVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLNDYGVSWVRQAPGKGLEWIGAIGSSGV	231
hu3-3F5-H2	AWYANWAKGRSTISRHTSKNTVYLQMNSLRAEDTAVYFCARDRDYGYRADDATSGM
	DLWGPGTLVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLNDYGVSWVRQAPGKGLEWVGAIGSSGV	232
hu3-3F5-H3	AWYANWAKGRSTISRHTSKNTVYLQMNSLRAEDTAVYFCARDRDYGYRADDATSGM
	DLWGPGTLVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLNDYGVSWVRQAPGKGLEWISAIGSSGV	233
hu3-3F5-H4	AWYANWAKGRSTISRHTSKNTVYLQMNSLRAEDTAVYFCARDRDYGYRADDATSGM
	DLWGPGTLVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLNDYGVSWVRQAPGKGLEWIGAIGSSGV	234
hu3-3F5-H5	AWYANWAKGRFTISRHTSKNTVYLQMNSLRAEDTAVYFCARDRDYGYRADDATSGM
	DLWGPGTLVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLNDYGVSWVRQAPGKGLEWIGAIGSSGV	235
hu3-3F5-H6	AWYANWAKGRSTISRHNSKNTVYLQMNSLRAEDTAVYFCARDRDYGYRADDATSGM
	DLWGPGTLVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLNDYGVSWVRQAPGKGLEWIGAIGSSGV	236
hu3-3F5-H7	AWYANWAKGRSTISRHTSKNTLYLQMNSLRAEDTAVYFCARDRDYGYRADDATSGM
	DLWGPGTLVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLNDYGVSWVRQAPGKGLEWIGAIGSSGV	237
hu3-3F5-H8	AWYANWAKGRSTISRHTSKNTVYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
	DLWGPGTLVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLNDYGVSWVRQAPGKGLEWIGAIGSSGV	238
hu3-3F5-H9	AWYANWAKGRSTISRHTSKNTVYLQMNSLRAEDTAVYFCARDRDYGYRADDATSGM
	DLWGRGTLVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLNDYGVSWVRQAPGKGLEWIGAIGSSGV	239
hu3-3F5-H10	AFYANWAKGRSTISRHTSKNTVYLQMNSLRAEDTAVYFCARDRDYGYRADDATSGM
	DLWGPGTLVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAVSGFSLNDYGVSWVRQAPGKGLEWIGAIGSSGV	240
hu3-3F5-H11	AWYADSVKGRSTISRHTSKNTVYLQMNSLRAEDTAVYFCARDRDYGYRADDATSGM
	DLWGPGTLVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLNDYGVSWVRQAPGKGLEWVSAIGSSGV	241
hu3-3F5-H12	AFYANWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
	DLWGRGTLVTVSS

VH	EVQLVESGGGLVQPGGSLRLSCAASGFSLNDYGVSWVRQAPGKGLEWVSAIGSSGV	242
hu3-3F5-H13	AFYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
	DLWGRGTLVTVSS

VH	EVQLLESGGGLVQPGGSLRLSCAASGFSLNDYGVSWVRQAPGKGLEWVGAIGSSGV	243
hu3-3F5-H14	AWYANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
	DLWGRGTLVTVSS

VH	EVQLLESGGGLVQPGGSLRLSCAASGFSLNDYGVSWVRQAPGKGLEWVGAIGSSGV	244
hu3-3F5-H15	AFYANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
	DLWGRGTLVTVSS

VH	EQQLLESGGGLVQPGGSLRLSCAASGFSLNDYGVSWVRQAPGKGLEWVGAIGSSGV	245
hu3-3F5-H16	AWYANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
	DLWGRGTLVTVSS

VH	EVQLLESGGGLVQPGGSLRLSCAASGFSLNDYGVSWVRQAPGKGLEWVGAIGSSGV	246
hu3-3F5-H17	AWYANWAKGRFTISRNTNLNTLYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
	DLWGRGTLVTVSS

VH	EVQLLESGGGLVQPGGSLRLSCAASGFSLNDYGVSWVRQAPGKGLEWVGAIGSSGV	247
hu3-3F5-H18	AWYANFAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
	DLWGRGTLVTVSS

VH	EVQLLESGGGLVQPGGSLRLSCAVSGFSLNDYGVSWVRQAPGKGLEWVGAIGSSGV	248
hu3-3F5-H19	AWYANFAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
	DLWGRGTLVTVSS

VH	EVQLLESGGGLVQPGGSLRLSCAASGFSLNDYGVSWVRQAPGKGLEWIGAIGSSGV	249
hu3-3F5-H20	AWYANFAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
	DLWGRGTLVTVSS

VH	EVQLLESGGGLVQPGGSLRLSCAASGFSLNDYGVSWVRQAPGKGLEWVGAIGSSGV	250
hu3-3F5-H21	AWYANFAKGRSTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
	DLWGRGTLVTVSS

VH	EVQLLESGGGLVQPGGSLRLSCAASGFSLNDYGVSWVRQAPGKGLEWIGAIGSSGV	251
hu3-3F5-H22	AWYANFAKGRSTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
	DLWGRGTLVTVSS

VH	EVQLLESGGGLVQPGGSLRLSCAASGFSLNDYGVSWVRQAPGKGLEWVGAIGSSGV	252
hu3-3F5-H23	AWYANFAKGRFTISRDTSKNTLYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
	DLWGRGTLVTVSS

VH	EVQLLESGGGLVQPGGSLRLSCAASGFSLNDYGVSWVRQAPGKGLEWVGAIGSSGV	253
hu3-3F5-H24	AWYANFAKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
	DLWGRGTLVTVSS

VH	EVQLLESGGGLVQPGGSLRLSCAASGFSLNDYGVSWVRQAPGKGLEWVGAIGSSGV	254
hu3-3F5-H25	AWYANFAKGRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
	DLWGRGTLVTVSS

VH	EVQLLESGGGLVQPGGSLRLSCAASGFSLNDYGVSWVRQAPGKGLEWIGAIGSSGV	255
hu3-3F5-H26	AWYANFAKGRSTISRDTSKNTVYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
	DLWGRGTLVTVSS

VH	EVQLLESGGGLVQPGGSLRLSCAASGFSLNDYGVSWVRQAPGKGLEWIGAIGSSGV	256
hu3-3F5-H27	AFYANFAKGRSTISRDTSKNTVYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
	DLWGRGTLVTVSS

VH	EX₁QLX₂ESGGGLVQPGGSLRLSCAX₃SGFSLNDYGVSWVRQAPGKGLEWX₄X₅AIGS	257
3-3F5,	SCVAX₆YAX₇X₈X₉KGRX₁₀TISRX₁₁X₁₂X₁₃X₁₄NTX₁₅YLQMNSLRAEDTAVYX₁₆CAR
hu3-3F5-H1 to	DRDYGYRADDATSGMDLWGX₁₇GTLVTVSS
hu3-3F5-H27	wherein X₁ is V or Q, X₂ is V or L, X₃ is V or A, X₄ is I
(consensus)	or V, X₅ is G or S, X₆ is W or F, X₇ is N or D, X₈ is W, S
	or F, X₉ is A or V, X₁₀ is S or F, X₁₁ is H, N or D, X₁₂ is
	T or N, X₁₃ is S or N, X₁₄ is K or L, X₁₅ is V or L, X₁₆ is
	F or Y, X₁₇ is P or R

VH	QEQLEESGGGLVKPGASLTLTCTVSGFSLTNNYVNFVMCWVRQAPGKGLEWIASID	258
9E3	PGDDSTDYASWATGRFTISKASSTTVTLQVTSLTAADTATYFCARGDAGTSYSFNF
	WGPGTLVTVS

VH	QEQLVESGGGLVKPGASLTLTCTASGFSLTDNYVMSWVRQAPGKGLEWIACIDPGD	259
10D10	DSTYYASWATGRFTISRASSTTVTLQVTSLTAADTATYFCARGDAAASYSFNFWGP
	GTLVTVSS

VH	QSLEESGGGLVKPGGTLTLTCKASGIDFNGGGIYWVRQAPGKGLEWIASIYPDHGS	260
12B3	VDYANWVNGRFTISLDNAQNTVFLQLTSLTVADTATYFCARESGGSYYDLWGPGTL
	VTVSS

VH	QSLEESGGGLVKPGGTLTLTCTASGFDFNGGGIYWVRQAPGKGLEWIAYIYPDHGS	261
1D10	ADYATWVNGRFTISLDNAQNTVFLQMTSLTVADTATYFCARETGGSWYDLWGPGTL
	VTVSS

LC Sequences

LC	DIQMTQSPASLSASLGETVTIQCRASEDIYSGLAWYQQKPGKSPQLLIYGATTLHD	262
14C8	GVPSRFSGSGSGTQYSLKISSMHSEDEGIYFCHQGLSFPYTFGAGTKLELKRADAA
	PTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDS
	KDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	DIQMTQSPASLSASLGETVTIECLASKNIYRNLAWYQQKPGKSPQFLISDASRLQD	263
14E12	GVPSRFTGSDSGSQYSLKINSLQSEDVATYFCQQYHDYPYTFGAGTKLELKRADAA
	PTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDS
	KDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	DVVMTQTASPVSAAVGGTVTIKCQASENIYSLLAWYQQKPGQPPKVLIYDASDLAS	264
8E11	GVPSRFKGSGSGTQFTLTISDLECADAATYYCQATAYGSSGNAFGGGTEVVVKRAD
	AAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQ
	DSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	DVVMTQTPASVSEPVGGTVTIKCQASENIYSLLAWYQQKPGQPPKVLIYDASDLAS	265
8G10	GVPSRFKGSGSGTQFTLTISDLECADAATYYCQATAYGSSGNAFGGGTEVVVKRAD
	AAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQ
	DSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	NIVMTQTPASVEVAVGGTVVIKCQASQNIGDYLSWYQQKPGQRPKLLIYSASTLAS	266
9B6	GVPSRFKGSGSGTQFTLTISDLECADAATYYCHQDYTSNDVENTFGGGTEVVVKRA
	DAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTD
	QDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	AYYMTQTPASVEVAVGGTVTIKCQASEDIGSYCSWYQQKPGQPPKLLIYDASDLAS	267
2.3F4	GVPSRFKGSGSGTDFTLTISGVQCDDAATYYCQQDYTGNNVDNTFGGGSEVVVKRA
	DAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTD
	QDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	AYDMTQTPASLEAAVGGTVTINCQASESISNELSWYQQKPGQPPDLLIYYASTLAS	268
10C5	GVPSRFKGSGSGTEFTLTISDLECADAATYYCAQGFGSSGVENVFGGGTEVVVKRA
	DAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTD
	QDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	AIRMTQSPSSFSASTGDRVTITCQASESISNELSWYQQKPGKAPKLLIYYASTLAS	269
10C5-L5	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCAQGFGSSGVENVFGGGTKVEIKRT
huKappa	VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
	QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSENRGEC

LC	AYYMTQTPASVEAAVGGTVTIKCQASQSISNYVAWYQQKPGQPPKLLIYRASTLAS	270
2B11	GVSSRFSGSGSGTEFTLTISDLECADAATYYCHQGYSSSNVDNIFGGGTEVVVKRA
	DAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTD
	QDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	AYEMTQTPASVEVAVGGTVTINCQASESISSDLAWYQQKPGQRPKLLIYAASTLAS	271
10H3	GVPSRFKGSGSGTEFTLSISGVQCADAATYYCQQGYTWNNVDNVFGGGTEVVVKRA
	DAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTD
	QDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	DIVMTQTPASVSEPVGGTVTIKCQASQNINNYLSWYQQKPGQPPKQLIYAASTLAS	272
9H3	GVPSRFKGSGSGTQFTLTISDLECADAATYYCHQDYTSNNVDNTFGGGTEVVVKRA
	DAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTD
	QDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	NIVMTQTPASVEVAVGGTVTIKCQASQSIGSYLSWYQQKPGQPPKLLIYDASNLAS	273
8B7	GVPSRFKGSGSGTQFTLSISDLECADAATYYCHQDYTSNNVDNTFGGGTEVVIKRA
	DAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTD
	QDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	NIVMTQTPASVEAAVGGTVTINCQASQSISSYLSWYQQKSGQRPKLLIFSASTLAS	274
9H5	GVPSRFTGSGSGTQFTLTISDLQCADAATYYCHQDYTSSNVDNTFGGGTEVVVKRA
	DAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTD
	QDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	DIQMTQSPSSLSASVGDRVTITCQASQSISSYLSWYQQKPGKAPKLLIYSASTLAS	275
9H5-L4	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQDYTSSNVDNTFGGGTKVEIKRT
huKappa	VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
	QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

LC	NIVMTQTPASVEVAVGGTVIIKCQASQSISNYLSWYHQKSGQRPRLLIYSASTLAS	276
9F2	GVPSRFKGSGSGTQFTLTISDLECADAATYYCHQDYTSNSVDNTFGGGTEVVVKRA
	DAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTD
	QDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	NIVMTQTPASVEVAMGGTVIIKCQASQSISTYLSWYQQKPGQPPKLLIYSASTLAS	277
10C8	GVSSRFEGSGSGTQFTLTISGVQCADAATYYCHQDYTSNNVDNTFGGGTEVVVKRA
	DAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTD
	QDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	AYDLTQTPASVEAAVGGTVTINCQASESIGNELSWYQQKSGQPPKLLIYQASTLAS	278
8F5	GVPSRFKGSGSGTDFTLTISDLECADAATYYCAQGFSSSGVENVFGGGTEVVVKRA
	DAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTD
	QDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	AYDMTQTPASVEAAVGGTVTIKCQASESIGNALAWYQQKPGQPPKLLIYDASDLAS	279
3-3F5	GVPSRFKGSGSGTQFTLTISGVECADAATYYCQQGDSHNNVDNIFGGGTEVVVKRA
	DAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTD
	QDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	AIRMTQSPSSFSASTGDRVTITCQASESIGNALAWYQQKPGKAPKLLIYDASDLAS	280
3-3F5-L5	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDSHNNVDNIFGGGTKVEIKRT
huKappa	VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
	QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

LC	AIEMTQTPSSASEPVGGTVTIKCQASESISRYLSWYQQKPGQPPKLLIYDASDLAS	281
9E3	GVSSRFKGSGSGTQFTLIISDVECADAATYYCQQDYSRSNIVNSFGGGTEVVVKRA
	DAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTD
	QDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	AYDMTQTPSSASEPVGGTVTIKCQASESISTYLSWYQQKPGQPPKLLIYDASDLAS	282
10D10	GVSSRFKGSGSGTQFTLTISDVECADAATYYCQQDYSSSNIVNSFGGGTEVVVKRA
	DAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTD
	QDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	AYDMTQTPASVEVAVGGTVTIKCQASQSISTYLAWYQQKPGQRPNLLIYKTSTLAS	283
12B3	GVPSRFRGSGSGTQFTLTISGVECADAATYYCQQGYSGSSVENTFGGGTEVVVKRA
	DAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTD
	QDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

LC	AYDMTQTPVSVEAAVGGTVTIKCQASQSISSYLAWYQQKPGQPPKLLIYKASTLAS	284
1D10	GVSSRFKGSGSGTEFTLTISDLECADAATYYCQQGYSGSNVENTFGGGTEVVVKRA
	DAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTD
	QDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

HC Sequences

HC	EVQLVESGGGLVQPGRSLKLSCTASGFTFSDYNMAWVRQAPKGGLEWVTTISYDAG	285
14C8	RTYYRDSVKGRFTISRDNAKRTLSLQMDSLRSEDTATYYCATGIFNYGTDYFDYWG
	QGVMVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLS
	SGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPT
	IKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQIS
	WFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPI
	ERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTE
	LNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRT
	PGK

HC	EVQLVESGGGLVRPGRSLRLSCAASGFTFSDYYMAWVRQAPTKGLEWVASISYDGD	286
14E12	TTYYRDSVKGRFTISRDNARSSLYLQMDSLRSDDTANYFCTTDGTIPAGSWFAYWG
	QGTLVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLS
	SGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPT
	IKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQIS
	WFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPI
	ERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTE
	LNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRT
	PGK

HC	QEQLEESGGDLVKPEGSLTLTCTASGFSFSSSYWICWVRQAPGKGLEWIACVYGLD	287
8E11	VNIYYASWTKGRFTISKTSSTTVTLQMTSLTAADTATYFCARGGGSADFGFDLWGP
	GTLVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSS
	GVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTI
	KPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISW
	FVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIE
	RTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTEL
	NYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTP
	GK

HC	QSLEESGGDLVKPEGSLTLTCTASGFSFSTSYWICWVRQAPGKGLEWIACVYGLDV	288
8G10	NIYYASWTEGRFTISKTSSTTVTLQVTSLTAADTATYFCARGGGSADFGFDLWGPG
	TLVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSG
	VHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIK
	PCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWF
	VNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIER
	TISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELN
	YKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPG
	K

HC	QSVKESEGGLFKPTDNLTLTCTVSGFSLSNYGVTWVRQAPGNGLEYIGFIGSGGSA	289
9B6	YYASWAKSRSTITRNTNLNTVTLKMTSLTAADTATYFCARDDVGGGKSLDIWGPGT
	LVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGV
	HTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKP
	CPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFV
	NNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERT
	ISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNY
	KNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

HC	QSVEESRGGLIKPTDTLTLTCTASGFSLSNYGVSWVRQAPGNGLEYIGFIGYGGST	290
2.3F4	YYASWAKSRSTITRNTNLNTVTLQMTSLTAADTATYFCARLCGVDCADALDSWGPG
	TLVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSG
	VHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIK
	PCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWF
	VNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIER
	TISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELN
	YKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPG
	K

HC	QSLEESGGGLVKPTDTLTLTCTVSGFSLSSYGVTWVRQAPGRGLEWIGYITSNYGV	291
10C5	SYYASWAKSRSTITRNTNLNTVTLKMTSLTAADTATYFCARENPDYGYAYDAWGPG
	TLVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSG
	VHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIK
	PCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWF
	VNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIER
	TISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELN
	YKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPG
	K

HC	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWIGYITSNYG	292
10C5-H28	VSYYASWAKSRSTISRDTSKNTVYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
hIgG1	GTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS
N297G	GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD
	KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW

	KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
	NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP
	GK

HC	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWIGYITSNYG	293
10C5-H28	VSYYASWAKSRSTISRDTSKNTVYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
hIgG4	GTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
5228P	GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGP

	GVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTI
	SKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
	TTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

HC	QSVKESEGGLFKPTDTLTLTCTVSGFSLINYGVSWVRQAPGKGLEWIGYIGSAGST	294
2B11	YYATWAKSRATITRNTNLNTVTLKMTSLTAADTATYFCARAAYSAGSADAEDIWGP
	GTLVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSS
	GVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTI
	KPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISW
	FVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIE
	RTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTEL
	NYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTP
	GK

HC	QSVKESEGGLIKPTDTLTLTCTVSGFSLSTFAINWVRQAPGNGLEWIGAIGRGGSA	295
10H3	YYASWAKSRSTITKNTNLNTVTLKMTRPTAADTATYFCARENAGSGWGELDIWGPG
	TLVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSG
	VHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIK
	PCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWF
	VNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIER
	TISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELN
	YKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPG
	K

HC	QSVKESEGGLFKPTDTLTLTCTVSGFSLSGYGVSWVRQAPGKGLEYIGFIGSGGSA	296
9H3	YYASWAKSRSTITRNTNLNTVTLKMTRLTAADTATYFCARDNVGGDMSLDIWGPGT
	LVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGV
	HTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKP
	CPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFV
	NNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERT
	ISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNY
	KNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

HC	QSVKESEGGLFKPTDNLTLTCTVSGFSLSNYGVTWVRQAPGNGLEYIGFIGSSGSA	297
8B7	YYASWAKSRSTITRNTNLNTVTLKMTSLTAADTATYFCARDDVGGGKSLDIWGPGT
	LVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGV
	HTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKP
	CPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFV
	NNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERT
	ISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNY
	KNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

HC	QSVKESEGGLFKPTDNLTLTCTVSGFSLSSYGVSWVRQAPGNGLEYIGFIGSGGFA	298
9H5	YYASWAKSRSTITRNTNLNTVTLKMTSLTAADTATYFCARDDVGGGKSLDIWGPGT
	VVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGV
	HTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKP
	CPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFV
	NNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERT
	ISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNY
	KNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

HC	EVQLVESGGGLIQPGGSLRLSCAASGFSLSSYGVSWVRQAPGKGLEYVGFIGSGGF	299
9H5-H14	AYYASWAKSRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDVGGGKSLDIWGQG
hIgG1	TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
N297G	VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK
	THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY

	TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
	YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVESCSVMHEALHNHYTQKSLSLSPG
	K

HC	EVQLVESGGGLIQPGGSLRLSCAASGFSLSSYGVSWVRQAPGKGLEYVGFIGSGGF	300
9H5-H14	AYYASWAKSRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDVGGGKSLDIWGQG
hIgG4	TLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSG
S228P	VHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP

	VEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS
	KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
	TPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

HC	QSVKESEGGLFKPTDNLTLTCTVSGFSLSSYGVSWVRQAPGNGLEYIGFIGSGGSP	301
9F2	YYASWAKSRSTITRNTNLNTVTLKMTSLTAADTATYFCARDDVGGGKSLDIWGPGT
	LVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGV
	HTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKP
	CPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFV
	NNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERT
	ISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNY
	KNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

HC	QSVKESEGGLFKPTDNLTLTCTVSGFSLSSYGVSWVRQAPGNGLEYIGFIGSGGFA	302
10C8	YYASWAKSRSTITRNTNLNTVTLKMTSLTAADTATYFCARDDVGGGRSLDIWGPGT
	VVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGV
	HTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKP
	CPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFV
	NNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERT
	ISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNY
	KNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

HC	QSVKESEGGLFKPTDTLTLTCTVSGFSLSSYPISWVRQAPGNGLEWIGYITSEYGV	303
8F5	AYYATWAESRSTITRNTNLNTVTLKMTSLTAADTATYFCVRENPTYGYAYDAWGPG
	TLVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSG
	VHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIK
	PCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWF
	VNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIER
	TISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELN
	YKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPG
	K

HC	QSVKESEGGLFKPTDTLTLTCTVSGFSLNDYGVSWVRQAPGNGLEWIGAIGSSGVA	304
3-3F5	WYANWAKGRSTITRNTNLNTVTLKMASLTAADTATYFCARDRDYGYRADDATSGMD
	LWGPGTLVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSG
	SLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPR
	GPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDV
	QISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLP
	APIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNG
	KTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSF
	SRTPGK

HC	EVQLLESGGGLVQPGGSLRLSCAVSGFSLNDYGVSWVRQAPGKGLEWVGAIGSSGV	305
3-3F5-H19	AWYANFAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
hIgG1	DLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
N297G	GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE
	PKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE

	PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
	GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
	LSLSPGK

HC	EVQLLESGGGLVQPGGSLRLSCAVSGFSLNDYGVSWVRQAPGKGLEWVGAIGSSGV	306
3-3F5-H19	AWYANFAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
hIgG4	DLWGRGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS
S228P	GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVE

	NWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS
	IEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP
	ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSL
	SLGK

HC	QEQLEESGGGLVKPGASLTLTCTVSGFSLTNNYVNFVMCWVRQAPGKGLEWIASID	307
9E3	PGDDSTDYASWATGRFTISKASSTTVTLQVTSLTAADTATYFCARGDAGTSYSFNF
	WGPGTLVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGS
	LSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRG
	PTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQ
	ISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPA
	PIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGK
	TELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFS
	RTPGK

HC	QEQLVESGGGLVKPGASLTLTCTASGFSLTDNYVMSWVRQAPGKGLEWIACIDPGD	308
10D10	DSTYYASWATGRFTISRASSTTVTLQVTSLTAADTATYFCARGDAAASYSFNFWGP
	GTLVTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSS
	GVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTI
	KPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISW
	FVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIE
	RTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTEL
	NYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTP
	GK

HC	QSLEESGGGLVKPGGTLTLTCKASGIDFNGGGIYWVRQAPGKGLEWIASIYPDHGS	309
12B3	VDYANWVNGRFTISLDNAQNTVFLQLTSLTVADTATYFCARESGGSYYDLWGPGTL
	VTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVH
	TFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPC
	PPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVN
	NVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTI
	SKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYK
	NTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

HC	QSLEESGGGLVKPGGTLTLTCTASGFDFNGGGIYWVRQAPGKGLEWIAYIYPDHGS	310
1D10	ADYATWVNGRFTISLDNAQNTVFLQMTSLTVADTATYFCARETGGSWYDLWGPGTL
	VTVSSASTKGPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVH
	TFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPC
	PPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVN
	NVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTI
	SKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYK
	NTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

Constant Regions

huKappa	RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV	311
	TEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSENRGEC

hIgG1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV	312
N297	LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC
	PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH

	QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
	LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

hIgG1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV	313
G297	LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC
	PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH

	QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
	LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

hIgG4	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV	314
S228
	EFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAK
	TKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
	EPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
	DGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

hIgG4	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV	315
P228
	EFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAK
	TKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
	EPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
	DGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

Miscellaneous Sequences

KLK5 thermo-	LRPNQL	316
dynamic
epitope
Region
1

KLK5 thermo-	QGVKSI	317
dynamic
epitope
Region
2

KLK5 thermo-	KRCEDAYPRQIDDT	318
dynamic
epitope
Region
3

KLK5 thermo-	DYPCARPNRPGVY	319
dynamic
epitope
Region
4

Hu SPINK9	IESAKQTKQMVDCSHYKKLPPGQQRFCHREYDPICGSDGKTYKNDCFFCSK	320
(I20-C86.	VKKTDGTLKFVHFGKCGNSVTDKTHTCPPCPAPELLGGPSVFLFPPKPKDT
C22S.H48R.	LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
M49E); Fc	VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP
human IgG1	PSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
E356.M358	FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

VL	AIRMTQSPSSFSASTGDRVTITCQASESISNELSWYQQKPGKAPKLLIYYASTLAS	321
hu10C5-L6	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCAQGFGSSGVENVFGGGTEVVVK

Fab HC	EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWIGYITSNYG	322
10C5	VSYYASWAKSRSTISRDTSKNTVYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQ
Humanized	GTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS
	GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD

Fab LC	AIRMTQSPSSFSASTGDRVTITCQASESISNELSWYQQKPGKAPKLLIYYASTLAS	323
10C5	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCAQGFGSSGVENVFGGGTKVEIKRT
Humanized	VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
	QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Fab HC	EVQLVESGGGLIQPGGSLRLSCAASGFSLSSYGVSWVRQAPGKGLEYVGFIGSGGF	324
9H5	AYYASWAKSRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDVGGGKSLDIWGQG
Humanized	TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
	VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD

Fab LC	DIQMTQSPSSLSASVGDRVTITCQASQSISSYLSWYQQKPGKAPKLLIYSASTLAS	325
9H5	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQDYTSSNVDNTFGGGTKVEIKRT
Humanized	VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
	QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Fab HC	EVQLLESGGGLVQPGGSLRLSCAVSGFSLNDYGVSWVRQAPGKGLEWVGAIGSSGV	326
3-3F5	AWYANFAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRDYGYRADDATSGM
Humanized	DLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
	GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
	KVDKKVEPKSCD

Fab LC	AIRMTQSPSSFSASTGDRVTITCQASESIGNALAWYQQKPGKAPKLLIYDASDLAS	327
3-3F5	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDSHNNVDNIFGGGTKVEIKRT
Humanized	VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
	QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Human KLK5	IINGSDCDMHTQPWQAALLLRPNQLYCGAVLVHPQWLLTAAHCRKKVFRVRLGHYS	328
Crystal	LSPVYESGQQMFQGVKSIPHPGYSHPGHSNDLMLIKLNRRIRPTKDVRPINVSSHC
Structure	PSAGTKCLVSGWGTTKSPQVHFPKVLQCLNISVLSQKRCEDAYPRQIDDTMFCAGD
Experiments	KAGRDSCQGDSGGPVVCNGSLQGLVSWGDYPCARPNRPGVYTNLCKFTKWIQETIQ
	ANS

Framework Sequences

FR-L1	AX₁RMTQSPSSFSASTGDRVTITC	329
10C5	wherein X₁ is Y or I
(consensus)

FR-L2	WYQQKPGKX₁PKLLIY	330
10C5	wherein X₁ is P or A
(consensus)

FR-L3	GVPSRFSGSGSGTDFTLTISX₁LQX₂EDFATYYC	331
10C5	wherein X₁ is C or S, X₂ is S or P
(consensus)

FR-L4	FGGGTX₁VX₂X₃K	332
10C5	wherein X₁ is E or K, X₂ is E or V, X₃ is I or V
(consensus)

FR-H1	EX₁QLVESGGGLVQPGGSLRLSCAX₂SGFSLS	333
10C5	wherein X₁ is V or Q, X₂ is V or A
(consensus)

FR-H2	WVRQAPGKGLEX₁X₂X₃	334
10C5	wherein X₁ is W or Y, X₂ is I or V, X₃ is G or S
(consensus)

FR-H3	RX₁TISRX₂X₃X₄X₅NTX₆YLQMGSLRAEDMAVYX₇CAR	335
10C5	wherein X₁ is S or F, X₂ is D or N, X₃ is T, L or N, X₄
(consensus)	is S or N, X₅ is K, T or L, X₆ is V or L, X₇ is F or Y

FR-H4	WGX₁GTTVTVSS	336
10C5	wherein X₁ is P or Q
(consensus)

FR-L1	DIQMTQSPSSLSASVGDRVTITC	337
9H5

FR-L2	WYQQKPGKX₁PKLLIX₂	338
9H5	wherein X₁ is R or A, X₂ is F or Y
(consensus)

FR-L3	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC	339
9H5

FR-L4	FGGGTX₃VX₄X₅K	340
9H5	wherein X₃ is E or K, X₄ is E or V, X₅ is V or I
(consensus)

FR-H1	EX₁QLVESGGGLIQPGGSLRLSCAX₂SGFSLS	341
9H5	wherein X₁ is V or Q, X₂ is V or A
(consensus)

FR-H2	WVRQAPGKGLEX₁X₂X₃	342
9H5	wherein X₁ is Y or W, X₂ is I or V, X₃ is G or S
(consensus)

FR-H3	RX₁TISRX₂X₃X₄X₅NTX₆YLQMNSLRAEDTAVYX₇CAR	343
9H5	wherein X₁ is S or F, X₂ is D or N, X₃ is T or N, X₄ is S
(consensus)	or N, X₅ is K or L, X₆ is V or L, X₇ is F or Y

FR-H4	WGX₁GTLVTVSS	344
9H5	wherein X₁ is P or Q
(consensus)

FR-L1	AX₁RMTQSPSSFSASTGDRVTITC	345
3-3F5	wherein X₁ is Y or I
(consensus)

FR-L2	WYQQKPGKX₁PKLLIY	346
3-3F5	wherein X₁ is P or A
(consensus)

FR-L3	GVPSRFSGSGSGTDFTLTISX₁LQX₂EDFATYYC	347
3-3F5	wherein X₁ is C or S, X₂ is S or P
(consensus)

FR-L4	FGGGTX₁VX₂X₃K	348
3-3F5	wherein X₁ is E or K, X₂ is E or V, X₃ is V or I
(consensus)

FR-H1	EX₁QLX₂ESGGGLVQPGGSLRLSCAX₃SGFSLN	349
3-3F5	wherein X₁ is V or Q, X₂ is V or L, X₃ is V or A
(consensus)

FR-H2	WVRQAPGKGLEWX₁X₂	350
3-3F5	wherein X₁ is I or V, X₂ is G or S
(consensus)

FR-H3	RX₁TISRX₂X₃X₄X₅NTX₆YLQMNSLRAEDTAVYX₇CAR	351
3-3F5	wherein X₁ is S or F, X₂ is H, N or D, X₃ is T or N, X₄ is
(consensus)	S or N, X₅ is K or L, X₆ is V or L, X₇ is F or Y

FR-H4	WGX₁GTLVTVSS	352
3-3F5	wherein X₁ is P or R
(consensus)

Human KLK5	NNDVSCDHPSNTVPSGSNQDLGAGAGEDARSDDSSSRIINGSDCDMHTQPWQAALL	353
HDX	LRPNQLYCGAVLVHPQWLLTAAHCRKKVFRVRLGHYSLSPVYESGQQMFQGVKSIP
Experiments	HPGYSHPGHSNDLMLIKLNRRIRPTKDVRPINVSSHCPSAGTKCLVSGWGTTKSPQ
	VHFPKVLQCLNISVLSQKRCEDAYPRQIDDTMFCAGDKAGRDSCQGDSGGPVVCNG
	SLQGLVSWGDYPCARPNRPGVYTNLCKFTKWIQETIQANSGNSDYKDDDDK